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CHAPTER 1
General introduction
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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
In our ageing society , with a life expectancy of 79 years in Dutch man, prostate 
cancer plays and will play a predominant role, with regard to cancer related mor-
bidity and mortality. It is traditionally stated that one does not die from, but that 
one dies with prostate cancer. Nonetheless, prostate cancer has become the sec-
ond cause of male cancer-related deaths, after lung cancer. At diagnosis, the risk 
of dying from the disease is 40%[1]. Fortunately, many men with prostate cancer 
have limited disease, that can be adequately treated surgically, radiotherapeuti-
cally or with a “wait and see” policy. More advanced tumours can be treated with 
anti-hormonal therapy. However, a signifi cant number of men have, or have ac-
quired, advanced hormone independent prostate cancer. It is in this group of men 
that prostate cancer is a killer and effi  cient therapy is lacking. For systemic disease 
local therapy is insuffi  cient. Chemotherapy has a long history in the treatment of 
(disseminated) cancer, but its use has not been generally advocated in advanced 
prostate cancer, due to disappointing treatment outcomes, certainly with regard 
to survival. It has easily been concluded that chemotherapy is ineff ective for the 
treatment of prostate cancer, although the cause of failure of chemotherapy has 
not been determined. Clarifi cation of the underlying cause(s) of its ineff ectiveness 
appears to be an obligation towards prostate cancer patients, before disregarding 
chemotherapy as a treatment option, thus leaving a patient with no alternative, 
except purely palliative, treatments. Unveiling of mechanisms that render prostate 
cancer cells resistant to cytotoxic drugs may justify omitting chemotherapy as a 
treatment option for prostate cancer patients. However, insight into the causing 
factors of resistance may help to determine how to use chemotherapy adequately 
in prostate cancer patients. Importantly, increased understanding may even result 
in the development of treatment strategies, based on chemotherapy, that amelio-
rates the anti-tumour eff ect of chemotherapy with regard to palliation and even 
cure.
It has been from this point of view that the present research has emerged. The 
role of Multidrug Resistance (MDR), which is a phenotype characterized by cross-
resistance against a wide range of chemotherapeutic agents, has been investigated 
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in vitro (human prostate cancer cell lines), in vivo (using human prostate cancer 
xenografts on athymic nude mice) and on clinical prostate cancer material.
In Chapter 2 a literature overview is given over the most important MDR mecha-
nisms in relation to prostate cancer including transmembrane pumps, detoxify-
ing pathways, apoptosis and topoisomerases. Also, strategies to challenge these 
mechanisms are reviewed.
In Chapter 3 expression of transmembrane pumps P-glycoprotein (Pgp) and 
Multidrug resistance associated protein1 (MRP1), of Glutathione-S-transferase-π 
(GST-π), which plays part in a detoxifying pathway, of Bcl-2 and Bax, involved in 
programmed cell death and of Topoisomerase (Topo) I, IIα and IIß, which are targets 
for cytotoxic drugs is assessed in human prostate cancer cell lines by immunocyto-
chemistry and Western blotting. Proliferative activity of the cell lines was assessed 
by immunocytochemistry. MTT assays were used to determine the sensitivity to 
etoposide, doxorubicin and vinblastine.
In Chapter 4 immunohistochemistry was used for detection of P-glycoprotein 
(Pgp), multidrug resistance-associated protein (MRP), lung resistance protein 
(LRP), glutathione-S-transferase-π, (GST-π), p53, Bcl-2, Bax, topoisomerase (Topo) 
I, IIα and IIβ and Ki-67 in clinical prostate cancer. Paraffi  n-embedded formalin fi xed 
prostate cancer specimens from archival sources of three groups of patients which 
were clearly distinct with regard to pathological stage and responsiveness to 
anti-hormonal therapy, representing early prostate cancer (pathological stage (p) 
T2N0M0 tumours) early advanced prostate cancer (disseminated prostate cancer 
before receiving anti-hormonal therapy) and late advanced prostate cancer (dis-
seminated prostate cancer that relapsed despite anti-hormonal treatment).
In Chapter 5 the involvement of the multidrug resistance associated protein 
(MRP1) and the glutathione (GSH) pathway in the multidrug resistant (MDR) phe-
notype of prostate cancer is assessed in vitro. Human prostate cancer cell lines PC3 
and DU145 were selected with etoposide (VP-16), resulting in the cell lines PC3-R 
and DU-R. Resistance against etoposide, doxorubicin and vincristine and its rever-
sal with leukotriene D4 antagonists MK-571 and zafi rlukast, and buthioninesulfoxi-
mine (BSO) was studied in MTT assays. Western blot analysis of MRP1 expression 
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and GSH content measurements were performed. MRP1 function was studied in 
fl uorescence assays. 
In Chapter 6 the objective was to assess the in vivo role of MRP1 in prostate 
cancer and its modulation aiming at chemosensitization. Expression of MRP1 was 
determined with Western blotting in a panel of human prostate cancer xenografts 
and xenograft derived cell line PC346C. Chemosensitization of PC346C to VCR, 
DOX and VP-16 with MK-571 was assessed in MTT assays. Carboxyfl uorescein ef-
fl ux blocking with MK-571 in PC436C, GLC4 and GLC4/ADR was measured in fl uo-
rescence assays. Toxicity and effi  cacy of VCR and VCR combined with MK-571 was 
determined in vivo with human prostate cancer xenografts.
In Chapter 7 (general discussion) the results of all chapters are discussed, con-
clusions are given and implications for the clinical situation are evaluated.
In Chapter 8 a English and Dutch summary of the thesis is given.
The research that has resulted in this thesis has been carried out at the Erasmus 
Medical Centre Rotterdam, Department of Urology, Pathology and Hematology.
 1. Aus G, Pileblad E, and Hugosson J. Impact of competing mortality on the cancer-related mortality in 
localized prostate cancer. Urology 1995; 46: 672-5.

CHAPTER 2
Multidrug Resistance in Prostate Cancer – 
review article
van Brussel JP, Mickisch GHJ.
Onkologie 2003;26:175-81
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SUMMARY
Advanced hormone refractory prostate cancer remains a therapeutic challenge, 
because all available pharmaceutical concepts have been proven to be ineff ective 
in improving on cancer specifi c survival. Among those, a multitude of chemothera-
peutic approaches did not off er a superior life expectancy. Failure of chemotherapy 
may be caused by multidrug resistance (MDR) mechanisms protecting cancer cells 
against cytotoxic drugs, and the question arises whether prostate cancer is also 
using MDR principles to develop resistance against chemotherapeutic agents. In 
consequence, an array of diverse pathways known to lead to MDR such as MDR1, 
MRPs, Glutathione, Apoptosis, and Topoisomerases have been examined and par-
tially established at varying degrees in hormone-refractory prostate cancer. Thus, 
evidence keeps accumulating for the involvement of some MDR mechanisms in 
the chemoresistance of prostate cancer in vitro and in vivo. For some of them, e.g. 
MRP-1, functional expression appears to be probable. This lends credit to the idea 
that reversal, circumvention or overcoming of MDR pathways in advanced prostate 
cancer may be feasible and well lead to new avenues with improved treatment 
effi  cacy in otherwise untreatable disease.
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INTRODUCTION
Prostate cancer is the most common cancer in men and one of the leading causes 
of cancer death[1; 2]. Localized prostate cancer has a good prognosis and can be 
managed by watchful waiting, early versus deferred hormonal treatment[3] exter-
nal radiotherapy, brachytherapy or by surgery. However, metastatic prostate can-
cer remains a major oncological problem. Metastatic disease is incurable, although 
palliation can be achieved in 75% of all patients with hormonal ablation therapy[4]. 
Despite initial response, eventually the patients will relapse and die of progres-
sive prostate cancer after an average period of 40 weeks[5]. Failure of androgen 
ablation is likely to be caused by the heterogeneous character of prostate can-
cer, which is composed of clones of both androgen dependent and independent 
prostatic cancer cells[6]. The life span of patients with metastatic disease may be 
determined by the hormone-independent cell populations. To increase survival of 
men with metastatic prostate cancer, treatment strategies that eff ectively targets 
androgen independent cancer cells are required.
Chemotherapy is the principal strategy to systemically challenge metastasized 
cancers. Unfortunately, prostate cancer is resistant to a broad range of antineo-
plastic agents[7-11]. Over the past decade new and more eff ective treatments 
have been developed based on an increased understanding of the morphological 
and functional characteristics of prostate cancer. Although several studies have 
reported favourably on response rates to chemotherapeutical regimens, patient 
selection, tumour heterogeneity, stage migration and defi nition of response have 
decisively confused evaluation of survival[12]. Altogether, results of chemotherapy 
in prostate cancer, single- as well as multiple agent regimens, have been disap-
pointing, so far. At present, none of them have exhibited a clear survival advan-
tage, although two recent randomized clinical trials have reported on a two to four 
month survival benefi t with combination therapies of docetaxel and prednisone 
or docetaxel and estramustine as compared to mitoxantrone and prednisone, re-
spectively[13; 14].
Resistance to anti-proliferative agents, which kill dividing cells, may be caused by 
large proportions of prostate cancer cells that are in interphase[15]. Importantly, 
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involvement of the multidrug resistance (MDR) phenomenon may well play a role 
in progressive therapy resistant prostate cancer and may off er an explanation for 
resistance to a variety of structurally- and functionally distinct cytotoxic agents. 
The resistance to cytotoxic chemotherapy is a major problem in the clinical man-
agement of cancer patients. Malignancies frequently respond to antineoplastic 
treatment initially, but eventually relapse and become progressive despite chemo-
therapy. Resistance has developed, not towards the applied drug alone, but often 
to a variety of structurally and functionally unrelated drugs as well. The MDR phe-
nomenon of cross-resistance to diff erent cytotoxic agents was fi rst described three 
decades ago[16]. Apart from tumours with acquired or induced MDR, malignancies 
can display intrinsic MDR: they are primarily unresponsive to chemotherapeutic 
regimens. The mechanisms of these types of resistance appear to be similar. The 
multidrug resistance phenotype of cancer cells can be caused by diff erent mecha-
nisms and various MDR pathways have been identifi ed over the years. Knowledge 
of the biological and molecular mechanisms of MDR is increasing. This is essential 
to develop new approaches to tackle the problem of chemotherapy-unresponsive 
tumours more successfully and fi nd modalities by which MDR can be overcome, 
circumvented or reversed. Such strategies are termed chemosensitization.
In this article we discuss the most important MDR mechanisms in relation to 
prostate cancer. Several mechanisms for MDR have been detected, including trans-
membrane pumps, detoxifying pathways, changes in apoptosis and drug targets. 
Involvement of MDR mechanisms in prostate cancer implicates that development 
of strategies to overcome MDR is essential. Therefore, we will review strategies to 
challenge these mechanisms in multidrug resistant prostate cancer, aiming at im-
provement of the treatment of advanced hormone refractory prostate cancer.
MDR1 / P-GLYCOPROTEIN (PGP)
Overexpression of the MDR gene MDR1[17] and its product P-glycoprotein (Pgp) 
has received a great deal of attention. Pgp acts as a transmembrane effl  ux pump 
by extruding diff erent classes of natural-product cytotoxic drugs from the cell in an 
energy-dependent manner.
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The role of P-glycoprotein mediated multidrug resistance in prostate cancer is 
questionable with studies reporting confl icting results. Expression of Pgp in the hu-
man prostate cancer cell lines PC3 and DU145 has been reported in one study[18], 
albeit at low levels. Doxorubicin resistant cell lines derived from the Dunning R3327 
rat prostate carcinoma model[19] expressed Pgp as well[20]. In contrast, using Pgp 
targeted-immunoconjugates harbouring Pseudomonas exotoxin, cell lines LNCaP 
and DU145 were described not to express Pgp at signifi cant amounts[21]. Results 
obtained by Western blotting and immunocytochemistry appear to confi rm the 
latter observation[22; 23]. Other groups were also unable to detect Pgp in clinical 
prostate cancer or prostate cancer cell lines[24; 25]. Although chemotherapeutic 
agents, such as vinblastine, doxorubicin and etoposide, are substrates for Pgp, 
resistance of prostate cancer to these products may not be caused by Pgp as this 
drug effl  ux pump is barely if not expressed in prostate cancer. Reversal of multi-
drug resistance by Pgp targeting chemosensitizers may therefore not be benefi cial. 
In contrast to this, Siegsmund et al.[26] found MDR1 expression at low level in 8 of 
11 prostate carcinoma tissues by RT-PCR and advocated the use of Ketoconazole as 
MDR reversing agent in prostate cancer. This antifungal imidazole has been dem-
onstrated to repress steroid synthesis, to have direct cytotoxic eff ect on tumour 
cells and to potentiate the effi  ciency of chemotherapeutic drugs as it blocks Pgp. 
According to the authors, this agent could be useful in relapsing hormone sensitive 
prostate cancer with its antihormonal and cytotoxic characteristics and its potency 
to revert Pgp-mediated resistance. However, Pgp expression in the prostate cancer 
samples in this study is questionable, as with the method applied it is not possible 
to distinguish epithelial MDR1 mRNA expression from stromal MDR1 expression. 
Furthermore, functional involvement of MDR1 was not proven. 
Chemosensitization
Much eff ort has been put in chemosensitization of cancer cells expressing the 
MDR1 phenotype. Drug-resistant cells have been exposed to a variety of alternate 
substrates for Pgp, which ideally in themselves are only slightly cytotoxic, if at 
all. Pgp modulators, which include calcium channel blocking agents, calmodulin 
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antagonists, cyclic peptides and steroids, interfere with drug binding to Pgp and 
may be competitive substrates for Pgp-mediated transport. In phase I and II clinical 
studies of several fi rst-generation MDR modulators, the achievement and mainte-
nance of biologically –relevant concentrations were barely feasible because of the 
development of adverse eff ects, such as cardiovascular toxicity with verapamil and 
immunosuppression with cyclosporin[27; 28]. The fi rst observations were done by 
Tsuruo et al.[29] who showed that verapamil was able to enhance drug accumula-
tion of vincristine and vinblastine in the P388/VCR drug-resistant cell line in vitro
and in vivo.
The fi rst generation of MDR reverters were existing drugs which appeared to have 
MDR reversal activity in vitro, but they were originally designed for other pharma-
cological properties. Levels necessary in vivo for effi  cient modulation of MDR could 
often not be obtained because of prohibitive toxicity. Numerous compounds have 
been described which effi  ciently inhibit the Pgp effl  ux pump[30; 31]: calcium chan-
nel blockers (e.g. amiodarone, verapamil), cyclic peptides (e.g. cyclosporine-A), 
protein kinase C inhibitors (e.g. staurosporine), calmodulin antagonists (e.g. trifl uo-
perazine), steroidal agents (e.g. progesterone, tamoxifen, megestrol acetate), Vinca 
alkaloid analogues, and miscellaneous compounds (e.g. quinidine).
Analogues of these modulators, that are devoid of these adverse eff ects are cur-
rently in clinical development[33-34]. These new generation of compounds (e.g. 
dexniguldipine, PAK-200, AHC-52, PSC 833, SDZ 280-446, dexverapamil) are espe-
cially selected for MDR reversal activity. They distract the drug-effl  ux pump, leading 
to decreased extrusion and increased intra-cellular accumulation of antineoplastic 
drugs. Effi  cacy and toxicity of modulators can be evaluated in xenograft-bearing-
mouse models of human tumours: multidrug resistant tumours are implanted in 
mice and the activity of a cytotoxic agent in the presence of a chemosensitizer is 
assessed.
The potential disadvantage of many chemosensitizers resides in increased 
toxicity as a result of higher doses of intracellular cytotoxins in normal tissue or 
cells. Myelotoxicity has often been and remains the dose limiting factor in chemo-
therapy. Strategies for preventing bone marrow toxicity have therefore become a 
high priority of research on dose escalation protocols. A promising approach was 
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the construction of transgenic mice[35]. Constructs of cDNA encoding full-length 
human MDR1 in a plasmid carrier were injected into fertilized mouse embryos. A 
homozygous line was obtained in which the expression of the MDR1 gene was 
limited to the bone marrow and the spleen[36]. The level of MDR1 expression in 
bone marrow cells was clinically signifi cant and comparable with that seen in an in 
vitro selected cell line (KB-8-5) that exhibits 3- to 18-fold resistance, depending on 
the drug. Expression of Pgp was of particular signifi cance, because the MDR1 gene 
expressing bone marrow was protected against chemotherapy induced toxicity 
in comparison to normal bone marrow. This protective advantage of the MDR1 
gene could be transferred to recipient animals by bone marrow transplantation. 
Subsequently, protection of bone marrow cells by virtue of expression of the drug 
resistance MDR1 gene was also clinically investigated using a gene therapeutic 
approach[140]. Due to technical limitations at the gene transduction level, no sig-
nifi cant dose escalation of chemotherapy in patients could be detected.
Use of drugs that are not susceptible to the Pgp effl  ux mechanism (non-MDR 
drugs) is another option to bypass Pgp mediated MDR. However, tumours do not 
tend to be sensitive to many diff erent anticancer drugs. Modifi cation of known 
active MDR drugs at the biochemical level in such a way that they are less sensitive 
to the Pgp extrusion mechanism, but retain their cytotoxic activity can be done by 
conjugation to other structures, such as conjugation of doxorubicin or methotrex-
ate to albumin[37; 38]. This results in prolonged intracellular accumulation of the 
drug and increased cytotoxicity. An alternate method of chemosensitization relies 
on circumventing, rather than distracting the activity of Pgp via false substrates. Li-
posomal encapsulation of drugs reduce the binding affi  nity to Pgp[39]. Liposomes 
themselves may inhibit the pump function of Pgp, modify the phospholipid mem-
brane structure and subsequently introduce functional and/or steric alterations of 
Pgp. Alternatively, delivery of drugs encapsulated in liposomes may bypass the cell 
membrane, directly discharging the drug into the cytoplasm.
Another approach is to use the drug transporter Pgp as target for immunother-
apy by monoclonal antibodies. The monoclonal antibody MRK16 specifi cally binds 
human Pgp and has moderate direct cytotoxic activity in xenografted MDR tumour 
models[40]. Anti-Pgp monoclonal antibodies like HYB-241 and MRK16 also act as 
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chemosensitizers by binding to Pgp, thus changing its action[41; 42]. Alternatively 
the Pgp related MDR can be challenged by selectively killing cells that express Pgp 
on their surfaces. This goal can be achieved experimentally by using protein toxins, 
such as Pseudomonas exotoxin, that are chemically linked to or recombinantly at-
tached to certain anti-Pgp antibodies, such as MRK16[43]. Recently Ihnat et al.[44] 
reported that application of sub-chemotherapeutic doses of DNA cross-linking 
agents could be used to modulate multidrug resistance through suppression of 
P-glycoprotein, prior to treatment with a second cytotoxic agent. These fi ndings 
should be further explored in vivo. 
Several studies were performed aiming at chemosensitization of MDR1 driven 
MDR of prostate cancer. Rat mdr1b mRNA was found in hormone-insensitive 
sublines of Dunning rat prostate carcinoma cells. Reversal of resistance against 
Vinblastine and Taxol was achieved with verapamil[45]. Experiments in a three 
dimensional in vitro model for prostate cancer revealed resistance against doxoru-
bicin, expression of Pgp and modulation of resistance with MDR1 modulators[46]. 
Downregulation of Pgp by reactive oxygen species in multicellular prostate tumour 
spheroids was observed[47]. In summary, clinical relevance of MDR1 expression 
in prostate cancer remains questionable and chemosensitization approaches in 
experimental and clinical prostate cancer models have to be further investigated 
for a potential benefi t in prostate cancer patients .
Figure 2.1 represents a schematic overview of multidrug transporter related 
multidrug resistance and chemosensitization.
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Figure 2.1.
MULTIDRUG-TRANSPORTER-RELATED MULTIDRUG RESISTANCE
Schematic representation of mechanisms of (A) action of a chemotherapeutic drug, (B) energy dependent extrusion of drugs by an active 
multidrug transporter, and (C) chemosensitization to chemotherapy by distracting the multidrug resistance pump with a chemical compound 
that competes for active transport with the chemotherapeutic drug. In A, chemotherapeutic agents (triangles) enter the cell and cause drug-
induced cell death. In B, decreased accumulation of the drug through active transport out of the cell by the multidrug resistance pump results 
in survival of the cell. In C, concomitant accumulation of a chemosensitizing agent (black dots) has enhanced intracellular accumulation of 
chemotherapeutic agents by competing for active transport by the multidrug resistance effl  ux pump. 
Multidrug resistance associated protein (MRP)
The role of the multidrug resistance associated protein in MDR of prostate cancer 
is the subject of recent and current investigations.
In 1992 the MDR-associated protein (MRP)[48] was found to mediate drug resis-
tance in distinct MDR tumour cell lines lacking Pgp. Since then fi ve more members 
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of the MRP family have been described[49; 50]. MRP1-3 transport MDR drugs at 
varying degree and are active as carriers for transport of glutathione S-conjugated 
endo- and xeno-biotics[51; 52]. The role of MRP4-6 as MDR transporter remains 
subject of investigation. 
Pgp and MRP1 confer resistance to doxorubicin, vincristine, and etoposide, but 
only Pgp confers high levels of resistance to paclitaxel and cholchicine[53-55]. The 
mechanism of MRP1-mediated drug resistance is less well defi ned than that con-
ferred by Pgp. Plasma membrane-associated MRP1 may lead to drug accumulation 
defects, whereas the presence of MRP1 in the endoplasmic reticulum or post-Golgi 
vesicles may sequester anticancer drug away from cellular targets[53; 56]. The spe-
cifi c determinants of whether a cell will acquire drug resistance through increased 
expression of MRP1 are not yet known; however, overexpression of Pgp and MRP 
is not mutually exclusive and increased levels of both proteins may occur in the 
same cell line[57].
Whereas Pgp transports substrates in an unmodifi ed form, MRP1 overexpression 
is associated with an increased ATP-dependent glutathione S-conjugate transport 
activity [51; 52]. Experiments with inside-out membrane vesicles indicated that 
MRP1 is able to transport a range of substrates that are conjugated to glutha-
thione (GSH), glucuronide, or sulfate[51; 54; 58]. Transporters with these charac-
teristics are known as GS-X pumps[57], multispecifi c organic anion transporters 
(MOAT; [60]) or leukotriene C4 (LTC4 ) transporters[61]. Besides the transport of 
glutathione S-conjugates, it was demonstrated that MOAT’s cause transport of 
amphipathic anti-cancer drug vinblastine. This raises the possibility that MOAT’s 
are ABC-transporters that potentially could be involved in multidrug resistance in 
mammalian cells. Vinca alkaloids are not known to be converted into negatively 
charged conjugates, and it is not yet clear how organic anion transporters, such 
as MRP1 or other MOAT’s, transport these compounds. Evidence that GSH is a pre-
requisite for MRP1-mediated MDR in intact cells was obtained by depleting cells 
of GSH, which resulted in the loss of resistance to vincristine[62]. Loe et al.[54] 
showed that high GSH concentrations are required for MRP1-mediated vincristine 
uptake into vesicles. Furthermore, direct binding of GSH to MRP1 was shown in 
a vanadate induced trapping experiment[63]. It is not known, however, whether 
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vincristine is transported as a short-lived complex with GSH, cotransported with 
GSH, or whether glutathione is only required allosterically[62]. 
This clearly raises the possibility that mechanisms which interfere with either 
the leukotriene C4 transport or the glutathione metabolism may also eff ectively 
interfere with the MRP1 driven effl  ux system. 
MRP1 expression is found in all major organs analysed including prostate and all 
cell types from peripheral blood[64]. MRP1 is a Mr.190.000 protein that is encoded 
by the MRP1 gene, which is located on chromosome 16p 13[48]. Some other mem-
bers of a putative 21 gene family[65] have been identifi ed[55; 66; 67], some of which 
show expression in the prostate like MRP1, MRP2 (cMOAT)[67], MRP3 (cMOAT-2) 
and MRP4 (MOAT-B). Nevertheless, an exact analysis of expression pattern of MRP-
genes other than MRP1 is still lacking and will be subject of future studies.
Chemosensitization
To date, strategies aimed at reversing MDR have principally focused on inhibition 
or modulation of Pgp activity. Various MDR reversal agents have been described 
that restore intracellular accumulation of drugs in MDR1-overexpressing cells by 
the inhibition of the drug effl  ux activity of Pgp[17; 27; 68] . 
Compounds with proven MRP1-associated MDR modulating capacity are rare 
at present. Some agents, however, which originally were found to circumvent a 
Pgp-mediated MDR eff ectively show some activity, such as verapamil[69], its L-
stereoisomer[70], cyclosporin A and its non-immunosuppressive derivative SDZ 
PSC 833[69], and dihydropiridines[69]. In addition, depletion of glutathione via the 
glutathione synthesis inhibitor D,L-buthionine-(S,R)-sulfoximine (BSO)[72], was 
successful in modulating MRP1 related MDR. Circumvention of MRP1-related MDR 
was achieved in Etoposide resistant prostate cancer cell lines by a dihydopyridine 
derivative NIK250[73].
Particular attention is paid, however, to the eff ective inhibition of MRP1 induced 
by the leukotriene D4 receptor antagonist MK571[74], a specifi c MRP1 blocker. 
MK571 is clinically used for relieving bronchoconstriction in asthma patients [75], 
and can be safely administered in high doses[76] either intravenously or orally. 
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Quite recently a similar leukotriene D4 receptor antagonist (ONO-1078) was also 
described to circumvent MRP1 modulated MDR in cancer cell lines[77]. Zafi rlu-
kast, another leukotriene inhibitor, was demonstrated to have MDR modulation 
potential in prostate cancer cell lines [78]. The compounds MK-571, ONO1078 and 
zafi rlukast would bind to leukotriene C4 and D4 receptors thus interfering with 
the MRP1 driven effl  ux of leukotrienes[61]. Functional testing by visualisation of 
MRP1 mediated effl  ux via specifi c fl uorescent substances with and without MRP1 
modulator MK-571 has also been achieved in acute myeloid leukemia blasts from 
patients and in several AML cell lines[79; 80]. MRP1 activity was a prognostic factor 
for achievement of complete remissions suggesting that MRP1 contributes signifi -
cantly to drug resistance in AML.
In prostate cancer, MRP1 is expressed even in early stages[81]. MRP1 expression 
increases in late disease stages[23] and is consistently present in all prostate cancer 
cell lines examined[22]. MRP2 expression has been found in prostate cancer cell 
lines and xenografts (van Brussel; unpublished results). MRP3 in prostate cancer 
cell lines[67] and MRP4 in prostate cancer[66]. MRP5 and MRP6 expression in pros-
tate cancer has not been reported thus far. A functional role for the members of 
the MRP family in prostate cancer is subject of current investigations. Clinically, 
establishment of the role of MRP in multidrug resistant prostate cancer would of-
fer a potential to apply MRP modulators in combination with chemotherapeutic 
regimens to treat patients with advanced hormone refractory prostate cancer. 
To elucidate the role of the multidrug resistance associated protein MRP1in the 
resistance of prostate cancer against chemotherapy multidrug resistant in vitro
prostate cancer models were developed from the human prostate cancer cell lines 
PC3 and DU145 [78]. Increased expression of MRP1 in multidrug resistant prostate 
cancer cells is functionally related to resistance against chemotherapy. Eff ective 
blockade of MRP1 pump function by leukotriene receptor antagonists, such as 
MK-571 and Zafi rlukast, resulted in the intracellular accumulation of MRP1 sub-
strate and increased sensitivity to cytotoxic drugs. This provides some evidence for 
a functional role of MRO1 in drug resistance of prostate cancer, however, results 
have to be interpreted cautiously. MRP homologs other than MRP1 and other MDR 
mechanisms may well be involved in the MDR phenotype of prostate cancer cells. 
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Studies on functional involvement of MRP2-6 in prostate cancer will be initiated. 
Furthermore, the role of MRP1 in clinical prostate cancer requires further study. 
Also, approaches to inhibit MRP1 clinically must be carefully designed, because 
MRP1 is ubiquitously expressed[49]. Fine-tuning of dosages schedules of che-
motherapy and reversal agent is necessary to limit toxicity. For instance, possible 
myelotoxicity may be reduced by chemoprotection of the bone marrow, achieved 
with retrovirus-mediated gene transfer of MRP cDNA[82].
GLUTATHIONE
Several studies have demonstrated that glutathione is an important factor in 
the sensitivity of cancer cells to cytotoxic drugs. Glutathione and glutathione-S-
tranferase detoxifi cation systems protect cancer cells against the lethal eff ects of 
chemotherapy. Changes in the anticancer drug detoxifying anti-oxidant gluta-
thione metabolism[83] and in expression or activity of Glutathione-S-transferase 
intracellular transport proteins (GST) have been described in relation to MDR. GSTs 
catalyze the conjugation of hydrophobic, electrophilic xenobiotics by glutathione, 
resulting in conjugated or transformed metabolites that are more easily excretable 
and less toxic. Some GST isozymes may participate in the repair of oxidative dam-
age to membrane lipids and DNA. Furthermore, GSTs are high capacity intracellular 
binding proteins which may serve in the storage, transport, or sequestration of 
many hydrophobic compounds. The relation to the multidrug resistance associ-
ated protein has been extensively reported (see above, MRP section). These prop-
erties suggest that GSTs may function as important cellular defences against the 
cytotoxic eff ects of antineoplastic agents.
Interestingly, expression of GST-π, a detoxifying enzyme and part of the glutathi-
one detoxifying pathway, is signifi cantly increased in advanced hormone indepen-
dent prostate cancer[23]. Expression of GST-π in advanced clinical prostate cancer 
is a novel fi nding. Previous studies have only reported the lack of its expression in 
locally confi ned prostate cancer obtained from radical prostatectomy samples [81; 
84; 85] and suggested a role of GST-π inactivation in the early steps of prostatic 
carcinogenesis[86]. Accordingly, in our series of tumours locally confi ned prostatic 
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carcinomas were entirely GST-π negative, whereas the disseminated cancers clearly 
expressed GST-π, especially in hormone-independent progressive disease[23]. Con-
comitant overexpression of MRP and GST-π may synergistically result in increased 
drug resistance of advanced prostate cancer. 
Another study reports expression of drug-metabolizing enzymes cytochrome 
P450 subfamilies CYP1A, CYP2C, CYP3A, GST-α and GST-µ[85] in prostate cancer.
Chemosensitization
In prostate cancer reversal of MDR by challenging the glutathione pathway has 
been successfully performed in vitro in only few studies. Ripple et al.[87] reported 
reversal of melphalan resistance of MDR LNCaP sublines by depletion of glutathi-
one with D,L-buthionine-(S,R)-sulfoximine (BSO). Van Brussel et al. demonstrated 
chemosensitization of MDR PC3 and DU145 derivatives with a similar approach 
[78]. Further in vivo and eventually clinical studies are warranted to clarify the im-
portance of glutathione-aiming strategies in prostate cancer.
Reversal of MDR that is related to increased glutathione- and glutathione-S-
transferase content and activity can be achieved by lowering intracellular con-
centrations of GSH by blocking the GSH biosynthesis with glutathione synthesis 
inhibitors, such as diethylmaleate, vitamin K3, sodiumselenite and BSO. BSO, which 
does not inhibit the glutathione-S-transferase but gamma-glutamyl-cystein-syn-
thetase, occurring earlier in the GSH metabolism, may be advantageous as it has 
fewer neurotoxic eff ects. BSO has been used successfully in vivo[70] and clinically 
in a phase I trial[88]. A putative role for the glutathione metabolism in prostate can-
cer is of importance, especially in the context of MRP expressing prostate cancer. 
Chemosensitization strategies combining GSH depletion and MRP blocking are the 
subject of current investigations and may ameliorate the results of chemotherapy 
in clinical prostate cancer. 
Figure 2.2 represents a schematic overview of glutathione-synthesis-related 
multidrug resistance.
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Figure 2.2.
Glutathione-synthesis-related multidrug resistance
Model of the glutathione-mediated detoxifi cation pathway. Oxidizing compounds are conjugated to reduced glutathione. Glutathione-S-
transferases mediate the energy-dependent extrusion of cytotoxic compounds by the multidrug resistance associated protein, MRP. Diff erent 
approaches can be applied to reverse multidrug resistance. Detoxifi cation can be blocked by depleting intracellular glutathione, with, for 
example, buthionine sulfoximine (BSO). BSO irreversibly inhibits the gamma-glutamyl-cysteine synthetase enzyme, which is essential 
for synthesis of glutathione. Another approach would be to inhibit the action of MRP. Such strategies will eventually lead to intracellular 
accumulation of cytotoxic drugs, resulting in cell death. NADP+, nicotinamide adenine dinucleotide phosphate, oxidized form; NADPH, 
nicotinamide adenine dinucleotide phosphate, reduced form.
APOPTOSIS
The phenomenon of apoptosis, also called programmed cell death, has received 
a great deal of attention. It is widely appreciated that changes in the regulatory 
processes of apoptosis contribute to the malignant phenotype of cancer cells. Im-
portantly, as many cytotoxic agents act through induction of apoptosis, alterations 
in apoptotic processes contribute to the multidrug resistant phenotype of malig-
nancies[89]. Many molecular regulators of cell death have been discovered and 
several mechanisms have been identifi ed in prostate cancer. Alterations of proteins 
regulating the apoptotic cascade, such as Bcl-2[90] and Bax[91] may cause a broad 
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spectrum of drug resistance. Upregulation of Bcl-2 and/ or downregulation of its 
counterpart Bax prevent cells from entering programmed cell death. Wild-type 
p53 is a suppressor of cell growth and transformation, causing a proliferation-in-
hibiting G1 block and regulating apoptosis. Mutation of the p53 gene is the most 
common molecular alteration in cancers resulting in decreased apoptosis and pos-
sibly resistance to apoptosis-inducing cytotoxic agents[92]. Bcl-2, which has been 
identifi ed as a powerful inhibitor of apoptotic cell death, appears to be expressed 
at low levels in low grade prostate carcinoma and at higher levels in high grade 
tumours[93]. Accordingly, Bcl-2 expression was increased in clinical hormone 
independent prostate cancers as compared to organ confi ned cancers[23]. Bcl-2 
expression in prostate cancer has previously been related to the androgen inde-
pendent phenotype[94; 95]. Relatively high Bcl-2 levels may promote cell survival 
and protect androgen independent prostate cancer cells from drug-induced apop-
tosis[96-98]. Bax, a pro-apoptotic protein, has been found to be well expressed in 
prostate cancer [93]. In a study on clinical prostate cancer Bax is equally and ho-
mogeneously expressed in normal prostate and prostate cancer cells in all phases 
of progression[24]. Correlation between p53 mutations and tumour progression 
has been presented in several studies, with mutations occurring as a late event 
in the development of prostate cancer[99-101]. This is in concordance with our 
fi nding of more frequently occurring p53 expression in advanced disease[23], 
which may explain the decreased susceptibility to apoptosis-inducing agents. We 
observed a signifi cantly increased number of p53 positive patients in hormone 
independent cancers. Also, p53 expression was statistically signifi cantly related 
to a higher histological grade. These fi ndings should be interpreted cautiously as 
immunohistochemical expression of p53 does not necessarily represent p53 muta-
tion[102]. Interestingly, transfection of a temperature sensitive p53 mutant into 
the LNCaP human prostate cancer cells produced a time-dependent increase in 
MRP1. Mutant p53 and increased MRP1 were related to drug accumulation and 
decreased drug sensitivity[103] . Apart from bcl-2 and p53, several other molecular 
alterations have been documented in prostate cancer, as reviewed by Bruckheimer 
[104] involving the androgen receptor and cell-cycle regulatory genes such as the 
retinoblastoma suppressor gene, c-myc and p21. Ras gene family mutations may 
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contribute to the pathogenesis of prostate cancer. Loss of heterozygosity and al-
terations in newly identifi ed tumour suppressor genes such as PTEN/MMAC1 may 
infl uence apoptosis in prostate cancer. The implication of these genetic changes 
for MDR of prostate cancer remains to be determined. Another important factor in 
the apoptotic chain is Fas, a member of the nerve growth factor/tumour necrosis 
factor receptor superfamily. It is present in benign and malignant prostate[105] 
and induces cell death. Disruption of the Fas/Fas ligand signaling pathway may 
result in acquired MDR[105]. Activation of protein kinase C (PKC) induces apoptosis 
in prostate cancer cells [106] and therefore pharmacological manipulation of PKC 
may be of interest in MDR prostate cancer.
Chemosensitization
Countering of Bcl-2 related MDR may become applicable in the future possibly by 
the development of small-molecule pharmaceuticals that can disrupt Bcl-2/Bax 
interactions and thus abrogate Bcl-2 protein function[107]. Sequence-specifi c 
down-regulation of Bcl-2 expression has been reported in vitro in lymphoma cell 
lines and AML cells using synthetic antisense oligonucleotides, showing that de-
creased expression of the Bcl-2 protein can result in markedly enhanced sensitivity 
to chemotherapeutic drugs[108]. Antisense approaches to down-regulation of 
Bcl-2 function in prostate cancer are feasible. Reduction in Bcl-2 protein levels in 
LNCaP cells by Bcl-2 antisense oligonucleotides resulted in enhanced sensitivity to 
the cytotoxic drug etoposide[109]. Another study treated Shionogi tumour cells 
with antisense bcl-2 oligonucleotides resulting in downregulation of bcl-2 expres-
sion and chemosensitization to taxanes in this model for androgen independent 
prostate cancer[110]. These fi ndings demonstrate that agents that diminish Bcl-
2 levels could possibly be used as chemosensitizers in the treatment of prostate 
cancer. Alternatively, it has been observed that certain lymphokines and retinoids 
can regulate the expression of the Bcl-2 gene and sensitize to antineoplastic drugs 
(reviewed by Reed[90]), rendering cancer cells more prone to induction of apopto-
sis by chemotherapeutic drugs. Paclitaxel, vinblastine and docetaxel induces bcl-2 
phosphorylation-associated apoptosis in bcl-2 expressing PC3 prostate cancer 
32
C
ha
pt
er
 2
cells [111; 112]. Other chemotherapeutic agents, such as mitomycin, actinomycin 
D, doxorubicin and etoposide do not induce bcl-2 phosphorylation[113]. The com-
bination of 13-cis-retinoic acid (CRA) and interferon-α (IFN-α) is cytotoxic in tumour 
cells that overexpress bcl-2 and reduces the expression of bcl-2, overcoming bcl-2 
mediated resistance [114; 115]. Clinical studies on this regimen combined with 
taxanes are currently underway[118]. Bax, Akt/P13K, BH3 peptides, Fas, NF-κB are 
targets in the apoptotic pathway that are under investigation[117]. With increased 
knowledge of apoptosis at the molecular level, it may be possible to develop novel 
approaches for cancer therapy that specifi cally aim at modulating the physiologic 
programmed cell death pathway. Apoptosis is likely to play an important role in 
prostate cancer and the development of apoptosis stimulating techniques may be 
of particular importance for the treatment of advanced prostate cancer.
Figure 2.3 represents a schematic overview of Bcl-2 related multidrug resistance.
Figure 2.3.
Bcl-2 related multidrug resistance.
Scheme of modulation of apoptosis (programmed cell death). Bcl-2 and bax form heterodimers. The ratio of Bcl-2 qnd bax determines the 
relative sensitivity of cells to apoptosis induced by chemotherapy. When the balance is shifted to Bcl-2, cell death is less likely to occur. Excess 
of bax leads to induction of apoptosis. Reversal of inhibition of apoptosis by increased levels of Bcl-2 can be achieved by Bcl-2 antisense 
oligonucleotide treatment. This results in enhanced apoptosis induced chemotherapy.
TOPOISOMERASES
The nuclear topoisomerase enzymes are targets for several cytotoxic drugs. Topoi-
somerases are involved in multidrug resistance through down-regulation of ex-
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pression or decreased enzymatic activity[118].This type of resistance was termed 
altered- or attenuated topoisomerase MDR[119] (at-MDR).
Changes in expression and activity of DNA topoisomerases may underlie the 
multidrug resistance phenotype of prostate cancer and further investigations will 
have to clarify this issue. Topoisomerase isoforms are at least partially regulated by 
testosteron in rat ventral prostate and may play a role in cellular proliferation[120]. 
Topoisomerase IIα expression is correlated with Gleason score in clinical prostate 
cancer. In our studies on clinical prostate cancer[23] expression of Topo IIα is sig-
nifi cantly increased in progressive disseminated prostate cancer and tumours with 
a higher histological grade. The Topo IIα enzyme is known to be related to cell pro-
liferation as well[121]. We found strong correlation between Topo IIα expression 
and expression of the proliferation marker Ki-67. This marker was demonstrated 
to be signifi cantly increased in the group of advanced prostate cancers and in 
tumours with a higher histological grade. A relation between proliferative activity 
and a more progressive phase of disease has been reported previously[122-124]. 
Increased expression of Ki-67 and Topo IIα in advanced prostate cancer possibly 
refl ects the more aggressive character of these tumours. Expression of the isoforms 
topo I and Topo IIβ is high and homogeneous in every phase of prostate cancer pro-
gression and is slightly increased in advanced disease. Topo IIβ negative tumours 
had a signifi cantly lower histological grade. Increased expression of topoisomer-
ases does not directly point towards a role for at-MDR in advanced prostate cancer. 
High expression of topoisomerases in end-stage prostate cancer may favour the 
introduction of topoisomerase targeting agents. However, effi  cacy of such drugs 
may be hampered by increased drug effl  ux and detoxifi cation through MRP and 
GST-π and by inhibition of apoptosis through the presence of p53 mutations and 
an increased Bcl-2/Bax ratio.
Chemosensitization
Sensitivity of the cancer cells to topoisomerase targeting drugs is thought to be 
related to the level- and activity of topoisomerase in the nucleus and the relation 
between Topoisomerase quantity and -activity and drug resistance has been shown 
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in several tumours[125; 126]. Several options for challenging Topoisomerase re-
lated drug resistance and improvement of topoisomerase directed chemotherapy 
have been proposed: increasing effi  cacy of established topo directed drugs by 
prolonged drug exposure or combination therapy and modulations leading to up-
regulation of topoisomerase levels and activity resulting in increased susceptibility 
to topoisomerase targeting drugs. Selection of a prostate cancer cell line for 9-
nitrocamptothecin resistance resulted in altered topoisomerase IIα activity and in-
creased sensitivity to etoposide[127]. Topoisomerase I and II targeting drugs have 
been applied in prostate cancer therapy. Pienta et al.[128] reported inhibition of 
prostate cancer growth by estramustine and etoposide (a topoisomerase II drug), 
acting synergistically at the nuclear matrix. Topotecan (a topo I drug) had limited 
activity in patients with hormone refractory prostate cancer. Alternative schedules 
of topotecan (e.g., prolonged infusion) or other camptothecin analogs with more 
potent topoisomerase inhibitory activity should be investigated[129]. Husain et 
al.[130] reported elevated Topo I quantity and activity in samples of prostatic ad-
enocarcinoma compared to normal tissue, implicating that Topoisomerase I may 
be a feasible target for chemotherapy and that Topoisomerase I directed drugs 
may be selectively cytotoxic to prostate cancer cells. Currently chemotherapy with 
mitoxantrone and prednisone is applied in patients with symptomatic hormone-
resistant prostate cancer to provide palliation. Two studies using mitoxantrone and 
a glucocorticoid demonstrated this regimen to be importance in prostate cancer 
patients. In the fi rst study[131], 38% of the mitoxantrone plus prednisone group 
had a palliative response versus 21% of the group receiving prednisone alone. 
There was no signifi cant diff erence in median survival between the two groups. In 
39% of the patients with available PSA data the mitoxantrone arm had evidence of 
response. In the second study[132] there was improvement in pain control in the 
chemotherapy arm as well as a delay in time-to-treatment failure and disease pro-
gression in the chemotherapy arm, but no diff erence in overall survival between 
the two arms.
Alternatively, estramustine and either a microtubule inhibitor such as paclitaxel 
or docetaxel, or a topoisomerase inhibitor such as etoposide is applied to treat 
patients with advanced metastatic prostate cancer[133]. Estramustine consists of 
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nornitrogen mustard bound to estradiol and was initially developed to deliver the 
nornitrogen mustard to estrogen receptor-positive prostate tumour cells. It was 
found to work primarily by inhibiting microtubules synergistically with taxanes or 
vinca alkaloids. Combination with taxanes appears to be the fi rst choice. Estramus-
tine has also been examined in combination with etoposide, a topoisomerase II in-
hibitor[134]. It shows a 50% tissue response and a 52% PSA response. A three-drug 
regimens was also studied combining estramustine, etoposide, and paclitaxel, 45% 
of patients had a measurable disease response and 65% had a PSA response[135]. 
Two recent randomized clinical trials have reported on a two to four month survival 
benefi t with combination therapies of docetaxel and prednisone or docetaxel and 
estramustine as compared to topoisomerase I inhibitor mitoxantrone and pred-
nisone, respectively. Taxane docetaxel, phosphorylates Bcl-2 in vitro. This results 
in its inactivation and, eventually, to programmed cell death[136]. Interestingly, 
anti-apoptotic Bcl-2 is increased in advanced prostate cancer. Docetaxel was stud-
ied earlier in vivo on doxorubicin resistant multidrug resistance protein express-
ing HT1080/DR4 tumour xenografts (sarcoma). It showed signifi cant anti-tumour 
activity and it was suggested that docetaxel may not as readily be transported by 
the multidrug resistance protein as paclitaxel. Therefore, docetaxel potentially has 
therapeutic advantages in the treatment of multidrug resistance protein express-
ing tumours[137].
Topoisomerase drug action fi nally triggers mechanisms leading to programmed 
cell death or apoptosis. Factors that inhibit apoptosis include p53 mutation and 
/or Bcl-2 overexpression and can at least partially be responsible for the ineff ec-
tiveness of several topoisomerase directed cytotoxic agents in prostate cancer. 
However, several authors[138; 139] reported that β-Lapachone eff ectively induced 
apoptosis in prostate cancer cell lines and that apoptosis is independent of p53 ex-
pression. Furthermore, overexpression of Bcl-2 did not confer signifi cant resistance 
to β-Lapachone. Altogether, β-Lapachone may be of importance for the treatment 
of advanced prostate cancer. However, no clinical data on this approach have been 
published until now.
Figure 2.4 represents a schematic overview of attenuated- or altered topoisom-
erase mediated multidrug resistance (at-MDR). 
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2.4a
2.4b
Figure 2.4.
Attenuated- or altered topoisomerase mediated multidrug resistance (at-MDR)
(A) The mode of action of topoisomerase enzymes: 1) binding to and cleaving of strands of DNA; 2) passage of another strand of DNA through 
the gap; 3) resealing of the broken DNA. The conformational changes of DNA are essential for many nuclear processes. (B) A topoisomerase-
targeting drug can either irreversibly stabilize complexes of toposiomerase and the broken DNA (as done by etoposide), or directly inhibit 
the enzymatic action of topoisomerase (as done by an intercalator). Approaches to increase the effi  cacy of anti-topoisomerase poisons are 
prolonged drug exposure, combination therapy and modulations resulting in upregulation of topoisomerase levels and activity, which increases 
susceptibility to targeting drugs. Using drugs that directly inhibit topoisomerase catalytic activity when at-MDR is due to low topoisomerase 
expression is another option.
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CONCLUSION
Metastatic hormone-independent prostate cancer remains a major oncological 
challenge. However, basic and clinical research have provided insight into underly-
ing mechanisms of drug resistance and further study of possibilities to circumvent 
this resistance, innovative use of established drugs and development of more 
potent antineoplastic agents will remain of the utmost importance. Modulation of 
MDR in prostate cancer is the subject of current studies and promising results were 
obtained in vitro and in vivo. Clinical relevance of modulation strategies are and 
will be the subject of investigation. Attempts at challenging progressive hormone 
independent prostate cancer more successfully are still experimental and should 
be carried out within the setting of controlled clinical studies.
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CHAPTER 3
Chemosensitivity of prostate cancer cell lines 
and expression of multidrug resistance related 
proteins
van Brussel JP, van Steenbrugge GJ, Romijn JC, 
Schröder FH, Mickisch GHJ.
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SUMMARY
Purpose: The aim of this study was to obtain insight in the role of the multidrug 
resistance (MDR) phenomenon in hormone-independent progressive prostate 
cancer.
Material and methods: Using immunocytochemistry and Western blotting we 
determined expression of P-glycoprotein (Pgp), Multidrug resistance associ-
ated protein (MRP), Glutathione-S-transferase-π (GST-π), Bcl-2, Bax, Topoisomerase 
(Topo) I, IIα and IIß in the human prostate cancer cell lines PC3, TSU-Pr1, DU145 and 
LNCaP derivatives -R, -LNO and -FGC. Proliferative activity was assessed by immu-
nocytochemistry. MTT assays were used to determine the sensitivity to Etoposide, 
Doxorubicin and Vinblastine.
Results: Pgp was not expressed in any of the cell lines. MRP was variably expressed. 
GST-π was expressed in TSU-Pr1, PC3 and DU145. Expression of Bcl-2 was restricted 
to TSU-Pr1, whereas Bax was found in all cell lines. Topo IIα was expressed at the 
highest level in the rapidly proliferating cell lines TSU-Pr1 and DU145. Topo I and 
IIß were equally expressed. Resistance profi les varied among the cell lines, with 
TSU-Pr1 being the most sensitive and LNCaP-LNO relatively resistant.
Conclusions: Multiple MDR proteins are expressed in prostate cancer cell lines 
and may well infl uence response to chemotherapy. Future functional studies, us-
ing chemo-selected MDR models, may further help to determine the mechanism 
or combination of mechanisms underlying the resistance of prostate cancer to 
chemotherapy.
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INTRODUCTION
Prostate cancer is the most common cancer in men and one of the leading causes 
of cancer death [1]. Metastatic disease is a major oncological problem and is not 
curable, but palliation can be achieved by hormonal deprivation therapy [2]. How-
ever, prostate cancer patients will relapse at some stage in time, in majority within 
one to two years after start of endocrine therapy. After failure of hormonal therapy, 
there are no successful treatment strategies available with respect to prolongation 
of survival and patients will die of progressive, hormone independent disease after 
an average period of 40 weeks after relapse [3]. 
Hormone-independent prostate cancer is resistant to a broad range of anti-
neoplastic agents [4], which may be caused by the fact that large proportions of 
prostate cancer cells are in interphase [5]. Also, multidrug resistance (MDR), the 
resistance of cancer cells to a variety of structurally and functionally distinct cyto-
toxic agents, may play an important role in progressive therapy resistant prostate 
cancer. However, the role of MDR in prostate cancer remains to be elucidated. 
A better understanding of mechanisms underlying in the resistance of prostate 
cancer to chemotherapy may lead to novel approaches to challenge hormone un-
responsive prostate cancer more successfully.
We determined the expression of eight multidrug resistance associated proteins 
in prostate cancer cell lines derived from patients with progressive disease: the 
drug transporter molecules P-glycoprotein (Pgp) [6] and Multidrug Resistance as-
sociated Protein (MRP) [7], the detoxifying enzyme Glutathione-S-Transferase-π 
(GST-π) [8], modulators of apoptosis Bcl-2 [9] and Bax [10] and the enzymes Topoi-
somerase (Topo) I, IIα and IIβ, which are related to one form of MDR: atypical- or 
attenuated MDR [11].
Furthermore, we measured response of the cell lines to treatment with the cyto-
toxic agents Etoposide, Doxorubicin and Vinblastine, which are commonly used in 
the treatment of several malignancies and have been used to challenge prostate 
cancer in clinical trials.
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MATERIALS AND METHODS
Cell lines and culture conditions
The human prostate cancer cell lines PC3 [12], TSU-Pr1 [13], DU145 [14] and LNCaP 
sublines that were established from the original LNCaP line [15]: the androgen 
dependent FGC (available through the ATCC), the hormone unresponsive R line 
[16] and the hormone independent LNO line [17] were maintained at 37oC in 5% 
CO2-95% air atmosphere. PC3, TSU-Pr1, DU145, LNCaP-R and LNCaP-FGC were 
cultured in RPMI 1640 medium, supplemented with 7,5% foetal calf serum (FCS), 
penicillin 1 unit/ml, streptomycin 1 µg/ml and glutamine 2 mM (GibcoBRL). The cul-
ture medium for LNCaP-LNO contained 5% Dextran coated charcoal (DCC) treated 
(androgen depleted) serum, instead of FCS. All cell lines were repeatedly tested for 
Mycoplasma by polymerase chain reaction and proven to be free of infection.
Antibodies
For detection of Pgp the mouse monoclonal antibody JSB1 (Sanbio, the Neth-
erlands) was used. MRP was detected with the rat monoclonal antibody MRPr1 
(Sanbio), GST-π with the rabbit polyclonal antibody NCL-GST-π (Novocastra, United 
Kingdom), Bcl-2 with mouse monoclonal antibody Bcl-2 (100) (Santa Cruz Biotech-
nology, Inc, CA, USA), Bax with rabbit polyclonal antibody Bax (P-19) (Santa Cruz 
Biotechnology), Topo I with the human Scl-70 antibody (Topogen, Inc, Columbus, 
Ohio), Topo IIα with the mouse monoclonal antibody Ki-S1 (Boehringer Mannheim, 
Germany). Topo IIβ was detected with a polyclonal rabbit antibody (Biotrend, Köln, 
Germany) for Western blotting and the monoclonal mouse antibody 3H10 (a kind 
gift of Dr. I. Hickson, Cambrigde, United Kingdom) for immunocytochemistry. 
BrdU was detected with the mouse monoclonal antibody 2B5 (Eurodiagnostics, 
the Netherlands). Horseradish peroxidase (HRP)-conjugated secondary antibodies 
were all purchased from Dako (Glostrup, Denmark).
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Antineoplastic drugs
For in vitro testing, drug solutions were freshly prepared in culture medium. The 
following compounds were tested: Etoposide (VP-16) (Pharmachemie BV, Haarlem, 
the Netherlands), Doxorubicin (DOX) (Farmitalia Carlo Erba, Italy) and Vinblastine 
(VBL) (Lilly, France). 
MTT assay
Sensitivities of all cell lines to the antineoplastic drugs were assessed by the MTT 
assay [18]. Cell lines were plated in 96-well plates (Costar Corp. Cambridge, MA, 
USA) at densities allowing logarithmic growth throughout the experiments. After 
allowing cells to attach for 24 hours, proliferating cells were incubated with culture 
medium containing a range of exponentially increasing concentrations of cytotoxic 
agents for a period of 72 hours. Subsequently, 30 µl of MTT (Sigma Chemical Co., St. 
Louis, MO, USA) solution (5 mg/ml in PBS) was added to each well and incubated 
for 4 hours at 37oC. The supernatant was carefully aspirated and 100 µl of dimeth-
ylsulfoxide (DMSO, Merck, Darmstadt, Germany) with alkalinizing buff er (0.1 M 
Glycin, 0.1 M NaCl, pH 10.5) was added to each well. The plates were shaken for 5 
minutes in order to dissolve the formazan crystals. The absorbance was measured 
photometrically at 570 nm using a Bio-Rad Microplate Reader (Model 450, Bio-Rad, 
CA, USA). The percentage of viable cells was calculated relative to untreated cells. 
All assays were done in triplicate. IC50 values for the separate drugs were calculated 
from the dose response curves by interpolation. Standard errors were calculated 
from the square root of the variance as determined with the Delta method [19].
Western blotting
Whole cell lysates were prepared from near-confl uent cell cultures (1 x 106 cells). 
Separate optimalized protocols were used for preparation of lysates for detec-
tion of Pgp and MRP, GST-π, Bcl2 and Bax and for Topoisomerase I, IIα and IIß. For 
topoisomerase detection cells were scraped and resuspended in lysis buff er (10 
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mM Tris-HCl, 1 mM MgCl2, 0.1 mM CaCl2, pH 7.8) containing protease inhibitors 
(phenylmethylsulfonylfl uoride 1mM, benzamidine 1 mM, Soy bean trypsin inhibi-
tor 10 µg/ml, leupeptin 50 µg/ml, pepstatin 1 µg/ml, aprotinin 20 µg/ml; all from 
Sigma) and put on ice for 20 minutes. Then 120 units of DNase I (Sigma) were 
added and incubated for 20 minutes at 37oC. For Bcl-2 and Bax detection cells were 
scraped and resuspended in another lysis buff er (10 mM Tris-HCl, 150 mM NaCl, 
1% Triton X100, 1% deoxycholate, 0.1% SDS, 5 mM EDTA, pH 7,4) supplemented 
with the fore-mentioned protease inhibitors. The suspension was kept on ice for 15 
minutes, subsequently centrifuged (14000 rpm) for 20 minutes at 4oC, whereafter 
the supernatant was recovered. For Pgp and MRP detection harvested cells were 
resuspended in lysis buff er (10 mM KCl, 1.5 mM MgCl2, 10 mM Tris-HCl, 0.5 (w/v) 
SDS, pH 7.4) supplemented with protease inhibitors. DNA was sheared by sonifi ca-
tion. For GST-π, near-confl uent cultures where trypsinized and homogenized in 2.5 
mM Tris-HCl buff er (pH 7.5) containing 0.25 mM EDTA, 1.25 mM EGTA and 31.3 mM 
sucrose. After two serial centrifugation steps of 10 minutes at 1000 g and 1 hour at 
105000 g the supernatant was recovered. Protein concentrations were measured 
(Bio-Rad Protein assay, Bio-Rad). All cell lysates were stored at -80oC. Whole cell 
lysate samples (40 µg protein) with Laemmli buff er [20] (15 µl) were fractioned 
onto a 10% SDS-polyacrylamide gel after boiling for 2 minutes (except the Pgp and 
MRP lysates) and electrophoresed for 45 minutes at 200 volts. Prestained markers 
(Novex, San Diego, CA, USA) were used as size standards. Proteins were transferred 
to a nitrocellulose membrane (Protan Nitrocellulose, Schleicher & Schuell, Dassel, 
Germany) by electroblotting at 100 volts. Membranes were blocked for 1 hour with 
Tris buff ered saline (TBS, pH 7.5) containing 1% blotting substrate (Boehringer 
Mannheim). Separate membranes were incubated overnight at 4oC with antibod-
ies directed to the specifi c MDR proteins. After washing with TBS containing 0.1% 
Tween 20 (Sigma), the membranes were incubated with the appropriate peroxi-
dase-conjugated secondary antibodies (see antibodies section in materials and 
methods). Protein bands were visualized by chemiluminescence. After incubation 
with detection solution (Boehringer Mannheim) X-ray fi lm (Fuji photo fi lm, Tokyo, 
Japan) was exposed and developed.
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Immunocytochemistry
Cells were grown on 3-aminopropyl-trietoxysilane (Sigma) coated glass slides until 
semi-confl uent cultures were obtained. For BrdU staining, cells were incubated 
with bromo-deoxy-uridine (BrdU, Sigma) for 2 hours. After fi xation in acetone 
(Pgp), 3.7% paraformaldehyde (MRP, GST-π, Bcl-2, Bax, Topo I, IIα and IIβ) or 70% 
ethanol (BrdU), endogenous peroxidase activity was blocked with 1% hydrogen 
peroxide (Merck) in 100% methanol. For BrdU detection, slides were incubated 
with 2N HCl followed by 0.1M Borax buff er, whereafter the slides were placed in a 
humid incubator (Sequenza, Shandon, United Kingdom) and incubated with nor-
mal goat- or rabbit serum (Dako) diluted 1:10 in PBS/ 5% bovine serum albumine 
(Sigma). Subsequently, slides were incubated overnight with antibodies directed 
against Pgp, MRP, GST-π, Bcl-2, Bax, Topo I, Topo IIα ,Topo IIβ and BrdU, respectively. 
For Pgp-, Bcl-2, Topo IIα and Topo IIβ the peroxidase-anti-peroxidase (mouse-PAP, 
Dako) method was applied to increase staining sensitivity. Slides were incubated 
with appropriate horseradish peroxidase-conjugated secondary antibodies (all 
from Dako) and the antigen-antibody binding was visualized with 0.075% 3,3'-
diaminobenzidine-tetrahydrochloride (Fluka, Germany) and 0.25% hydrogen per-
oxide in PBS. The slides were counterstained with hematoxylin, dehydrated and 
covered. Negative controls were included for all stainings by replacing the primary 
antibody by PBS.
RESULTS
Chemosensitivity assay
Drug-induced inhibition of human prostate cancer cell growth by the anticancer 
agents Etoposide, Doxorubicin and Vinblastine was established in vitro. Growth of 
the cell lines during the assay, defi ned as the optical density (OD) value after 72 
hours divided by the OD value after plating of the cells, was 5.4, 2.6, 3.3, 1.5, 3.3 
and 3 for TSU-Pr1, LNCaP-FGC, PC3, LNCaP-LNO, LNCaP-R and DU145, respectively. 
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This indicates that drug testing was performed under the condition of cell lines 
in proliferative growth. Dose response curves of each cell line for the three drugs 
tested are shown in fi gure 3.1 and IC50 values are given in Table 3.1. The cell 
lines showed a variable response to a 72-hour exposure to Etoposide: TSU-Pr1 was 
the most sensitive, followed by DU145 and LNCaP-FGC. PC3 had an intermediate 
pattern of response, whereas LNCaP-LNO and -R were relatively insensitive (fi g 
3.1a). The sensitivity profi les of the cell lines with Doxorubicin were similar to those 
found for Etoposide, as shown in fi gure 3.1b. The MTT assay with Vinblastine (fi g 
3.1c) showed that TSU-Pr1 is the most sensitive followed by PC3 and DU145. The 
LNCaP derivatives were less sensitive: LNCaP-FGC was nearly as sensitive as DU145, 
but LNCaP-R was two-fold more resistant and LNCaP-LNO was relatively insensitive 
to Vinblastine.
Table 3.1. IC50 values of human prostate cancer cell lines as determined with the MTT assay.*
TSU-Pr1 LNCaP-FGC PC3 LNCaP-LNO LNCaP-R DU145
Etoposide (µg/ml) 0.48 ± 0.05 1.9 ± 0.14 6.1 ± 0.15 21 ± 0.4 16 ± 0.6 3.6 ± 0.1
Doxorubicin 
(ng/ml)
7.2 ± 0.2 16.7 ± 0.2 176 ± 7.4 272 ± 4.5 222 ± 10 41 ± 2.5
Vinblastin (ng/ml) 0.5 ± 0.01 1.8 ± 0.2 0.8 ± 0.02 35 ± 2 2.4 ± 0.2 1.2 ± 0.1
* IC50 values are calculated by interpolation, standard errors of the mean are calculated by taking the square root of the variance of the IC50 
value as determined by the Delta method [19].
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Figure 3.1. Dose response curves of human prostate cancer cell lines TSU-Pr1, LNCaP-FGC, PC3, LNCaP-LNO, LNCaP-R and DU145 after 72 hours 
of exposure to (a) Etoposide, (b) Doxorubicin and (c) Vinblastine. Values are given as percentage of the untreated controls. Y-axis, percentage of 
viable cells as calculated relative to untreated controls (n=24), x-axis, concentrations of the drug solutions on a log scale.
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Western Blotting 
Pgp, MRP, GST-π, Bcl-2, Bax, Topo I, IIα and IIß were detected by immunoblotting 
of total cell lysates. All experiments were performed in triplicate and reproduc-
ible results were obtained. Representative protein bands are shown in fi gure 3.2. 
Expression of Pgp was below detection level in all cell lines. The Pgp positive, 
multidrug resistant cell line RC21E [21], served as positive control and was run on 
the same gel. MRP was variably expressed, but at much lower level than in the 
control sample, the human multidrug resistant lung cancer cell line GLC4/ADR [22] 
(not shown). GST-π is clearly expressed in the cell lines TSU-Pr1, PC3 and DU145 , 
whereas the LNCaP-FGC, -LNO and -R had no detectable levels of GST-π, with the 
colon carcinoma cell line HT-29 [23] serving as positive control. Expression of Bcl-2 
was restricted to TSU-Pr1, whereas Bax was found in all cell lines. Bcl-2 expression 
in TSU-Pr1 was low in comparison to Chinese hamster ovary cells transfected with 
Bcl-2 (kindly provided by Dr H. Burger, Department of Oncology, Erasmus Univer-
sity, the Netherlands), which was run on the same gel. The topoisomerase proteins 
were expressed in all cell lines. The topoisomerase IIα isoform was most clearly 
expressed in the rapidly proliferating cell lines TSU-Pr1 and DU145. The IIβ isoform 
was uniformly expressed in all cell lines. which also applied to the Topoisomerase 
I protein.
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Figure 3.2. Expression of multidrug resistance proteins P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP), glutathione-S-
transferase-π (GST-π), Bcl-2, Bax, topoisomerase (Topo) I, IIα and IIβ in the human prostate cancer cell lines TSU-Pr1, LNCaP-FGC, PC3, LNCaP-
LNO, LNCaP-R and DU145 as determined by Western blotting of total cell lysates. Bands represent protein expression. Positive controls are shown 
for Pgp (RC21E), GST-π (HT-29) and Bcl-2 (CHO-Bcl-2) detection and were run on the same gel.
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Immunocytochemistry
In addition to Western blot analysis, cultured prostate cancer cells were analyzed for 
the expression of the same multidrug resistance proteins by immunocytochemical 
staining. Nearly confl uent cultures of all cell lines were stained with antibodies di-
rected against the MDR proteins. A selection of the immunocytochemical stainings 
is shown in fi gure 3.3 The immunocytochemical stainings matched the Western 
Blotting results well. All prostate cancer cell lines were negative for Pgp (A), whereas 
RC21E control cells were clearly Pgp positive, with evident cell membrane-bound 
localization (not shown). MRP was expressed in all cell lines, demonstrated as a 
cytoplasmatic staining (B). GST-π stained positively in cell lines TSU-Pr1, PC3 (C) 
and DU145 and showed a reticular cytoplasmatic pattern and nuclear staining. Bcl-
2 was only expressed at a low level in TSU-Pr1. The other cell lines showed some 
staining of mitotic cells (D). All cell lines were Bax positive (E). Topo I was present 
in the nuclei of all cell lines, with prominent nucleolar staining (F). Also, a light 
cytoplasmatic background staining was observed. Nuclear and nucleolar topoi-
somerase IIα was present in all cell lines but varied between cell lines. DU145 (G) 
and TSU-Pr1 cells stained intensely in comparison to the other cell lines. Topo IIα 
expression was compared to bromo-deoxy-uridine incorporation of cells (I) during 
the S phase of the cell cycle (see table 3.2). The BrdU staining results corresponded 
well with the proliferative status of cells as observed during the MTT assay. Topo IIα 
expression appears to be related to the proliferative activity of most of the prostate 
cancer cell lines. Topo IIβ was expressed in all cell lines with predominant granular 
staining of the nuclei and absence of staining of nucleoli (H) and was expressed in 
the majority of the cells.
Table 3.2.  Percentages of cells staining positively for Topoisomerase IIα (Topo IIα) and bromo-deoxy-uridine (BrdU) as determined by 
immunocytochemistry.
TSU-Pr1 LNCaP-FGC PC3 LNCaP-LNO LNCaP-R DU145
Topo IIα 68 40 80 48 33 87
BrdU 41 17 32 18 27 43
Chemosensitivity of prostate cancer cell lines and multidrug resistance related proteins 59
Figure 3.3. Immunocytochemical staining of P-glycoprotein (Pgp) in PC3 (A) , multidrug resistance-associated protein (MRP) in PC3 (B), 
glutathione-S-transferase-π (GST-π) in PC3 (C), Bcl-2 in PC3 (D), Bax in PC3 (E), topoisomerase (Topo) I in DU145 (F), Topo IIα in DU145 (G), Topo 
IIβ in DU145 (H) and bromodeoxyuridine (BrdU) in DU145 (I) (magnifi cation 400x).
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DISCUSSION
To gain insight into the mechanisms involved in the resistance of metastatic hor-
mone independent prostate cancer against chemotherapy we determined the ex-
pression of multidrug resistance proteins, which may lead to the MDR phenotype, 
in prostate cancer cell lines. Furthermore, we assessed the resistance profi les to 
three commonly used antineoplastic agents, Etoposide, Doxorubicin and Vinblas-
tine, which action is aff ected by multidrug resistance. 
MDR proteins expression
We found that expression of Pgp, the energy-dependent drug transporter molecule, 
was below detection level in all cell lines. Expression of Pgp in the human prostate 
cancer cell lines PC3 and DU145 has been reported in one study [24], albeit at low 
levels. Doxorubicin resistant cell lines derived from the Dunning R3327 rat prostate 
carcinoma model [25] expressed Pgp as well [26]. In contrast, Mickisch et al. [27] 
reported that MDR1 mRNA was undetectable in prostate cancer cell lines LNCaP 
and DU145. Exposure of non-MDR1 expressing prostate carcinoma cells to Pgp tar-
geted-immunoconjugates harbouring Pseudomonas exotoxin did not aff ect these 
cells, whereas Pgp expressing renal cell cancer cell lines were killed. Goldstein et 
al. [28] were also unable to detect Pgp in clinical prostate cancer or prostate cancer 
cell lines. The generally negative results for Pgp suggest that Pgp is probably not 
signifi cantly involved in MDR of prostate cancer.
MRP, the multidrug resistance associated protein, which acts as a transporter 
molecule for glutathione-S-conjugates [22], was variably expressed at low levels 
compared to the MRP overexpressing cell line GLC4/ADR. Little is known about 
expression and function of the drug-transporter MRP in prostate cancer. Low ex-
pression levels have been reported in clinical prostate cancer samples by Nooter et 
al. [29] The expression of MRP in our models indicates that this MDR protein may 
play a functional role in prostate cancer. 
GST-π was expressed in TSU-Pr1, PC3 and DU145. Among the glutathione-S-
conjugates, which participate in the detoxifi cation of xenobiotics by conjugation 
Chemosensitivity of prostate cancer cell lines and multidrug resistance related proteins 61
to reduced glutathione, the GST-π isoenzyme is especially associated with the 
resistance of tumours against alkylating agents and cisplatin [30]. GST-π was found 
in normal prostate tissue, but was absent in locally confi ned prostate cancer [31, 
32]. Our results with GST-π were in line with the observations of Lee et al., who 
reported that cell lines TSU-Pr1, PC3 and DU145 expressed GST-π, but the LNCaP 
cells did not. This lack of expression in LNCaP is possibly due to hypermethylation 
of GST-π promotor sequences [31]. The expression of GST-π in several of our cell 
lines suggests a potential role of this enzyme in drug resistance of advanced pros-
tate cancer.
Bcl-2 [9], has cell survival promoting capacity and blocks cancer cells in their abil-
ity to undergo drug-induced apoptosis (e.g. by Etoposide). In our cell lines, Bcl-2 
was only expressed in TSU-Pr1. Confl icting data have been reported about the ex-
pression of Bcl-2 in LNCaP, but generally expression of this protein was low or un-
detectable. Expression of Bcl-2 in PC3 has been reported by Sinha et al. [33], which 
is in contrast to our fi ndings. Diff erences between cell lines originating from one 
parental cell line may have arisen after culturing in diff erent laboratories. In clinical 
prostate cancer Bcl-2 appears to be expressed at relatively low levels in low grade 
carcinomas and at higher levels in high grade tumours [34]. The expression of Bcl-2 
in one of our prostate cancer cell lines together with the results of several studies 
[33, 35] reporting modulation of drug resistance with changed Bcl-2 expression, 
support the idea that Bcl-2 contributes to the MDR phenotype of prostate cancer. 
The role of Bcl-2 in MDR of prostate cancer clearly requires further investigation.
Bax [10] is an apoptosis promoting protein and acts as opponent of Bcl-2. Bax 
was expressed in all cell lines tested, as it was also found to be well expressed in 
most cancers including prostate cancer [34]. The ratio of Bcl-2 and Bax in prostate 
cancer cells may be of importance to determine if the apoptotic cascade will be 
triggered by treatment with chemotherapy.
The Topo IIα enzyme was expressed in all cell lines. The highest expression was 
found in the rapidly proliferating cell lines TSU-Pr1 and DU145. Topo I and IIß were 
equally expressed in all cell lines. This is in line with the fi ndings of Boege et al. [36] 
that topoisomerase I and IIβ are constantly expressed during the cell cycle, whereas 
IIα is proliferation-associated. The topoisomerase enzymes are essential for several 
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cellular processes and constitute targets for a number of clinically important drugs, 
which induce lethal DNA damage by irreversibly stabilizing topoisomerase-DNA 
complexes. Topoisomerase directed drugs, such as Etoposide and Doxorubicin, are 
generally believed to target the IIα isotype [36], although Topo I [37] and IIβ [38] 
may constitute targets as well. Changes in amount or activity of topoisomerases 
have been described in relation to one form of MDR: atypical- or attenuated MDR 
[11]. The relation between the resistance of prostate cancer to chemotherapy and 
expression of topoisomerase enzymes is still unclear. However, drug resistance to 
topoisomerase poisons may arise from decreased expression or activity of the drug 
targets Topo I, IIα and/or IIβ or reduced proliferative activity related to Topo IIα.
Drug resistance
The presence of several MDR proteins in the prostate cancer cell lines suggests 
that drug resistance may arise by up- or down regulation of one- or multiple MDR 
proteins. In our experiments, the cell lines responded variably to exposure to cy-
totoxic drugs (fi gure 3.1a-c, table 3.1). It is likely that this response is infl uenced 
by a combination of MDR mechanisms, rendering interpretation of the dose re-
sponse curves diffi  cult. However, certain patterns can be distinguished. The cell 
line TSU-Pr1 is sensitive to all three drugs. Its sensitivity to Vinblastine, a mitotic 
spindle blocker, can be expected, as TSU-Pr1, together with DU145, is one of the 
most rapidly proliferating cell lines among our models, as measured by BrdU incor-
poration (table 3.2). The sensitivity of TSU-Pr1 to Etoposide and Doxorubicin, both 
topoisomerase II targeting drugs, relates well to the high expression of topo IIα en 
β enzymes. TSU-Pr1 expresses Bcl-2, which may protect these cells from Etoposide 
mediated apoptosis [35]. However, immunocytochemistry shows an inhomoge-
neous expression of Bcl-2 and the majority of cells do not express the protein, 
suggesting that only a small proportion of the cells may be relatively resistant. 
DU145, which has high expression of topo IIα, is also sensitive to Etoposide and 
Doxorubicin. The sensitivity of LNCaP-FGC, having a lower expression of Topo IIα 
and a lower proliferative activity, is nearly identical to that of DU145. Possibly GST-
π, the detoxifying enzyme, induces a certain degree of drug resistance in DU145, 
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PC3 and TSU-Pr1, whereas LNCaP-FGC, which does not express GST-π, remains 
relatively sensitive, resulting in similar resistance profi les of these cell lines. The 
LNCaP derivatives -LNO and -R, which in contrast to LNCaP-FGC, are both hormone 
independent, are relatively resistant to Etoposide, Doxorubicin and Vinblastine. 
This may be in agreement with the fi nding that transition of prostate cancer cells to 
a hormone independent state concomitantly leads to resistance to chemotherapy 
[35, 39]. Proliferative activity of cell line LNCaP-R is higher than that of LNCaP-LNO 
and its sensitivity to Vinblastine is comparable to that of PC3, DU145 and FGC. The 
role of MDR in this cell line is questionable as it lacks Pgp, signifi cant amounts of 
MRP, GST-π and Bcl-2 and expresses Bax and all topoisomerases. The slow growth 
rate of LNCaP-LNO may explain its resistance to Vinblastine. 
CONCLUSIONS
This study shows that the resistance of prostate cancer cells to chemotherapy may 
be determined by MDR mechanisms and proliferative activity. Furthermore, drug 
resistance is potentially multifactorial, as several MDR proteins are expressed in our 
models. As the provided evidence of the contribution of MDR associated proteins 
to drug resistance in prostate cancer is indirect, the development of multidrug 
resistant models from relatively sensitive prostate cancer cell lines is an obliga-
tory step for future investigations. Such models off er the possibility of further 
functional studies of regulation of activity and expression of MDR proteins in vitro. 
Also, modulation and circumvention of MDR could be investigated. Furthermore, a 
detailed search for expression of MDR proteins in clinical prostate cancer samples 
at diff erent stages of disease and progression may help elucidate the role of the 
various MDR-related factors, which were described in the present study of experi-
mental systems. Eventually, a better understanding of mechanisms causing resis-
tance of prostate cancer to antineoplastic agents may lead to new approaches to 
treat hormone independent metastatic prostate cancer more successfully.
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CHAPTER 4
Expression of multidrug resistance related 
proteins and proliferative activity is increased 
in advanced clinical prostate cancer.
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SUMMARY
Purpose: Advanced disseminated prostate cancer is highly resistant to cytotoxic 
chemotherapy. In this study we aimed at identifying proteins that may be involved 
in multidrug resistance in clinical prostate cancer. Expression of these proteins was 
examined in the context of tumour progression.
Materials and Methods: Paraffi  n-embedded formalin fi xed prostate cancer speci-
mens from archival sources of three distinct patient groups were examined. These 
groups were clearly distinct with regard to pathological stage and responsiveness 
to anti-hormonal therapy. Group 1 consisted of patients with organ confi ned pros-
tate cancer, treated by radical prostatectomy (early prostate cancer, pathological 
stage (p) T2N0M0 tumours). Group 2 had disseminated prostate cancer and was 
treated with transurethral resection of the prostate (TURP) for urinary obstruction 
before receiving anti-hormonal therapy (early advanced prostate cancer). Group 3 
had disseminated prostate cancer and relapsed despite anti-hormonal treatment 
(late advanced prostate cancer) and were treated with TURP to relieve symptoms of 
urinary obstruction. Immunohistochemistry was used for detection of P-glycopro-
tein (Pgp), multidrug resistance-associated protein (MRP), lung resistance protein 
(LRP), glutathione-S-transferase-π, (GST-π), p53, Bcl-2, Bax, topoisomerase (Topo) I, 
IIα and IIβ and Ki-67.
Results: Advanced tumours could be distinguished from locally confi ned tumours 
because they exhibited a signifi cantly higher histological grade and proliferative 
activity than organ confi ned prostate cancer. Expression of MRP, p53, Topo IIα, Ki-67 
and Topo IIβ was signifi cantly related to a higher Gleason sum score. The number 
of patients expressing MRP, LRP, GST-π, p53, Bcl-2, Topo IIα and Ki-67 was signifi -
cantly increased in the group with advanced disseminated prostate cancer. Topo 
I and Topo IIβ were homogeneously and highly expressed in all stages of prostate 
cancer progression. Pgp was not expressed in any of the tumours, regardless of the 
patient group. 
Conclusions: Upregulation of expression of drug transporters MRP and LRP, de-
toxifying enzyme GST-π and apoptosis inhibiting proteins Bcl-2 and P53 may off er 
an explanation for the resistance of disseminated progressive prostate cancer to 
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chemotherapy. Increased proliferation, as shown by upregulation of Ki-67 and Topo 
IIα, refl ects the aggressiveness of metastatic prostate cancer. Research on agents 
that counteract multidrug resistance mechanisms and that may sensitize prostate 
carcinomas to cytotoxic chemotherapy, will possibly lead to more eff ective treat-
ment of patients with progressive disseminated prostate cancer.
INTRODUCTION
Disseminated prostate cancer that has relapsed despite anti-hormonal treatment 
has an unfavorable prognosis. The treatment of choice for many metastasized can-
cers is systemic chemotherapy. Unfortunately, metastatic prostate cancer is highly 
resistant to treatment with cytotoxic agents[1].
Resistance to functionally- and structurally distinct cytotoxic drugs is termed 
multidrug resistance (MDR) and several mechanisms are held responsible for the 
MDR phenotype of various malignancies. Decreased intracellular concentration of 
cytotoxic agents may be caused by active drug extrusion by drug transporter mol-
ecules. These include the multidrug resistance (MDR1) gene product P-glycoprotein 
(Pgp)[2], the multi resistance associated protein (MRP)[3] and the Lung resistance 
protein (LRP)[4]. Increased detoxifi cation by GST-π, which is part of the glutathione 
detoxifying mechanism, generally causes resistance to several cytotoxic drugs[5]. 
Furthermore, glutathione-S-conjugates are transported by MRP in an energy-
dependent manner[6]. Mutations in p53[7], overexpression of the anti-apoptotic 
protein Bcl-2[8] and decreased expression of the pro-apoptotic protein Bax[9] may 
protect cancer cells from chemotherapy-induced programmed cell death and lead 
to drug resistance. Downregulation of nuclear proteins Topo I, IIα and/or IIβ, which 
are targets for several cytotoxic agents, is associated with multidrug resistance[10] 
and is termed altered- or attenuated topoisomerase MDR (at-MDR).
Recently, involvement of several MDR mechanisms in organ confi ned prostate 
cancer has been demonstrated[11-13]. In prostate cancer patients treated by 
radical prostatectomy high proliferative activity, as determined by Ki-67 labelling 
index, was related to unfavorable prognosis[14]. Prostate cancer is characterized 
by heterogeneity and clones of tumour cells expressing diff erent MDR-associated 
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proteins and exhibiting high proliferative activity may very well determine the clini-
cal behaviour of organ confi ned and advanced prostate cancer and its response to 
therapy.
We hypothesize that MDR mechanisms that are present in locally confi ned pros-
tate cancer are upregulated in advanced prostate cancer and may cause failure 
of treatment with cytotoxic drugs in this stage of disease. To address this issue 
we examined and compared the expression of the above-mentioned MDR-asso-
ciated proteins and proliferation markers in three clearly distinct patient groups, 
each group representing a particular phase in prostate cancer progresssion. These 
groups cover the range from clinically curable disease, prostate cancer with eff ec-
tive palliative treatment options and aggressive cancers, that have escaped both 
curative and palliative approaches.
MATERIALS AND METHODS
Tissue specimens
Formalin-fi xed, paraffi  n embedded prostate tissue collected from archival sources 
available at our institutions of 53 prostate cancer patients was examined.
Patient groups
Three distinct patient groups were studied.
Group 1 consisted of 19 consecutive radical prostatectomy specimens obtained 
from all patients who were recently operated for locally confi ned (pT2N0M0) 
prostate cancer from April to November 1998 and represents the group with early 
phase prostate cancer.
Group 2 consisted of seventeen transurethral resection of the prostate (TURP) 
specimens of patients with disseminated prostate cancer treated for urinary ob-
struction prior to anti-hormonal therapy, representing an intermediate phase of 
prostate cancer. Group 3 consisted of seventeen TURP specimens of patients with 
disseminated prostate cancer that relapsed during anti-hormonal treatment, rep-
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resenting the group of advanced hormone-independent prostate cancer. Group 2 
and 3 comprised all archival material from patients that matched the defi nition of 
these groups.
These groups represent three, clinically diff erent, phases of prostate cancer and 
were chosen by review of medical records: group 1 consists of non-metastatic dis-
ease (pathological stage N0M0) and group 2 and 3 of metastatic disease (N+/M+), 
with the diff erence that group 3 patients are unresponsive to anti-hormonal ther-
apy. Table 4.1 shows the patient characteristics of the groups: patient age, extent 
of disease, Gleason sum score, prostate specifi c antigen (PSA) and prior therapy. In 
groups 2 and 3, which were obtained from archival sources, PSA values were only 
known in a limited number of patients (6 and 5, respectively). Therefore, a relation 
between PSA levels and other parameters was only studied in group 1.
Table 4.1. Patient characteristics.
Group
No.
Mean Pt. Age
(range)
Min./Max. 1992 
International Union 
Against Cancer Stage
Mean Gleason 
Score Sum 
(range)
Mean PSA (ng/
ml) (range)
Previous
Systemic Therapy
1 63.7 
(56 –71)
T2aN0M0-T2cN0M0 6.5
(5 – 7)
6.4 (n=19)
(1.6 – 21)
None
2 75.2
(65 – 89) 
T1N0M1-T4N0M1 9
(8 – 10)
112 (n=5)
(5.6-199)
None
3 71
(54 – 94)
T2N2M0-T4N2M1 9.1
(7 – 10)
13.3 (n=6)
(0.1 – 46)
Androgen 
deprivation
Antibodies
Antibodies were used that recognize antigenic epitopes which are well preserved 
in formalin-fi xed, paraffi  n embedded tissue. Optimal dilution of an antibody was 
determined using human tissues reported to have distinct and relatively high ex-
pression of a particular antigen. All antibodies were diluted in 5% bovine serum 
albumin (Sigma Chemical Co, St. Louis, USA) in phosphate buff ered saline (BSA/
PBS) (Table 4.2).
72
C
ha
pt
er
 4
Table 4.2. Antibodies, applied dilution, control tissue used for detection of the studied proteins.
Antigen Antibody Source control Dilution (times)
P-glycoprotein JSB1 M ileum 100x
Multidrug resistance associated protein MRPr1 M ileum 100x
Lung resistance protein LRP-56 M ileum 20x
Glutathione-S-transferase-π NCL-GST-pi N liver 500x
p53 Clone DO-7 D bladder ca. 25x
Bcl-2 Clone 124 D tonsil 60x
Bax sc-526 SC ileum 50x
Topoisomerase I Anti-Topo I I.B. ovary ca. 10x
Topoisomerase IIα Ki-S1 BM tonsil 250x
Toposiomerase IIβ 3H10 I.H. - 900x
Ki-67 MIB-1 I tonsil 3000x
M.:Monosan, Sanbio, the Netherlands; N.: Novocastra, United Kingdom;
D.: Dako, Glostrup, Denmark; SC.: Santa Cruz biotechnology, USA;
I.B.: Dr. Igor Bronstein, Department of Chemistry, University of York, England;
BM.: Boehringer Mannheim, Germany; I.H.: Dr Ian Hickson, Institute of Molecular Medicine, University of Oxford, United Kingdom;
I.: Immunotech, France.
Immunohistochemistry
Staining conditions were optimized using positive control tissues (table 4.2). For 
all stainings negative controls were included by substituting PBS for the primary 
antibody. Tissue sections were cut at 4µm and mounted on amino-trietoxy-silane 
(Sigma) coated glass slides. After overnight incubation at 37oC, slides were dewaxed 
in xylene and rehydrated through graded alcohols. Endogenous peroxidase activity 
was blocked in 10% H2O2 in methanol. Antigen retrieval was performed for Pgp, 
MRP, Bcl-2, Bax, p53, Topo I, Topo IIα, Topo IIβ and Ki-67 in a 700W microwave for 10 
to 12 minutes, by boiling slides in citrate buff er (pH 6.0). For Pgp antigen retrieval 
in EDTA buff er (pH 8.0) was used to achieve detection with the JSB1 antibody. After 
rinsing in PBS, the avidin-biotin complex method[15] was applied for detection of 
all antigens, except for Pgp, which was detected through the peroxidase-anti-per-
oxidase method[15], to reduce background staining. All compounds were diluted 
in 5% BSA/PBS. Antibody-antigen binding was visualized with diaminobenzidine/
hydrogen peroxidase. Nuclei were counterstained with hematoxyline, dehydrated 
in graded alcohols and xylene and mounted with coverslips.
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Scoring and statistics
Representative sections were examined for expression of every antigen. Scoring 
was performed by a pathologist (Th. vd K.). The pathologist was masked to the 
clinical categories of the specimens. In case of scoring by counting positive cells, 
one thousand cells were counted. A tumour was scored positive if more than 5% of 
the cells in a tumour area were stained.
Statistical analysis was performed using the SPSS and STATA statistical computer 
packages. Diff erences in histological grade between the three patient groups as 
refl ected by Gleason sum score were examined using the Kruskal Wallis H test. 
Diff erences in expression of the studied proteins between patient groups were 
assessed using the chi-square test for trend (Fisher’s exact test) for Pgp, MRP, LRP, 
GST-π, p53, Bcl-2, Bax, Topo I and TopoIIβ, Topo IIα and Ki-67. Correlation between 
Topo IIα and Ki-67 expression, between MDR-and proliferation related proteins and 
Gleason sum score, between PSA and histological grade (group1) and between 
PSA and MDR-and proliferation related proteins (group 1) was determined by the 
Pearson’s test and Spearman’s test.
RESULTS
The expression of MDR related proteins and proliferation related proteins was 
studied immunohistochemically in tissue specimens from patients with locally 
confi ned, hormonally untreated disseminated, and hormone independent dis-
seminated prostate cancer. Diff erences between these clinically distinct patient 
groups with regard to MDR- and proliferation related protein expression were ana-
lyzed. The relation between proliferation related proteins Ki-67 and Topo IIα was 
calculated. The relation between the groups and histological grade was studied. 
Also, the relation between histological grade and expression of MDR proteins and 
proliferation associated proteins was assessed. Furthermore, the relation between 
PSA value and MDR- and proliferation related protein expression and between PSA 
value and histological grade was assessed in patients with locally confi ned pros-
tate cancer (group 1). 
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Diff erences in expression of MDR proteins and proliferation associated proteins 
between the patient groups.
Figure 4 (A to V) shows representative stainings for all studied proteins in locally 
confi ned (left side of the fi gure) and hormone independent disseminated prostate 
cancer (right side of fi gure).
Pgp. The MDR1 gene product Pgp was not expressed in any of the normal pros-
tatic (luminal and/or basal) or prostate cancer cells, whatever the stage of disease 
as shown in fi gure 4A and B.
MRP. Prostate cancer cells homogeneously expressed MRP in the cytoplasm and 
cell membrane (fi gure 4C and 1D) in 53% of locally confi ned prostate carcinomas, 
100% of hormonally untreated disseminated prostate carcinoma and 100% of the 
hormone independent disseminated prostate carcinoma (table 4.3). This diff er-
ence is stastically signifi cant (p<0.001; table 4.4).
LRP. LRP was clearly expressed in the cytoplasm of prostate cancer cells in all 
three patient groups (fi gure 4E and F; table 4.3). The number of patients express-
ing LRP was signifi cantly increased in disseminated hormone independent prostate 
cancer (p<0.05; table 4.4).
GST-π. Prostate cancer cells of locally confi ned disease did not express GST-π, 
although it was clearly expressed in the cytoplasm of the basal cells of benign 
prostatic epithelia (fi gure 4G). Hormonally untreated disseminated prostate car-
cinoma cells expressed GST-π in 18% of the tumours and hormone independent 
disseminated prostate carcinoma expressed GST-π in 53% (fi gure 4H, table 4.3), 
which is a signifi cant increase in hormone independent disseminated disease 
(p<0.001; table 4.4), compared to organ confi ned disease.
Bcl-2. Bcl-2 was expressed in the cytoplasm of the basal cells of normal prostatic 
glands. Locally confi ned tumours (fi gure 4I) and hormonally untreated dissemi-
nated prostate cancer equally expressed Bcl-2. A signifi cantly higher number of 
tumours with expression of Bcl-2 (p<0.05; table 4.4) (fi gure 4J) was found in hor-
mone independent metastatic prostate cancer (82%, table 4.3).
Bax. Bax (fi gure 4K-L) was equally and homogeneously expressed in the cyto-
plasm of normal prostatic tissue and in the tumours of all three patient groups 
regardless of the phase in prostate cancer progression (table 4.3).
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P53. A signifi cantly larger number of tumours from the group with progressive 
disseminated disease were p53 positive (fi gure 4M-N) in comparison to locally 
confi ned disease (p<0.001; table 4.4).
Topo I. Topo I was highly and homogeneously expressed in the nuclei and nucleoli 
of the prostate cancer cells (fi gure 4O-P) in all three patient groups. The number of 
patients expressing Topo I was increased (table 4.3), although not signifi cantly, in 
the two groups with metastatic prostate cancer (table 4.4).
Topo IIα. Prostate cancer cells heterogeneously expressed the nuclear enzyme 
topo-IIα (fi gure 4Q and R). Compared to locally confi ned prostate cancers, the 
number of prostate carcinomas with topo IIα expression was signifi cantly increased 
in the tumours of both groups with metastatic disease (p<0.05; table 4.4). Similar 
diff erences in the number of positive prostate cancer cells were also observed: 3 
percent (range: 0 – 11), 10 percent (range: 2-27) and 11 (range: 1 – 37) percent, 
respectively in locally confi ned, early metastatic and progressive prostate cancer.
Topo IIβ. Expression of topo IIβ (fi gure 4S-T) was high and homogeneous in 
nuclei of the prostate cancer cells of all three patient groups. Expression of topo 
IIβ was more frequently seen in disseminated prostate cancer specimens (100% of 
the specimens were positive; table 4.3), although this increase was not statistically 
signifi cant (table 4.4).
Ki-67. Expression of the nuclear Ki-67 antigen (fi gure 4U-V), refl ecting prolif-
erative activity, was signifi cantly increased in advanced prostate cancer (non-hor-
monally treated disseminated disease and hormone independent disseminated 
prostate cancer: p< 0.05 and p<0.001, respectively; table 4.4). Nuclear expression 
of Ki-67 displayed a heterogeneous pattern within tumour areas and between dif-
ferent tumour foci. Ki-67 was expressed in 4 percent (range: 1-12), 6 percent (range: 
1-26) and 9 percent (range: 1-49) of the cells in locally confi ned, early metastatic 
and progressive prostate cancer, respectively. Expression of Ki-67 was closely cor-
related to Topo IIα expression (correlation coeffi  cient: 0.89; p<0.01).
76
C
ha
pt
er
 4
Relation between histological grade and patient groups 
Patients with either hormonally untreated disseminated- or hormone independent 
disseminated prostate cancer had signifi cantly higher Gleason sum scores than 
patients with locally confi ned tumours (mean 9.0 and 9.1 versus 6.5 respectively 
(table 4.1); p<0.001). The diff erence in Gleason sum score between the two groups 
with disseminated disease was not statistically signifi cant.
Relation between histological grade and expression of MDR proteins and proliferation 
associated proteins
In all groups histological grade was signifi cantly higher in patients expressing pro-
liferation associated proteins Topo IIα (p=0.02) and Ki-67 (p=0.008). Also, tumours 
of patients had a signifi cantly higher Gleason sum score when expressing Topo IIβ 
(p=0.007), p53 (p=0.001) and MRP (p=0.01).
Relation between PSA value and MDR- and proliferation related proteins and between 
PSA value and histological grade in patients with locally confi ned prostate cancer 
(group 1)
In this group of patients MDR- and proliferation related proteins and histological 
grade were not correlated to PSA value.
Table 4.3. Percentages of tumours expressing the studied proteins p-glycoprotein (Pgp), multidrug resistance associated protein (MRP), 
glutathione-S-transferase-π (GST-π), Bcl-2, bax, p53, topoisomerase (Topo) I, II, β and Ki-67.
Pgp MRP LRP GST-π Bcl-2 Bax p53 Topo I Topo IIα Topo IIβ Ki-67
1 0 53 32 0 47 100 5 79 16 89 16
2 0 100 47 18 47 100 29 94 59 100 65
3 0 100 71 53 82 100 65 94 65 100 82
Group 1: Locally confi ned prostate cancers (pT2N0M0, radical prostatectomy specimens; n=19). Group 2: disseminated prostate cancer before 
anti-hormonal therapy (transurethral resection of the prostate (TURP); n=17). Group 3: progressive disseminated prostate cancer, relapsed after 
anti-hormonal treatment (TURP; n=17).
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Table 4.4. Statistical analysis of diff erences in expression of the studied proteins in three prostate cancer groups.
Group 1 vs 2 vs 3
(No. of tumours)
group 1 vs 2 group 1 vs 3 group 2 vs 3
P-glycoprotein 1 (0-0-0) 1 1 1
Multidrug resistance protein 0.00001 (10-17-17) 0.0006 0.0003 1
Lung resistance protein 0.09 (6-8-12) 0.29 0.03 0.27
Glutathione-S-transferase-π 0.0007 (0-3-9) 0.05 0.0003 0.04
Bcl-2 0.09 (9-8-14) 0.59 0.08 0.04
Bax 1 (19-17-17) 1 1 1
P53 0.002 (1-5-11) 0.1 0.0006 0.05
Topoisomerase I 0.35 (15-16-16) 0.5 0.15 1
Topoisomerase II α 0.006 (3-10-11) 0.002 0.016 0.99
Topoisomerase IIβ 0.15 (17-17-17) 0.18 0.15 1
Ki-67 0.001 (3-11-14) 0.007 0.0009 0.23
p-values are shown. The absolute number of positive tumours for respectively group 1, group 2 and group 3 are shown between brackets. Group 
1 (n=19): Locally confi ned prostate cancers (pT2N0M0, radical prostatectomy specimens). Group 2 (n=17): disseminated prostate cancer before 
anti-hormonal therapy (transurethral resection of the prostate (TURP)). Group 3 (n=17): progressive disseminated prostate cancer, relapsed 
after anti-hormonal treatment (TURP).
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Figure 4.
Representative examples of immunohistochemical analysis of paraffi  n-embedded formalin fi xed prostate cancer samples. Tumours of 
patients with locally confi ned prostate cancer (pT2N0M0, radical prostatectomy specimens) are shown on the left side; tumours of patients with 
progressive disseminated prostate cancer, relapsed after anti-hormonal treatment (treated by transurethral resection of the prostate (TURP)) are 
shown on the right side of the fi gure . A and B: P-glycoprotein; C and D: Multidurg resistance associated protein; E and F: Lung resistance protein; 
G and H: Glutathione-S-transferase-π; I and J: Bcl-2; K and L: Bax; M and N: p53; O and P: Topoisomerase I; Q and R: Topoisomerase IIα; S and T: 
Topoisomerase IIβ; U and V: Ki-67. Magnifi cation 200x.
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DISCUSSION
Systemic chemotherapy has generally been ineff ective in the treatment of hormone 
independent prostate cancer[1]. Advanced stage prostate cancer appears to have an 
intrinsic resistance to chemotherapeutic drugs. Resistance to structurally- and func-
tionally distinct chemotherapeutic agents has been described in many tumours and 
termed multidrug resistance (MDR), which can be caused by several mechanisms. 
Although reports on mechanisms underlying MDR in prostate cancer are scarce and 
such studies were often limited to a small number of MDR proteins[5, 11-13, 16-18], 
together they off er support for the hypothesis that failure of treatment of advanced 
prostate cancer with systemic chemotherapy may be caused by MDR mechanisms.
To address this issue, we studied the expression of a large panel of multidrug 
resistance-related proteins in three groups of prostate carcinoma patients, which 
are clearly distinct with regard to progression of disease. Patients with prostate 
cancer ranging from locally confi ned to progressive therapy resistant disease were 
allocated to the diff erent groups by reviewing medical records and were obtained 
from archival material. The clinical diff erences between these groups were refl ected 
by a signifi cantly higher histological grade in the advanced tumours.
We investigated the presence and expression pattern of proteins involved in 
drug transport (including Pgp, MRP and LRP) and drug detoxifi cation (GST-π), the 
expression of proteins involved in modulation of apoptosis (p53, Bcl-2 and Bax), 
the nuclear drug targets (Topo I, IIα and IIβ) and the cell proliferation associated 
proteins (Ki-67 and also Topo IIα). We found that expression of several of these 
proteins was signifi cantly increased in the groups of more advanced types of car-
cinomas as shown in table 4.3 and table 4.4. Upregulation of the expression of 
multiple multidrug resistance related proteins may play a role in chemotherapy 
resistance of advanced prostate cancer. Emergence or upregulation of several of 
the studied proteins was also associated with a signifi cantly higher histological 
grade. These proteins may provide cancer cells with protective mechanisms, result-
ing in more progressive- and multidrug resistant tumours. However, although we 
demonstrated expression of a panel of MDR related proteins, a functional role of 
these proteins in advanced prostate cancer remains to be established. 
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Remarkably, Pgp, the MDR1 gene product and member of the ATP-binding cas-
sette (ABC) superfamily of membrane transporter proteins, which is held respon-
sible for multidrug resistance in numerous tumours[19], is not expressed in the 
prostate carcinomas of the three patient groups, whatever the phase of progres-
sion. Most reports studying Pgp expression in prostate cancer had negative results 
as well[11, 16]. In contrast, MRP, which is a second member of the membrane trans-
porter proteins family, was clearly expressed in the prostate cancer samples ana-
lyzed and we could demonstrate a signifi cantly increased expression in advanced 
disease. Also, MRP positive tumours had a signifi cantly higher histological grade. 
These fi ndings suggest that during tumorogenesis and progression amplifi cation 
and/or overexpression of the MRP gene[3] occurs which may contribute to the 
multidrug resistant phenotype of advanced disease by decreasing the intracellular 
drug content. Expression of MRP was previously reported in locally confi ned pros-
tate cancer[11, 17] and a relation with progression has been suggested[11]. This 
is confi rmed in the present study showing expression of MRP in all patients with 
metastasized disease.
Apart from being a transmembrane drug pump, MRP is a glutathione S-conju-
gate carrier[6]. Interestingly, expression of GST-π, a detoxifying enzyme and part 
of the glutathione detoxifying pathway, is also signifi cantly increased in advanced 
hormone independent prostate cancer. Concomitant overexpression of MRP and 
GST-π may synergistically result in increased drug resistance of advanced prostate 
cancer. Expression of GST-π in clinical prostate cancer is a novel fi nding. Previous 
studies have only reported the lack of its expression in locally confi ned prostate 
cancer obtained from radical prostatectomy samples[5, 11]. Indeed, in our series 
of tumours locally confi ned prostatic carcinomas were entirely GST-π negative, 
whereas the disseminated cancers clearly expressed GST-π, especially in hormone-
independent progressive disease. 
LRP, which has been identifi ed as the human major vault protein (MVP)[20] and 
is involved in transmembrane transport of various substrates, was the third drug 
transporter studied. To our knowledge, this is the fi rst study reporting expression of 
LRP in prostate cancer. This protein was expressed in nearly one third of the organ 
confi ned prostate cancer samples and its expression was signifi cantly increased 
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in hormone independent disseminated prostate cancer. Altogether, three out of 
four proteins of the panel of drug-transporter and detoxifying proteins are more 
frequently expressed in patients with hormone independent prostate cancer. This 
may indicate that failure of chemotherapy in progressive prostate cancer could be 
caused by these MDR mechanisms.
Additionally, we have studied the expression of proteins involved in the apop-
totic process. Wild-type p53 is a suppressor of cell growth and transformation, 
causing a proliferation-inhibiting G1 block and regulating apoptosis. Mutation of 
the p53 gene is the most common molecular alteration in cancers resulting in de-
creased apoptosis and possibly resistance to apoptosis-inducing cytotoxic agents. 
We observed a signifi cantly increased number of p53 positive patients in hormone 
independent cancers. Also, p53 expression was statistically signifi cantly related 
to a higher histological grade. These fi ndings should be interpreted cautiously as 
immunohistochemical expression of p53 does not necessarily represent p53 mu-
tation[21]. However, correlation between p53 mutations and tumour progression 
was presented in several studies, with mutations occurring as a late event in the 
development of prostate cancer[22-24]. This is in concordance with our fi nding of 
more frequently occurring p53 expression in advanced disease, which may explain 
the decreased susceptibility to apoptosis-inducing agents. This may also be caused 
by expression of the Bcl-2 protein, which has been identifi ed as a powerful inhibi-
tor of apoptotic cell death, and which was increased in the group of hormone inde-
pendent prostate cancer. Bcl-2 expression in prostate cancer has previously been 
related to the androgen independent phenotype[25, 26]. Relatively high Bcl-2 lev-
els may promote cell survival and protect the androgen independent prostate can-
cer cells from drug-induced apoptosis. The Bax protein, which forms heterodimers 
with Bcl-2 and promotes apoptosis[9], is equally and homogeneously expressed in 
normal prostate and prostate cancer cells in all phases of progression. It has been 
suggested that the ratio of Bcl-2 and Bax determines cells to enter the apoptotic 
process. With the observed unchanged levels of Bax, increased number of patients 
with Bcl-2 and p53 positive tumours in the group with hormone independent dis-
ease, apoptosis of cancer cells is possibly less likely to occur when challenged with 
drugs that act through triggering apoptosis, resulting in increased resistance.
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The nuclear topoisomerase enzymes are targets for a number of cytotoxic drugs. 
They are involved in multidrug resistance through down-regulation of their expres-
sion or decreased enzymatic activity (at-MDR)[27]. Expression of the isoforms topo 
I and Topo IIβ is high and homogeneous in every phase of prostate cancer pro-
gression and is slightly increased in advanced disease. Topo IIβ negative tumours 
had a signifi cantly lower histological grade. Expression of Topo IIα is signifi cantly 
increased in progressive disseminated prostate cancer and tumours with a higher 
histological grade. Increased expression of topoisomerases does not point towards 
a role for at-MDR in advanced prostate cancer. Interestingly, the Topo IIα enzyme is 
known to be related to cell proliferation as well[28]. We report that this holds true 
for prostate cancer, as was confi rmed by the strong correlation between Topo IIα 
expression and expression of the proliferation marker Ki-67. This marker was dem-
onstrated to be signifi cantly increased in the group of advanced prostate cancers 
and in tumours with a higher histological grade. A relation between proliferative 
activity and a more progressive phase of disease has been reported previously[14, 
29, 30]. The diff erences in proliferative activity between the three patient groups 
are in agreement with their clinical phase of prostate cancer and increased expres-
sion of Ki-67 and Topo IIα in advanced prostate cancer possibly refl ects the more 
aggressive character of these tumours.
High expression of topoisomerases in end-stage prostate cancer may favour the 
introduction of topoisomerase targeting agents. However, effi  cacy of such drugs 
may be hampered by increased drug effl  ux and detoxifi cation through MRP, LRP 
and GST-π and by inhibition of apoptosis via p53 mutations and an increased Bcl-2 
to Bax ratio.
CONCLUSION
This study demonstrates that advanced disseminated prostate cancer overex-
presses MDR-, anti-apoptotic- and proliferation-related proteins. Three out of four 
proteins of the panel of drug-transporter and detoxifying proteins (MRP, LRP and 
GST-π ) are more frequently expressed in patients with hormone independent 
prostate cancer. This indicates that failure of chemotherapy in progressive pros-
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tate cancer could be caused by these MDR mechanisms. Furthermore, increases 
in Bcl-2/ Bax ratio and p53 positive tumours in hormone independent prostate 
cancer, may inhibit cell death when challenged with drugs that act through trig-
gering apoptosis. Overexpression of topoisomerases in advanced prostate cancer 
may favour the application of topoisomerase targeting agents. Further studies will 
have to provide evidence for a functional role of the MDR proteins in advanced 
chemotherapy resistant disseminated prostate cancer. Such functional studies, us-
ing prostate cancer models, could include chemo-sensitization by MRP blocking 
agents and glutathione-depleting agents or agents which down-regulate Bcl-2 in 
combination with topoisomerase-targeting drugs that act independently of p53 
and Bcl-2. If this functional role could be established, application of approaches 
to overcome drug resistance may become an important strategy to clinically chal-
lenge advanced prostate cancer.
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CHAPTER 5
Identifi cation of MRP1 and glutathione as 
multidrug resistance mechanisms in human 
prostate cancer cells: chemosensitization 
with leukotriene D4 antagonists and 
buthioninesulfoximine 
van Brussel JP, Oomen MA, Vossebeld PJM, Wiemer 
EAC, Sonneveld P, Mickisch GHJ.
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SUMMARY
Purpose: To assess the involvement of the multidrug resistance associated pro-
tein (MRP1) and the glutathione (GSH) pathway in the multidrug resistant (MDR) 
phenotype of prostate cancer in vitro.
Materials and methods: chemo-selection of human prostate cancer cell lines PC3 
and DU145 with etoposide (VP-16), resulted in the cell lines PC3-R and DU-R. Resis-
tance against etoposide, doxorubicin and vincristine and its reversal with leukotri-
ene D4 antagonists MK-571 and zafi rlukast, and buthioninesulfoximine (BSO) was 
studied in tetrazolium-dye viability (MTT) assays. Western blot analysis of MRP1 
expression and GSH content measurements were performed. MRP1 function was 
assessed in fl uorescence assays.
Results: MRP1 was increased in the MDR models. The GSH content was signifi -
cantly higher in PC3-R. No increase in GSH was found in DU-R. Adding non-toxic 
doses of MK-571, zafi rlukast or BSO signifi cantly increased the sensitivity of the 
MDR models to cytotoxic drugs. Inhibition of MRP1 function was inhibited with 
MK-571 in the MDR models.
Conclusion: MRP1 and glutathione mediate MDR in newly developed prostate 
cancer models.
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INTRODUCTION
Resistance against chemotherapeutic regimens has hampered treatment of clini-
cally advanced metastatic prostate cancer[1]. Data have been provided regarding 
the functional role in resistance against chemotherapy of MRP1 and glutathione 
in acute myeloid leukemia cells[2] and human colorectal cells, respectively[3]. The 
role of both MRP1 and the glutathione pathway in drug resistant prostate cancer, 
remains to be established. Several studies have recently reported the expression of 
the multidrug resistance related protein1 (MRP1) in experimental prostate cancer 
models and in specimens of prostate cancer tissues of patients with organ-con-
fi ned prostate cancer and metastatic prostate cancer[4-6]. It was found that the 
number of patients expressing MRP1 was clearly increased in metastatic prostate 
cancers, as compared to organ-confi ned prostate cancers. Recently, we also de-
scribed increased expression of glutatione-S-transferase-π (GST-π), a key-protein in 
the glutathione pathway[7], in advanced clinical prostate cancer[6]. 
Confi rmation of a functional role for MRP1 and glutathione in the resistance 
against cytotoxic drugs in advanced prostate cancer would be of great interest for 
the development of novel strategies for treatment of patients suff ering from this 
disease. We therefore have addressed the roles of MRP1 and glutathione using in 
vitro prostate cancer models.
MATERIALS AND METHODS
Cell lines
The human prostate cancer cell lines PC3[8] and DU145[9] were maintained at 
37oC in a 5% CO2-95% air atmosphere and cultured in RPMI 1640 medium, with 
7.5% foetal calf serum, 100 units/mL penicillin, 100 µg/mL streptomycin and 2 mM 
glutamine (all GibcoBRL, Paisley, United Kingdom). Drug resistant derivatives of 
PC3 and DU145 were cultured under identical conditions. The cell lines were regu-
larly tested for Mycoplasma infection by a sensitive PCR-based assay.
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Selection and cloning of drug resistant cell lines
Etoposide (VP-16; Pharmachemie BV, Haarlem, The Netherlands) was dissolved in 
culture medium and PC3 and DU145 were incubated in cycles of 72 hours with cu-
mulative concentrations of VP-16. Between cycles cultures were allowed to recover 
in fresh medium without VP-16 until confl uent. After 12 and 13 cycles for DU145 
and PC3 respectively, the chemoselected cell lines were cloned using the limit-
ing dilution technique: single cell solutions were plated on 96-well plates (Costar 
Corp., Cambridge, Massachusetts) and allowed to form monocultures in culture 
medium without VP-16. Viable clones were harvested and the limiting dilution 
technique was repeated. Clones were cultured in the absence of VP-16 and stored 
in liquid nitrogen. Low passages of the newly obtained cell lines were used in fur-
ther experiments. Cells cultured without VP-16 maintained their level of resistance 
against chemotherapeutic drugs for up to three months.
MRP1 detection by Western blot analysis
Cell lines were grown to near-confl uency, harvested by scraping in PBS and re-
suspended in lysis buff er [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 
1% deoxycholate, 0.1% SDS, 5 mM EDTA supplemented with protease inhibitors 
(1 mM phenylmethylsulphonylfl uoride, 1 mM benzamidine, 10 µg/mL soy bean 
trypsin inhibitor, 50 µg/mL leupeptin, 1 µg/mL pepstatin, 20 µg/mL aprotinin )]. 
The cell lysates were stored on ice for 15 minutes, centrifuged (14000 x g) for 20 
minutes at 4oC, after which the supernatant was removed and further processed. 
Cell lysate samples (20 µg protein) in Laemmli buff er[10] (15 µl) were heated at 
100oC for three minutes and loaded on a 10% SDS-polyacrylamide gel and elec-
trophoresed for 45 minutes at 200 Volts. Prestained markers (Novex, San Diego, 
California) were used as size standards. The in vitro-selected adriamycin-resistant 
human small-cell lung-carcinoma cell line GLC4/ADR[11], expressing MRP1 at high 
levels, served as positive control and 2 µg protein was loaded. Subsequently, the 
proteins were transferred to a nitrocellulose membrane (Protan Nitrocellulose, 
Schleicher & Schuell, Dassel, Germany) by electroblotting at 100 V for 45 minutes. 
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The remaining protein binding sites were blocked by incubating the blot for 1 hour 
in Tris buff ered saline (TBS, pH 7.5) containing 1 % blotting substrate (Boehringer 
Mannheim, Germany). The membranes were then incubated overnight at 4oC with 
the MRPr1 (Sanbio, the Netherlands) antibody at 1 : 3000 dilution in TBS, pH 7.5, 
containing 1 % blotting substrate. After washing with TBS containing 0.1% Tween 
20 (Sigma), the membranes were incubated with rabbit-anti-rat immunoglobulines 
conjugated to HRP (1/4000; Dako). Immune complexes were detected by chemi-
luminescence (Boehringer Mannheim, Germany) and visualised on Hyperfi lm ECL 
(Amersham Pharmacia Biotech, Uppsula, Sweden).
Measurement of glutathione content
The glutathione content of parental and selected drug resistant cell lines was 
measured. One million cells were plated and incubated without or with 50 µM 
buthioninesulfoximine during 24 hours. Afterwards the cells were harvested and 
resuspended in 250 µl PBS and 250 µl 2 M HClO4 / 4 mM EDTA. After centrifugation, 
the supernatant was neutralised with 250 µl 2M KOH / 0.3 M MOPS. Glutathione 
content was then measured in 25 µl of this cell extract supplemented with 1 ml 2 
M HClO4 / 4 mM EDTA, 50 µl NADPH, 20 µl DTNB (5,5-dithio-bis(2-nitrobenzoicacid) 
and 20 µl glutathione reductase after 30 minutes. The absorbance was measured 
photometrically at 412 nm using an Ultrospec 3000 (Amersham Pharmacia Biotech, 
Roosendaal, the Netherlands). All measurements were performed in triplicate.
MDR1 detection by Western blot analysis and FACS
Western blotting experiments were performed as described for MRP1, without 
boiling the samples. The monoclonal antibody JSB1 (Sanbio, the Netherlands) was 
used for MDR1 detection in a 1 : 100 dilution in TBS, pH 7.5.
Also, fl uorescence assay was used for MDR1 detection. Cells were fi xed by resus-
pending in 2% formaldehyde (37%) in acetone for 10 seconds. After washing, cells 
were incubated with 0.2 µg/µl JSB1 antibody diluted in PBS with 1% rabbit serum, 
0.2% goat serum and 0.02% BSA or mIgG1 control antibody for 45 minutes at room 
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temperature. Cell-bound antibodies were detected by fl uorescein isothiocyanate 
(FITC)-labelled rabbit anti-mouse immunoglobulin antibodies (Dako). Fluorescence 
was measured using the FACScalibur (Becton Dickinson). The MDR1 expressing 
drug resistant cell line 8226 D6[12] was used as positive control.
Function of MRP1 and MDR1
MRP1 function was studied using a modifi cation of a previously described func-
tional assay[2]. The fl uorescent molecule carboxyfl uorescein diacetate (DCFDA) 
(Sigma) was used as an MRP1 substrate. Rhodamine 123 (Sigma) was used as a 
P-glycoprotein substrate. Cells were incubated at 37oC for 1 hour in the absence or 
presence of 100 µM of the MRP1 modulator MK-571 (Alexis Biochemicals) or 2 µM 
of the MDR1 modulator PSC 833 (Novartis Pharma, Basel, Switzerland). Following 
this incubation, 0.1 µM carboxyfl uorescein diacetate or 200 ng/mL rhodamine 123 
was added to the cells. A sample was taken at 60 minutes to assay MRP1 func-
tion or at 75 minutes to assay MDR1 function via intracellular carboxyfl uorescein 
diacetate or rhodamine accumulation, respectively, after optimalization of ex-
perimental protocols. Cells were incubated with 0.1 µM TO-PRO-3 to identify dead 
cells that were subsequently excluded from further calculations. Fluorescence was 
measured using a FACScalibur. GLC4/ADR, served as positive control in the DCFDA 
experiment, whereas the cell line 8226 D6 served as positive control in rhodamine 
123 accumulation assay and 8226 S as negative control[12]. All experiments were 
done in triplicate.
Measurement of response to chemotherapy with the MTT assay
Sensitivities of all cell lines to the antineoplastic drugs with or without addition 
of MK-571, were assessed by the MTT assay[13]. Cell lines were plated in 96-well 
plates (Costar Corp. Cambridge, MA, USA) at densities allowing logarithmic growth 
throughout the experiments. After allowing cells to attach for 24 hours, cells were 
incubated with culture medium containing a range of exponentially increasing 
concentrations of cytotoxic agents for a period of 72 hours. Etoposide (VP-16; 
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Pharmachemie BV, Haarlem, the Netherlands), doxorubicin (DOX; Farmitalia, Carlo 
Erba, Italy) and vincristine (VCR; Pharmacia, the Netherlands) were tested. MK-571, 
zafi rlukast and BSO dose-response curves were obtained by exposing cells to ex-
ponentially increasing concentrations of these drugs. Then, cells were incubated 
with a maximum non-toxic concentration of MK-571 together with the cytotoxic 
drugs for 72 hours. This same procedure was followed with zafi rlukast and BSO and 
the combination of MK-571 and BSO. Subsequently, 30 �l of MTT (3-[4,5-dimethyl 
thiazol-2-4]-2,5 diphenyl tetrazoliumbromide, Sigma Chemical Co., St. Louis, MO, 
USA) solution (5 mg/mL in PBS) was added to each well and incubated for 4 hours 
at 37oC. The supernatant was carefully aspirated and 100 �l of dimethylsulfoxide 
(DMSO, Merck, Darmstadt, Germany) with alkalinizing buff er (0.1 M glycine, 0.1 
M NaCl, pH 10.5) was added to each well. The plates were shaken for 5 minutes 
in order to dissolve the formazan crystals. The absorbance was measured photo-
metrically at 570 nm using a Bio-Rad Microplate Reader (Model 450, Bio-Rad, CA, 
USA). The percentage of viable cells was calculated relative to untreated cells. All 
assays were done in triplicate.
Statistical analysis
We calculated 95% confi dence intervals to determine statistically signifi cant dif-
ferences between IC50 values in the cell viability assays. Statistically signifi cant 
diff erences are indicated in table 5.1 with a *. Statistically signifi cant modulation 
of drug resistance is indicated in table 5.1 with #. IC50 values and standard errors 
of the mean were calculated from three representative experiments with the Delta 
method[14].
RESULTS
Induction of multidrug resistance by chemoselection with etoposide
Culturing PC3 and DU145 in the presence of increasing concentrations of etopo-
side and cloning as described resulted in the selection of drug resistant clones 
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PC3-R and DU-R. PC3-R is signifi cantly more resistant to etoposide, doxorubicin 
and to a lesser extend to vincristine than PC3. Resistance of DU-R to doxorubicin 
and vincristine is signifi cantly increased compared to DU145. Resistance against 
etoposide was increased in DU-R, although not signifi cantly (Table 5.1).
Table 5.1. Sensitivity of prostate cancer cell lines to various cytotoxic drugs and modulation of drug resistance by MK-571, zafi rlukast and 
buthioninesulfoximine (BSO).
DU145 DU-R PC3 PC3-R
IC50 (SE)
RF
IC50 (SE)
RF
IC50 (SE)
RF
IC50 (SE)
RF
VP-16 [µM] 9.3 (2.5) 16 (3.9)
1.7
13.6 (2.2) 85.6 (10.7)*
6.3
VP-16 +
30 µM MK-571
9.2 (2.7)
1
5.9 (0.34) #
0.6
15.3 (4.6)
1.1
57.3 (7.1)
4.2
Dox [nM] 81 (11.6) 313 (82.8)*
3.9
137 (15.3) 935 (187)*
6.8
Dox +
30 µM MK-571
28.5 (2.2) #
0.4
100 (9.9) #
1.3
99 (27.2)
0.7
740 (92.4)
5.4
VCR [nM] 7.1 (0.12) 8.4 (0.12)*
1.2
3.6 (0.12) 4.1 (0.12)*
1.1
VCR +
30 µM MK-571
0.36 (0.02) #
0.05
0.24 (0.01) #
0.03
0.12 (0.02) #
0.03
0.097 (0.01) #
0.03
VCR +
ZLK 25 µM
ZLK 100 µM 4.0 (0.2) #
0.6
5.0 (0.3) #
0.7
3.5 (0.1)
1
3.9 (0.2)
1.1
VCR +
50 µM BSO
3.8 (0.2) #
0.5
8.4 (0.7)
1.2
3.6 (0.6)
1
0.8 (0.04) #
0.2
The in vitro sensitivity to cytotoxic drugs of two prostate cancer cell lines (DU145; PC3) and their drug resistant derivatives (DU-R; PC3-R) was 
examined using MTT assays. The values are the calculated IC50 values with standard error of the mean (SE) for etoposide (VP-16); doxorubicin 
(DOX) and vincristine (VCR), either in the absence or presence of the multidrug resistance associated protein-1 (MRP1) modulators and 
leukotriene inhibitors MK-571 and zafi rlukast (ZLK) and the glutathione depleting agent buthioninesulfoximine (BSO).
Also shown are the resistance factor values which indicate changes in IC50 values after chemo-selection and/or after exposure to a modulator 
and a chemotherapeutic drug. Note that the resistance factor in the parental cell lines DU145 and PC3 is set at 1.
Abbreviations: VP-16: etoposide; Dox: doxorubicin; VCR: vincristine; RF: resistance factor
*: statistically signifi cant increase in resistance between parental and chemo-selected cell lines.
#: Statistically signifi cant modulation of drug resistance by MK-571
Note that diff erences are considered statistically signifi cant if 95% confi dence intervals for IC50 values did not overlap.
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Expression of MRP1 and MDR1
Figure 5.1 shows a representative Western blotting experiment demonstrating 
the expression of MRP1 in PC3, PC3-R, DU145 and DU-R. MRP1 expression in PC3 
and DU145 is relatively low. MRP1 expression is clearly increased in the resistant 
chemo-selected PC3-R and DU-R. GLC4/ADR expresses MRP1 at a high level.
MDR1 could not be detected in any of these cell lines in Western blotting ex-
periments or in experiments involving the fl uorescent tagging of MDR1 expressing 
cells with JSB1 and fl uorescently labelled secondary antibody (data not shown). 
However, both procedures clearly detected MDR1 expression in the positive con-
trol 8226 D6.
Figure 5.1. MRP1 expression in prostate cancer cell lines
Cell extracts were prepared from the drug sensitive parental prostate cancer cell lines PC3 and DU145 and their drug resistant derivatives PC3-R 
and DU-R. A cell extract from the MRP1 overexpressing small cell lung cancer cell lines GLC4/ADR was used as a positive control. Twenty µg of 
total protein, except for GLC4/ADR where 2 µg was loaded, was subjected to SDS-PAGE and blotted onto nitrocellulose fi lters. MRP1 expression is 
clearly increased in PC3-R and in DU-R as compared to the parental cell lines PC3 and DU145.
Glutathione content
The concentration of glutathione, measured with or without a 24-hour exposure to 
the glutathione depleting agent buthioninesulfoximine, was 40 µM and 55 µM in 
PC3 and DU145, respectively, and was reduced to 10 µM and 12.5 µM, respectively, 
after treatment with BSO. Glutathione concentration was increased to 80 µM in 
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the selected drug resistant cell line PC3-R. After BSO treatment glutathione was 
reduced to 27.5 µM. In DU-R glutathione concentration was not increased (40 µM), 
but markedly decreased after BSO treatment: 7.5 µM.
MRP1 function; inhibitory eff ect of MK-571
The activity of MRP1 was tested in cells by measuring the ability to extrude DCFDA 
in the absence or presence of the MRP1 inhibitor MK-571. Fluorescence histograms, 
showing fl uorescence intensity and refl ecting carboxyfl uorescein content, with or 
without MK-571, are shown in Figure 5.2 for DU145 and DU-R, PC3 and PC3-R, GLC4 
and GLC4/ADR. Ratios of DCFDA content with and without MK-571 are shown in 
Figure 5.2, representing the relative inhibition of MRP1 function (blocking factor). 
MRP1 function was inhibited by MK-571 resulting in a higher DCFDA content in all 
cell lines exposed to MK-571. No toxicity was observed of the 100 µM MK-571 used 
during the course of the experiment. This was verifi ed with TO-PRO-3 to exclude 
non-viable cells, revealing a survival of 98 to 99% of cells during the experiment in 
every cell line.
The absence of MDR1 function in prostate cancer cell lines was confi rmed by fl ow 
cytometry using and a rhodamine retention assay in conjunction with PSC833. 
MDR1 function was clearly detected in the drug resistant plasma cell line 8226 D6, 
which served as positive control. The blocking factor (increased rhodamine accu-
mulation) was 5.6 for the positive control and 0.96 for the negative control 8226 S.
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Figure 5.2. Modulation of MRP1-mediated carboxyfl uorescein transport by MK-571.
MRP1 function was measured using carboxyfl uorescein diacetate (DCFDA) in the presence (dashed line) or absence (solid line) of MK-571. 
Fluorescence histograms show fl uorescence intensity and refl ect carboxyfl uorescein content for cell lines GLC4 and GLC4/ADR (control), DU145, 
DU-R, PC3 and PC3-R. Exposure of cells to MK-571 results in accumulation of carboxyfl uorescein in all cell lines. Values shown in the upper right 
hand corner of the histograms represent the ratio of the carboxyfl uorescein content of the cells determined in the presence of MK-571 and the 
carboxyfl uorescein content of the cells detemined in the presence of MK-571 and that of the cells with no MK-571.
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Decreased multidrug resistance with MK-571
PC3, DU145, PC3-R and DU-R, were exposed to etoposide, doxorubicin and vincris-
tine. In these experiments, 30 µM of MK-571 was added. MK-571 dose-response 
experiments revealed that this concentration was not cytotoxic in our cell lines 
(data not shown). Signifi cant reversal of drug resistance against etoposide was ob-
served in DU-R (IC50 values for all experiments are shown in table 5.1). Signifi cant 
reversal of doxorubicin resistance was seen in DU145 and DU-R. The combination 
of vincristine and MK-571 enhanced cytotoxicity signifi cantly and most strongly in 
both parental and chemo-selected cell lines PC3, DU145, PC3-R and DU-R.
Decreased vincristine resistance with zafi rlukast
Zafi rlukast (ZLK), another leukotriene inhibitor, was tested for its ability to enhance 
vincristine toxicity in the cell lines PC3, PC3-R, DU145 and DU-R.
Maximum non-toxic doses of zafi rlukast were titrated to 25 µM for PC3 and PC3-R 
and 100 µM in DU145 and DU-R. The combination of vincristine and 25 µM zafi r-
lukast did not increase cytotoxicity in PC3 and PC3-R. However, 100 µM zafi rlukast 
in combination with vincristine signifi cantly increased cytotoxicity in DU145 and 
DU-R (Table 5.1).
Decreased drug resistance with BSO
A signifi cant reduction in glutathione level was achieved by incubating cell lines 
with BSO for 24 hours (see result section, glutathione content). Addition of a non-
toxic dose of 50 µM BSO in combination with vincristine reduced IC50 values sig-
nifi cantly in DU145 and PC3-R, respectively (Table 5.1).
Combination of 50 µM BSO with 3.4 µM etoposide or 36.8 nM doxorubicin re-
duced the viable cell count of DU145 by 15% and 0%, respectively and the viable 
cell count of DU-R by 46% and 36%, respectively. In PC3 and PC3-R no sensitization 
occurred with the BSO – etoposide / doxorubicin combination.
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DISCUSSION
Intrinsic or acquired resistance to cytotoxic drugs may cause failure of chemo-
therapy in prostate cancer patients. In this report, we study the role of MRP1 and 
glutathione in in vitro prostate cancer resistance against chemotherapy and its 
reversal targeting these proteins.
Extensive laboratory studies on mechanisms of drug resistance have revealed 
that MDR is a complex phenomenon, refl ected by a vast array of genetic, molecular 
and biochemical alterations in resistant tumour cells and tissues. These include 
reduced intracellular drug uptake, increased drug effl  ux, drug sequestration into 
cytoplasmic compartments, alterations in drug metabolism and/or target enzymes, 
increased detoxifi cation, enhanced ability to repair DNA damage and failure to 
undergo apoptosis[15-17].
Evidence is accumulating to support the view of involvement of MRP1 and the 
glutathione metabolism in clinically relevant drug resistance[18, 19]. Expression of 
MRP1 and GST-π in in vitro and clinical prostate cancer has been reported in several 
publications[4-6]. Their expression appears to be increased in advanced prostate 
cancer, but a functional role remains uncertain.
To investigate the role of MRP1 and glutathione in prostate cancer, experiments 
were performed in human prostate cancer cell lines. Chemo-selection of cell lines 
PC3 and DU145 with etoposide resulted in the resistant cell lines PC3-R and DU-R. 
Etoposide, which is used clinically in combination therapy for advanced prostate 
cancer[20] is a well-known MDR drug and may up-regulate diff erent MDR mecha-
nisms, and was therefore chosen for selection. Resistance was signifi cantly and 
reproducibly increased with a factor 1.7 and 6.3 in DU-R and PC3-R, respectively 
(table 5.1). Resistance against doxorubicin was increased with a factor 3.9 and 6.8 
in DU-R and PC3-R, respectively. Resistance against vincristine was signifi cantly in-
creased although resistance factors were quite low: 1.2 and 1.1 in DU-R and PC3-R, 
respectively. In a clinical setting, a comparable increase of resistance to cytotoxic 
regimens could result in treatment failure due to unacceptable toxicity of higher 
dosages of cytotoxic drugs. Cross-resistance against doxorubicin and vincristine 
implies involvement of the multidrug resistance phenomenon in our cell lines.
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We observed MRP1 expression in parental prostate cancer cell lines PC3 and 
DU145. Chemoselection resulted in increased MRP1 expression in PC3-R and DU-R. 
Glutathione content was increased in the selected cell line PC3-R, but not in DU-R. 
It is known that MRP1-mediated transport requires glutathione[21]. Upregulation 
of MRP1 and glutathione in PC3-R explains increased resistance against etoposide 
and doxorubicin. In DU-R, a moderate increase in MRP1 expression and a slightly 
decreased glutathione content may result in a relatively low increase of resistance. 
Resistance against vincristine is only slightly increased. One can speculate that 
vincristine toxicity is already effi  ciently countered by MRP1 and glutathione in the 
non-selected cell lines. An increase in expression of these MDR factors may then 
not further increase vincristine resistance.
To further clarify the possibility of MRP1 and glutathione mediated resistance, 
experiments with putative MRP1 and glutathione mediated-MDR reverting agents 
were performed. An inhibitor of MRP-mediated transport[2], leukotriene D4 recep-
tor antagonist MK-571, and another leukotriene inhibitor, zafi rlukast[22] which is 
clinically applicable, were used to study reversal. Furthermore, cellular depletion 
of glutathione with BSO was performed to study glutathione mediated multidrug 
resistance.
Complete reversal of resistance in the MK-571 experiments was seen in DU-R with 
etoposide and vincristine and nearly complete reversal with doxorubicin. Complete 
reversal in PC3-R was seen with vincristine and partial reversal with etoposide 
and doxorubicin (table 5.1). A less effi  cient reversal of resistance in PC3-R may be 
caused by upregulation of both MRP1 and glutathione, resulting in enhanced drug 
transport. If MRP1 were not totally blocked by MK-571, the remaining active MRP1 
could continue to extrude cytotoxic drugs, supported by an increased glutathione 
content. In DU-R, a lower glutathione content may facilitate the inhibiting action of 
MK-571 on MRP1, resulting in reversal of drug resistance.
Signifi cant reversal of resistance with zafi rlukast in combination with vincristine 
was seen in DU-R, but not in PC3-R (table 5.1). Zafi rlukast appears to be less ef-
fective than MK-571 and its action may be infl uenced by MRP1 and glutathione 
synergy as proposed for MK-571. Also, the highest achievable non-toxic concentra-
tion of zafi rlukast (25 µM) may be too low to block MRP1 in PC3-R.
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Signifi cant reduction of vincristine resistance by glutathione depletion with BSO 
was achieved in PC3-R (table 5.1). Signifi cant reduction of etoposide and doxoru-
bicin resistance was observed in DU-R (see results section). Depletion of glutathi-
one with BSO was signifi cant in all cell lines, but BSO does not consistently reduce 
resistance. It is speculative whether diff erent cell lines require diff erent glutathione 
concentrations for MRP1 mediated drug transport. Combination of MK-571 and 
BSO led to markedly increased cell death without addition of a cytotoxic drug (data 
not shown). Apparently, blocking of MRP1 and depletion of glutathione is highly 
lethal to our models. This may support the idea of MRP1 mediated transport of 
glutathione S-conjugated endo- and xenobiotics in prostate cancer cells.
MRP1 function and blocking of MRP1 by leukotriene inhibitor MK-571 was fur-
ther studied in fl ow cytometric assays. Increased MRP1 expression was related to 
a more pronounced effl  ux of carboxyfl uorescein. Exposure to MK-571 resulted in 
accumulation of the MRP1 substrate carboxyfl uorescein, demonstrating that MRP1 
can be blocked by a leukotriene inhibitor in prostate cancer cells (Figure 5.2). 
Blocking MRP1 in PC3-R was less eff ective, which is in concordance with a less ef-
fi cient reversal of drug resistance in PC3-R. Increased MRP1 expression combined 
with an increased glutathione content may result in enhanced drug transport, 
which is more diffi  cult to overcome by MK-571. In contrast, DU-R cells contain less 
glutathione and blocking of MRP1 results in a more profound accumulation of 
MRP1 substrate.
We observed accumulation of MRP1 substrate by MK-571 in both chemo-naive 
and chemo-selected cells and enhanced cytotoxicity in chemo-naive and chemo-
selected cells in the chemo-modulation experiments with MK-571 and BSO, which 
appears to refl ect a role of MRP1 and glutathione in MDR of prostate cancer cells. 
The possibility to modulate drug resistance in the chemo-naive parental prostate 
cancer cell lines is of importance because most patients have not previously re-
ceived chemotherapy. Applied concentrations of MK-571 in the MTT assay are 20 
times less than clinically achievable peak plasma levels: the concentration of MK-
571 in our experiments was 30 µM, whereas peak plasma level can reach as high 
as 610 µM in man[23]. BSO has been used in clinical trials[24] and concentrations 
used in this study are clinically achievable as well.
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CONCLUSION
Active drug transport by MRP1 and glutathione metabolism mediated detoxifi ca-
tion appears to infl uence the response to cytotoxic drugs in our prostate cancer 
models and may cause the multidrug resistant phenotype of prostate cancer cells. 
Although we have ruled out involvement of MDR1, upregulation of other MDR 
mechanisms may also play a role. 
As MRP1 can be blocked and glutathione can be depleted in vitro, further in vivo
experiments are imperative as a step towards clinical application of MDR modula-
tion strategies aiming at increased effi  cacy of chemotherapy with respect to pallia-
tion or even prognosis of prostate cancer patients with progressive disseminated 
prostate cancer.
103Identifi cation of MRP1 and glutathione as multidrug resistance mechanisms in prostate cancer cells
REFERENCES
 1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. 
Cancer 1993:71:1098-1109
 2. van der Kolk DM, de Vries EG, Koning JA, van den Berg E, Muller M, Vellenga E. Activity and expression 
of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumour 
cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 1998:4:1727-
36
 3. Kramer RA, Zakher J, Kim G. Role of the glutathione redox cycle in acquired and de novo multidrug 
resistance. Science 1988:241:694-7
 4. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance 
gene products during the progression of human prostate cancer. Clin Cancer Res 1998:4:1393-
403
 5. van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH. Chemosensitivity of 
prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 
1999:35:664-671
 6. Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Sch-
roder FH, et al. Expression of multidrug resistance related proteins and proliferative activity is 
increased in advanced clinical prostate cancer. J Urol 2001 Jan:165:130-5
 7. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990:2:15-22
 8. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a 
human prostatic carcinoma cell line (PC-3). Invest Urol 1979:17:16-23
 9. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma 
cell line (DU 145). Int J Cancer 1978:21:274-81
 10. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature 1970:227:680-5
 11. Zijlstra JG, de Vries EG, Mulder NH. Multifactorial drug resistance in an adriamycin-resistant human 
small cell lung carcinoma cell line. Cancer Res 1987:47: 1780-4
 12. Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, et al. Immunohistochemical detec-
tion and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: as-
sociation with level of drug resistance and drug accumulation. Blood 1989:73:747-52
 13. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT Assay to Human Prostate Cancer Cell 
Lines in Vitro: Establishment of Test Conditions and Assessment of Hormone-Stimulated Growth 
and Drug-Induced Cytostatic and Cytotoxic Eff ects. The Prostate 1988:12:99-110
 14. Armitage P, Berry G. Statistical methods in medical science. 2nd ed. Oxford: Blackwell scientifi c pub-
lications:1987.
 15. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug trans-
porter. Annu Rev Biochem 1993:62:385-427
 16. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to 
Fas-mediated apoptosis. Blood 1997:89:1854-61
 17. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumours. Proc Natl 
Acad Sci U S A 1994:91:3497-504
 18. Hipfner DR, Deeley RG, Cole SP. Structural, mechanistic and clinical aspects of MRP1. Biochim Bio-
phys Acta 1999:1461:359-76
 19. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associ-
ated proteins. J Natl Cancer Inst 2000:92:1295-1302
 20. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II trial of oral estramustine, oral 
etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 
1999:17:1664-71
104
C
ha
pt
er
 5
 21. Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (MRP)-mediated transport of 
leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathi-
one-dependent vincristine transport. J Biol Chem 1996:271:9675-82
 22. Krell RD, Aharony D, Buckner CK, Keith RA, Kusner EJ, Snyder DW, et al. The preclinical pharmacology 
of ICI 204,219. A peptide leukotriene antagonist. Am Rev Respir Dis 1990:141:978-87
 23. Depre M, Margolskee DJ, Hsieh JY, Van Hecken A, Buntinx A, De Lepeleire I, et al. Plasma drug profi les 
and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man. Eur J Clin 
Pharmacol 1992:43:427-430
 24. O’Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, et al. Phase I trial of buthionine 
sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996:14:249-
56
CHAPTER 6
In vitro- and in vivo reversal of resistance 
against chemotherapy with leukotriene D4 
antagonist MK-571 in MRP1-expressing human 
prostate cancer cell line PC346C and xenografts 
PC339 and PC346BI.
van Brussel JP, de Ridder C, van Weerden WW, 
Mickisch GHJ. 
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SUMMARY
Purpose: effi  cacy of chemotherapy has been limited in advanced prostate cancer, 
possibly as a result of the multidrug resistance phenomenon (MDR). The multidrug 
resistance associated protein (isoform 1; MRP1) mediated MDR can be selectively 
modulated with the leukotriene inhibitor MK-571. The objective of the present 
study was to investigate the possibility to chemosensitize prostate cancer In vitro
and in vivo aiming at modulation of MRP1-related MDR.
Methods: expression of MDR associated proteins P-glycoprotein (MDR1), MRP 
isoforms 1 and 2 was determined with Western blotting in a panel of human pros-
tate cancer xenografts and in the xenograft derived cell line PC346C. The eff ect 
of chemosensitization of PC346C to vincristine (VCR), doxorubicin (DOX) and eto-
poside (VP-16) with MK-571 on cell growth was assessed with cell viability assays. 
Effi  ciency of blocking the MRP1 pump with MK-571 was investigated in PC346C by 
measuring the carboxyfl uorescein effl  ux in fl uorescence assays. Toxicity and anti-
tumour eff ect of VCR and VCR combined with MK-571 was determined in vivo using 
the human prostate cancer xenografts PC339 and PC346BI.
Results: MRP1 and MRP2 were expressed in all xenografts and in PC346C. No 
expression of MDR1 was found. Signifi cant chemosensitization with MK-571 was 
achieved In vitro in PC346C. MRP1-mediated carboxyfl uorescein effl  ux was dem-
onstrated in PC346C which was signifi cantly inhibited with MK-571. In vivo applica-
tion of tolerable doses of intravenous VCR to PC339 tumour-bearing mice, with 
relatively high MRP1 expression, resulted in signifi cant although transient reduc-
tion of tumour volumes. Intravenous VCR combined with intraperitoneal MK-571 
resulted in signifi cant in vivo chemosensitization to VCR to the xenograft PC346BI, 
which had relatively low MRP1 expression.
Conclusions: eff ective chemosensitization with MK-571 was demonstrated, both 
in vitro and in vivo, indicating that MRP1 plays a role in the in vitro and in vivo MDR 
phenotype of prostate cancer. These fi ndings may encourage clinical chemosensi-
tization strategies to improve results of chemotherapy in advanced prostate cancer 
patients.
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INTRODUCTION
Clinically, metastasized prostate cancer can progress to a hormone-independent 
state. Failure of androgen deprivation to halt tumour growth necessitates alterna-
tive treatment modalities to challenge advanced prostate cancer. Chemotherapy 
results have been disappointing, with limited response rates in metastatic prostate 
cancer[1, 2]. Recently, two randomized clinical trials have reported on a two to four 
month survival benefi t with combination therapies of docetaxel and prednisone or 
docetaxel and estramustine as compared to mitoxantrone and prednisone, respec-
tively[3, 4]. Resistance against a variety of chemotherapeutic agents- multidrug 
resistance-(MDR), has been well described in many studies, among which several 
have focussed on prostate cancer[5]. In vitro experiments have demonstrated the 
expression of MRP1 in human prostate cancer cell lines, among other multidrug 
resistance related proteins[6, 7]. Further experiments have pointed out a role of the 
multidrug resistance associated protein 1 (MRP1) in in vitro prostate cancer, which 
was upregulated in cells treated with etoposide resulting in increased resistance 
against etoposide, doxorubicin and vincristine. Reversal of resistance of prostate 
cancer cells was achieved with leukotriene inhibitor MK-571, which blocked the 
function of MRP1, namely ATP-dependent extrusion of MRP1 substrates, compris-
ing several chemotherapeutic drugs, including vincristine, doxorubicin and eto-
poside[8]. In clinical prostate cancer, increased expression of MRP1 in advanced 
prostate cancer was found[9] , as compared to locally confi ned disease, possibly 
explaining the clinical resistance of disseminated progressive prostate cancer 
against chemotherapy.
Elaborating on these fi ndings, the goals of the present study were to confi rm the 
relevance of in vitro expression of MRP1 and modulation of drug resistance by tar-
geting MRP1 for an in vivo situation. We have studied a xenograft derived prostate 
cancer cell line PC346C[10] to determine the possibility to modulate etoposide, 
doxorubicin and vincristine response with MK-571. After verifying the concept of 
chemosensitization in PC346C, we proceeded to in vivo experiments using athymic 
nude mice bearing human hormone independent prostate tumours: xenograft 
models PC-346BI and PC-339 established in our laboratory [10, 11] were used to 
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investigate modulation of vincristine response with leukotriene inhibitor MK-571 
in vivo.
Application of chemo-sensitization strategies in advanced prostate cancer have 
been successful in cell cultures. Therefore, these in vivo experiments aim at provid-
ing the important link between in vitro reversal of multidrug resistance and the 
clinical application of chemo-modulation. To proceed to clinical studies, informa-
tion on effi  cacy and, particularly, on toxicity of such strategies in a biological set-
ting is of the utmost importance. Patients with metastatic hormone-independent 
prostate cancer, in whom, at present, eff ective therapy is lacking, may benefi t from 
chemo-sensitization.
MATERIALS AND METHODS
Cell lines
The human prostate cancer cell line PC-346C was established from the PC-346 xe-
nograft [10] derived from primary tumour tissue from a transurethral resection of 
the prostate (TURP) from a non-progressive prostate cancer patient. Both the xeno-
graft and the cell line PC-346C are androgen responsive, secrete prostate specifi c 
antigen (PSA) and express the wild type androgen receptor. PC-346C cells were cul-
tured in a modifi ed medium based on Dulbecco’s modifi ed Eagle’s medium/Ham’s 
F12 (1:1) (Invitrogen, Breda, The Netherlands) supplemented with 2% (v/v) foetal 
calf serum, 1% Insulin-Transferrin-Selenium-general (ITS-G) (Invitrogen, Breda, The 
Netherlands), 10 ng/ml epidermal growth factor (EGF, Sigma Aldrich, St Louis, MO, 
USA), 0.1 nM of the synthetic androgen R1181 (NEN, Boston, MA, USA). Serving as 
control cell lines in the MRP1 experiments, the human small-cell lung-carcinoma 
cell line GLC4 and the in vitro-selected adriamycin-resistant GLC4/ADR[12] were 
cultured in RPMI 1640 medium, supplemented with 7.5% (v/v) foetal calf serum, 
100 units/mL penicillin, 100 µg/mL streptomycin and 2 mM glutamine (all Gibco-
BRL, Paisley, United Kingdom). The multiple myeloma cell line 8226 S (MDR1 nega-
tive control cell line) and its doxorubicin selected variant 8226 D6 (MDR1 positive 
control cell line) [13] were cultured in RPMI 1640 (Invitrogen – Life Technologies, 
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Paisley, Scotland) supplemented with 10% foetal calf serum, 2 mM L-glutamin, 100 
U/ml penicillin and 100 µg/ml streptomycin in a humidifi ed atmosphere of 5% CO2 
in air at 37oC. The 8226 D6 cell line was routinely cultured in the presence of 60 nM 
doxorubicin, however at least two days before use in an experiment the cells were 
cultured in medium without doxorubicin. The cell lines were regularly tested for 
mycoplasma infection by a sensitive PCR-based assay.
Xenografts
The PC-339 and PC-346BI human prostate tumour xenografts were selected from a 
panel of 13 human prostate tumour xenograft models [10, 11] on the basis of their 
MRP1 and MRP2 expression levels. The origin and main characteristics of PC-339 
and PC-346BI have previously been published: PC-339 was derived from a patient 
who underwent a transurethral resection and who was progressive under hormon-
al therapy whereas PC-346 was derived from an untreated patient who underwent 
a TURP. PC-346BI is an androgen unresponsive variant of the original PC-346 and 
although androgen independent, still exhibits characteristics of diff erentiation 
such as secretion of PSA (van Weerden, personal communication). The androgen 
independent PC-339 model lacks PSA expression and histologically shows an ana-
plastic nature, representing late stage, hormone refractory disease. 
MDR1, MRP1 and MRP2 expression - Western blotting
PC346C cells were harvested by trypsinization and washed three times with 4oC 
pre-cooled phosphate buff ered saline (pH 7.4). Snap frozen (-80oC) material of 
xenografts PC339 and PC346BI were disrupted in a Polytron blender (Kinematica, 
Switzerland), washed three times with 4oC pre-cooled phosphate buff ered saline 
pH 7.4 and fi nally pelleted in 0.5 ml polypropylene Eppendorf tubes at 13.000 rpm 
and 4oC. Supernatants were removed without disturbing the cell pellets. Pellets 
of 5-50x106 cells were solubilized in 100 µl 20 mM tris-HCl pH7.4 containing 1 mM 
MgCl2, 2% (v/v) Triton X-100, 0.1% (w/v) SDS and protease inhibitors (Complete 
tablets, Roche Diagnostics GmbH, Mannheim, Germany), by end over end rotation 
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on a Westbart RM10A roller apparatus overnight at 4oC. After the cell lysates were 
centrifuged at 13.000 rpm for 30 minutes at 4oC the resulting supernatants were 
fi ltrated over an Acrodisc LC13 PVDF 0.45 µM fi lter (Gelman Sciences, USA). Each fi l-
trate was mixed with 3 volumes of SDS-PAGE (4x) sample buff er, pH 6.8, containing 
0.25 M Tris-HCl, 40% (v/v) glycerol, 8% (w/v) SDS, 20% (v/v) â-mercaptoethanol and 
0.02% (w/v) pyronin G. Cell lysate samples (4 µg protein for MDR1, 20 µg for MRP1 
and 4µg for MRP2) in Laemmli buff er[14] (15 µl) were heated for three minutes 
(100 oC) and loaded on a 10% SDS-polyacrylamide gel and electrophoresed for 60 
minutes at 100 Volts. Prestained markers (Novex, San Diego, California) were used 
as size standards. Subsequently, the proteins were transferred to a nitrocellulose 
membrane (Protan Nitrocellulose, Schleicher & Schuell, Dassel, Germany) by elec-
troblotting at 100 V for 60 minutes. The blotting paper was blocked by incubating 
the blot for 1 hour in Tris buff ered saline (TBST, pH 7.5) containing 5% (v/v) NFDM 
(non fat dry milk protifar plus; Nutricia, the Netherlands). The membranes were 
then incubated overnight in TBST, pH 7.5, containing 5 % NFDM at 4oC with the 
C219 MDR1 antibody (Signet, Dedham, MA; dilution 1:1000), the MRPr1 (Sanbio, 
the Netherlands) MRP1 antibody and the M2III-6 MRP2 antibody (Sanbio, the 
Netherlands) at 1 : 1000 dilution in TBST, pH 7.5, containing 5 % NFDM blotting 
substrate. After washing with TBS containing 0.1% Tween 20 (Sigma), the mem-
branes were incubated with rabbit-anti-rat immunoglobulines conjugated to HRP 
(1/1000; Dako). Protein bands were visualised by chemiluminescence.
In vitro response to chemotherapy with or without the MRP1-modulator MK-571 - MTT 
assay
Sensitivity of PC346C to antineoplastic drugs with or without addition of MK-571, 
was assessed by the MTT assay [15]. Cells were plated in 96-well plates (Costar 
Corp. Cambridge, MA, USA) at densities allowing logarithmic growth throughout 
the experiments. After allowing the cells to adhere for 24 hours, cells were then 
incubated with culture medium containing a range of exponentially increasing 
concentrations of cytotoxic agents for a period of 72 hours. For in vitro testing, 
drug solutions were freshly prepared in culture medium. The following compounds 
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were tested: etoposide (VP-16; Pharmachemie BV, Haarlem, the Netherlands), 
doxorubicin (DOX; Farmitalia Carlo Erba, Italy) and vincristine (VCR; Pharmacia, the 
Netherlands). MK-571 dose-response curves were obtained by exposing cells to 
exponentially increasing concentrations of these drugs in an identical manner as 
the cytotoxic drugs. In addition, cells were incubated with a maximum non-toxic 
concentration of MK-571 together with the cytotoxic drugs. After 72 hours, 30 ml 
of MTT (Sigma Chemical Co., St. Louis, MO, USA) solution (5 mg/mL in PBS) was 
added to each well and incubated for 4 hours at 37oC. The supernatant was care-
fully aspirated and 100 ìl of dimethylsulfoxide (DMSO, Merck, Darmstadt, Germany) 
with alkalinizing buff er (0.1 M glycin, 0.1 M NaCl, pH 10.5) was added to each well. 
The plates were shaken for 5 minutes in order to dissolve the formazan crystals. The 
absorbance was measured photometrically at 570 nm using a Bio-Rad Microplate 
Reader (Model 450, Bio-Rad, CA, USA). The percentage of viable cells was calculated 
relative to untreated cells. All assays were done in triplicate.
Measurement of MRP1 and MDR1 function in a fl uorescence assay
For measurement of the function of MRP1 in cell lines PC346C, GLC4 and GLC4/ADR, 
the fl uorescent molecule DCFDA (Sigma Chem Co. St Louis, MO, USA) was used as 
an MRP1 substrate[16]. For measurement of the function of MDR1 (P-glycoprotein) 
in cell lines PC346C, 8226 D6 and 8226 S, Rhodamine 123 (Sigma) was used as a 
MDR1 substrate[17] . Cells were incubated at 37oC for 1 hour at 5% CO2 in the ab-
sence or presence of 100 µM of the MRP1 modulator MK-571 (Alexis Biochemicals) 
or 2 µM of the MDR1 modulator PSC 833[18] (Novartis Pharma, Basel, Switzerland). 
Following this incubation, 0.1 µM DCFDA or 200 ng/mL rhodamine 123 was added 
to the cells. A sample was taken at 60 minutes to assay MRP1 function or at 75 min-
utes to assay MDR1 function via intracellular DCFDA or rhodamine accumulation, 
respectively, after optimalization of experimental protocols. Cells were incubated 
with 0.1 µM TO-PRO-3 (Molecular Probes, Inc. OR, USA) to exclude non-viable cells. 
Fluorescence was measured using a FACScalibur (Becton Dickinson, USA). The in 
vitro-selected adriamycin-resistant human small-cell lung-carcinoma cell line 
GLC4/ADR, expressing MRP1 at high levels, as well as parental cell line GLC4, served 
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as positive control. Cell line 8226 D6 served as positive control in rhodamine 123 
accumulation assay and 8226 S as negative control[13]. All experiments were done 
in triplicate.
In vivo treatment of human prostate cancer cells with Vincristine and/ or MK-571
- Mice
Intact male NMRI athymic nude mice [19] were obtained from Harlan Holland 
(Horst, The Netherlands). Mice were kept under specifi c pathogen-free conditions 
with water and food ad libitum. The study was authorized by the Institutional 
Committee for the Use of Experimental Animals in research in compliance with the 
Dutch Law on Animal Experiments.
- Drug treatment
Treatment of non-tumour bearing (control) mice with VCR and MK-571 was per-
formed to ascertain the relative safety, in terms of toxicity, in the strain of athymic 
nude mice used (NMRI) prior to application to tumour-bearing mice. Maximum 
tolerated dosages (MTD) were identifi ed for a single dose schedule. Dosages were 
chosen according to literature data[20-22] and based on tolerated dosages of the 
chemotherapeutics and modulators as resulting from the outcome of previous in 
vitro studies[8]. Criteria of toxicity are based on guidelines of the “Code of Practice 
of the use of experimental animals in cancer research”.
- Experimental study
PC-339 and PC-346BI tumour fragments were implanted subcutaneously in the 
right shoulder of intact male athymic nude mice. Treatment was started when 
tumours were established. Maximum tolerated dose (MTD) of vincristine intrave-
nously (i.v.) and MK-571 intraperitoneally (i.p.) were used as was fi rst determined 
in non-tumour-bearing animals. PBS (control) was administered intraperitoneally. 
Mice were assigned to the following treatments: a PBS control group, a group in 
which MK-571 was administered intraperitoneally at a 40 mg/kg concentration, a 
group in which MK-571 was administered at a 80 mg/kg concentration (in PC346BI 
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only), a group in which vincristine was administered intravenously at a 0.8 mg/kg 
concentration, a group in which vincristine (0.8 mg/kg intravenously) was admin-
istered in combination with MK-571 (40 mg/kg intraperitoneally) and a group in 
which vincristine (0.8 mg/kg) was administered in combination with a 80 mg/kg 
concentration of MK-571 (in PC346BI only).
- Tumour measurement and body weight
Tumour growth was followed twice weekly by caliper measurements of tumour 
nodules. Tumour volume was estimated using the following formula: TV = π/6 * 
(d1*d2) 3/2, with d1 and d2 being two perpendicular tumour diameters. Body 
weight of mice was followed concomitantly.
- Antitumour activity
Tumour growth curves (tumour volume versus time) were determined for the dif-
ferent treatments. Slopes of the growth curves, defi ned as the regression line of 
tumour volume versus time, were calculated. Antitumour activity was determined 
by comparing slopes to PBS control experiments and calculating signifi cant diff er-
ences (p< 0.05) between treatments.
Statistical analysis
We calculated 95% confi dence intervals to determine statistically signifi cant dif-
ferences between IC50 values in the cell viability assays. IC50 values and standard 
errors of the mean were calculated from three representative experiments with the 
Delta method[14].
Analyses of xenograft experiments was done with SAS procedure PROC MIXED, 
version 8.02 (SAS Institute Inc, Cary, NC, USA). In order to calculate the doubling 
time of tumour volume, the value was converted to 2Log(tumour volume). Us-
ing this logarithmic value, the slope of tumour volume rise was calculated. The 
doubling time was calculated by taking 1/slope. p-Values were calculated for the 
comparison of the doubling time of the diff erent treatment groups among each 
other and with the placebo group.
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RESULTS
MRP1 and MRP2 expression in xenografts and xenograft derived cell line PC346C.
MRP1 and MRP2 were variably expressed in prostate cancer xenografts PC82, 
PC133, PC135, PC295, PC310, PC324, PC329, PC339, PC346, PC346I, PC346B, 
PC346BI, PC374, PC374F and cell line PC346C.
Figure 6.1 shows a representative Western blotting experiment with detection 
of MRP1 and MRP2 in prostate cancer xenografts PC339, PC346BI and cell line 
PC346C. MRP1 and MRP2 had similar expression patterns in the xenografts.
PC339, with relatively high MRP1 expression and PC346BI, with relatively low 
MRP1 expression, were chosen for further in vivo experiments. 
MDR1 could not be detected in Western blotting experiments, although the 
positive control cell line 8226 D6 showed MDR1 expression (data not shown) .
Figure 6.1. Western blotting
MRP1 expression in prostate cancer xenografts PC339 and PC346BI and in prostate cancer cell line PC346C.
Cell extracts (20 µg for MRP1 and 4µg for MRP2) were loaded and subjected to SDS-PAGE and blotted onto nitrocellulose fi lters.
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Chemosensitization of cell line PC346C to etoposide, doxorubicin and vincristine with 
MK-571.
Table 6.1 shows the results of exposure of PC346C to etoposide, doxorubicin and 
vincristine (IC50 values). Signifi cant sensitization of PC346C was achieved in the 
presence of a non-toxic dose of 5 µM MK-571 (as determined in preliminary experi-
ments, data not shown), refl ected by 2.4-, 3.6- and 7.7-fold decreased resistance 
factors (RF) for etoposide, doxorubicin and vincristine, respectively.
Table 6.1. Sensitivity of prostate cancer cell line PC346C to various cytotoxic drugs and modulation of drug resistance by 5 µM MK-571.
RF IC50 (Molar)
VP-16 1 8.7 x 10-7 ± 0.9 x 10-7
VP-16 + MK-571 0.41 ± 0.1* 3.6 x 10-7 ± 0.4 x 10-7
DOX 1 5.6 x 10-8 ± 0.15 x 10-8
DOX + MK-571 0.28 ± 0.013* 1.6 x 10-8 ± 0.04 x 10-8
VCR 1 5.0 x 10-10 ± 0.3 x 10-10
VCR + MK-571 0.13 ± 0.04* 6.6 x 10-11 ± 0.4 x 10-11
The in vitro sensitivity to cytotoxic drugs of xenograft derived prostate cancer cell line PC346C was examined using the MTT assay. The values 
are the calculated mean IC50 values ± standard error of the mean (SEM) for etoposide (VP-16), doxorubicin (DOX) and vincristine (VCR) either 
in the absence or presence of MRP1 modulator MK-571. Also shown are the resistance factor values which indicate changes in IC50 values after 
exposure to MK-571 and a chemotherapeutic drug. 
RF= resistance factor.
IC50= drug concentration which inhibits the cell growth by 50%. 
* signifi cant modulation: 95% confi dence intervals do not overlap.
DCFDA effl  ux blocking with MK-571 in PC436C, GLC4 and GLC4/ADR.
The possibility to modulate MRP1 activity was studied in cells by measuring their 
ability to extrude DCFDA in the absence or presence of MK-571. Ratios of DCFDA 
content with and without MK-571 (blocking factor) representing the relative inhi-
bition of MRP1 function by MK-571 were 7.2 in PC346C, 12.2 in GLC4 and 28.9 in 
GLC4/ADR. Figure 6.2 shows fl uorescence histograms, representing fl uorescence 
intensity and refl ecting DCFDA content, with and without MK-571. No toxicity was 
observed of the 100 µM MK-571 used during the course of the experiment. This 
was verifi ed with TO-PRO-3 to exclude non-viable cells, revealing a survival of 98 to 
99% of cells during the experiment in every cell line.
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Flow cytometry using a rhodamine retention assay with MDR1 substrate PSC833 
showed no MDR1 function in cell line PC346C. MDR1 function was clearly detected 
in the drug resistant plasma cell line 8226 D6, which served as positive control. 
The blocking factor (increased rhodamine accumulation) was 5.6 for the positive 
control and 0.96 for the negative control 8226 S.
Figure 6.2. Modulation of MRP1-mediated carboxyfl  uorescein transport by MK-571
Signifi cant tumour reduction with the vincristine – MK-571 combination compared to 
vincristine alone - in vivo experiments
To investigate adequate bio-activity of our in vitro chemosensitization strategy, 
combinations of vincristine and MK-571 were tested in athymic nude mice bear-
ing either the human prostate tumour models PC339 (relatively high expression of 
MRP1) or PC346BI (relatively low expression of MRP1). 
In these xenografts, vincristine dosages were tolerated equally well: maximum 
tolerated dose (MTD) of vincristine i.v. was determined at 0.8 mg/kg in PC339 and 
PC346BI. The MTD of MK-571 was higher in PC346BI than in PC339 (80 mg/kg versus 
40 mg/kg). No major side eff ects (neurotoxic or gastro-intestinal) were observed 
for single drug administration or combined treatments. In PC339 we measured no 
weight loss at all, whereas in PC346BI we observed a weight loss of 17,8% in 7 days 
in the group treated with vincristine and MK-571, but mice recovered to a weight 
loss of 6% over a 14 days period. In both xenografts, tumourgrowth was highest in 
GLC4 ratio 12.2 GC4/ADR ratio 28.9  PC346C ratio 7.2 
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the group treated with PBS. Treatment with MK-571 did not alter tumour growth 
during the course of the experiments.
For PC339, the average growth curves are shown in fi gure 6.3a for the treatment 
with 0.8 mg/kg vincristine and for 0.8 mg/kg vincristine combined with 40 µg/kg 
MK-571. A signifi cant anti-tumour eff ect of vincristine alone (p= 0.0002) and of vin-
cristine combined with MK-571 (p< 0.0001) is seen as compared to placebo (PBS) 
over a 14 day interval. We observed a trend for a stronger anti-tumour eff ect in the 
vincristine combined with MK-571 group, although this did not reach signifi cance 
(p= 0.16). Tumour volumes decreased during the course of the experiment, without 
signifi cant regrowth until the end of this experiment at 14-days.
For PC346BI the average growth curves are shown in fi gure 6.3b for the treat-
ment with 0.8 mg/kg vincristine and for 0.8 mg/kg vincristine combined with 80 
µg/kg MK-571.  An anti-tumour eff ect is observed when vincristine is administered, 
although not signifi cant (p= 0.081 at 7 days and p= 0.29 at 14 days). However, ad-
dition of MK-571 to vincristine resulted in a signifi cant anti-tumour eff ect after 7 
days, when compared to PBS (p=0.004 at 7 days and p= 0.058 at 14 days) and when 
compared to vincristine alone (p= 0.039 at 7 days; p= 0.12 at 14 days). Growth 
curves show maximum tumour regression around the seventh treatment day, fol-
lowed by regrowth of tumours, refl ected by increased slopes of the growth curves. 
Three mice were again treated with the vincristine and MK-571 regimen at day 
14, without signifi cant anti-tumour eff ect, although in one mouse a 28% tumour 
volume reduction was measured at day 21. 
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Figure 6.3.
For PC339, the average growth curves are shown in fi gure 6.3a for the single dose treatment with 0.8 mg/kg vincristine and for 0.8 mg/kg 
vincristine combined with 40 µg/kg MK-571. For PC346BI, the average growth curves are shown in fi gure 6.3b for the treatment with 0.8 
mg/kg vincristine and for 0.8 mg/kg vincristine combined with 80 µg/kg MK-571.
Table 6.2a summarizes the slopes of the growth curves of tumours in diff erent 
treatments, refl ecting the regression line of tumour volume in time, representing 
the anti-tumour eff ect of the treatment. The anti-tumour eff ects of the treatments 
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are compared in table 6.2b and p-values are given. A higher slope refl ects a more 
aggressively growing tumour. 
Table 6.2a: Anti-tumour eff ects of phosphate buff ered saline (PBS), MRP1 modulator MK-571, cytotoxic drug vincristine and the combination 
of MK-571 and vincristine on in vivo prostate cancer models PC339 and PC346BI.
PC339
slope 14 days
PC346BI
slope 7 days
PC346BI
slope 14 days
PBS 98.8 65.2 64.2
MK-571 40 mg/kg 98.8
MK-571 80 mg/kg 58.8 61.2
vincristine 0.8 mg/kg -38.5 12.6 44.3
vincristine 0.8 mg/kg
+ MK-571 40 mg/kg
-58.7
vincristine 0.8 mg/kg
+ MK-571 80 mg/kg
-48.1 12.9
Anti-tumour eff ects are refl ected as slopes, which is defi ned as the regression line of tumour volume versus time. Xenografts PC339 and PC346BI 
are treated with placebo (PBS), respectively 40 and 80 mg/kg of MK-571, 0.8 mg/kg of vincristine and the combination of vincristine and 
MK-571.
Table 6.2b: Comparison of anti-tumour eff ects of phosphate buff ered saline (PBS), MRP1 modulator MK-571, cytotoxic drug vincristine and the 
combination of MK-571 and vincristine (VCR) in in vivo prostate cancer models PC339 and PC346BI.
MK 40 mg/kg MK80 mg/kg VCR 0.8 
mg/kg
VCR 0.8 mg/kg + 
MK 40 mg/kg
VCR 0.8 mg/kg + 
MK 80 mg/kg 
PC339 PBS 0.88 0.0002* <0.0001*
(14 days) VCR 0.8 0.16
PC346BI PBS 0.89 0.081 0.004*
(7 days) VCR 0.8 0.039*
PC346BI PBS 0.91 0.29 0.058
(14 days) VCR 0.8 0.12
p-values refl ect diff erences in anti-tumour eff ects. * indicates a signifi cantly stronger anti-tumour eff ect.
DISCUSSION
Advanced prostate cancer patients that have failed on hormonal therapy have 
a poor prognosis. Chemotherapy, the treatment modality of choice in many dis-
seminated malignancies, has provided very little help for these patients, due to 
the resistance of most prostate cancer cells to cytotoxic drugs[1-4]. The multidrug 
resistance phenomenon has received a great deal of attention and several papers 
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have reported on its relevance for prostate cancer based on prostate cancer cell 
lines and material obtained from clinical prostate cancer[6, 7, 9]. Also, strategies to 
modulate multidrug resistance in prostate cancer in an in vitro setting have been 
reported and reviewed[5, 8]. The present research aims at further determining the 
relevance of the multidrug resistance phenomenon in clinical prostate cancer, in 
particular MRP1 mediated multidrug resistance. To achieve this in vivo experiments 
are essential because such experiments may form a bridge from the in vitro results 
to future clinical application of strategies to improve results of chemotherapy in 
prostate cancer. However, in vivo experiments, using models for human prostate 
cancer, have not been described. Therefore, experiments to determine effi  cacy 
and toxicity of the in vivo application of a MDR reversal strategy were performed. 
Although the nude mouse model used in our experiments diff ers from man in a 
variety of pharmacological, immunological and endocrine factors, these models 
off er the possibility to study the behaviour of human prostate cancer tissue in a 
physiological setting.
Based on prior studies, showing that MRP1 is expressed in in vitro and clinical 
prostate cancer and in which chemosensitization was achieved in vitro by modula-
tion of MRP1 function with MK-571 [8], this research was focussed on the role of 
MRP1 related MDR in vivo.
In the present study MRP1 expression, as well as MRP2 and MDR1 expression 
were assessed in a panel of human prostate cancer xenografts. In concordance with 
earlier reports[7-9, 23], MDR1 was not found in the in vivo prostate cancer models. 
Therefore, MDR1 probably does not play a role in prostate cancer chemotherapy 
resistance. MRP1 and MRP2 are expressed in all xenografts, as well as in xenograft 
derived cell line PC346C, at varying levels. MRP2 expression appears to follow MRP1 
expression relatively closely. It has been described that kinetic transport properties 
of MRP1 and MRP2 are diff erent but substrate specifi cities of MRP1 and MRP2 are 
quite similar [24]. This may indicate that MRP2, next to MRP1, may be of impor-
tance in MDR of prostate cancer. Further study should be carried out to confi rm this 
hypothesis. The non chemo-selected MRP1 expressing cell line PC346C, derived 
from xenograft PC346[10] was studied in a cell viability assay (MTT). We found that 
the viable cell count was signifi cantly reduced in the presence of chemotherapeu-
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tic agents etoposide, doxorubicin and vincristine when putative MRP1 inhibitor 
MK-571 was added. This may be a result of accumulation of the chemotherapeutic 
agents caused by decreased MRP1 pump activity through inhibition by MK-571, 
leading to increased cell death. This was further studied in fl uorescence assays, 
which revealed signifi cantly increased concentration of MRP1 substrate DCFDA 
in the presence of MK-571. Apparently, MK-571 inhibits MRP1 mediated DCFDA 
cellular effl  ux in PC346C, as well as in the control cell lines. This clearly points at 
a functional role of drug transporter MRP1 in prostate cancer, represented by cell 
line PC346C. Furthermore, MK-571 may be a valuable tool for chemosenstization 
of prostate cancer. 
To proceed towards eff ective and safe clinical application of MDR reversal 
strategies in vivo experiments were initiated to determine effi  cacy and toxicity of 
experimental regimens. Two human prostate cancer in vivo models were selected 
with clear MRP1 expression for further experiments, PC339, with relatively high 
MRP1 expression and PC346BI, with relatively low MRP1 expression. Treatment of 
non-tumour bearing NMRI mice with VCR and MK-571 was performed to ascertain 
maximum tolerated dosages according to criteria of toxicity, based on guidelines 
of the “Code of Practice of the use of experimental animals in cancer research” for 
a single dose schedule (data not shown). These dosages were further applied in 
PC339 and PC346BI. In PC339, vincristine and vincristine combined with MK-571 
produced a signifi cant anti-tumour eff ect compared PBS over a 14 day interval. The 
combination regimen of VCR and MK-571 appeared to have a stronger anti-tumour 
eff ect than VCR alone, with a lower p-value (p<0.0001 and p=0.0002, respectively), 
when comparing to the control (PBS). Although this additive eff ect of MK-571 was 
measured it did not reach signifi cance (p= 0.16). Tumour volume decreased during 
the course of the experiment, without signifi cant regrowth in the 14-day duration 
of the experiment. After this time interval mice were sacrifi ced. In PC346BI an anti-
tumour eff ect was observed when vincristine was administered, although this ef-
fect was not signifi cant (p=0.29). The combination of VCR and MK-571 resulted in a 
signifi cant anti-tumour eff ect after 7 days (p=0.004). Importantly, when comparing 
VCR alone versus VCR + MK-571 at day 7, the latter regimen had a signifi cantly 
stronger anti-tumour eff ect than VCR alone (p=0.039). Growth curves showed max-
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imum tumour regression around the seventh treatment day, followed by regrowth 
of tumours, refl ected by increased slopes of the growth curves. Although regrowth 
occurred, at the 14 days measurement the combination of VCR and MK-571 ap-
peared to have a superior anti-tumour eff ect over VCR alone, with a lower slope 
(44,3 versus 12,9; table 6.2a) and a lower p-value than VCR alone (p=0.058 and 
p=029, respectively). However this diff erence in anti-tumour eff ect did not reach 
signifi cance at day 14. Re-treatment at day 14 resulted in a 28% tumour volume 
reduction in only one mouse.
When comparing both xenografts, PC339 showed a stronger response to vin-
cristine alone, although it had higher MRP1 expression. Apparently, PC339 is more 
sensitive to VCR. It is speculative if other mechanisms of MDR limit the eff ect of 
VCR in PC346BI. MRP2 is expressed in both xenografts and may play a similar role 
in both PC339 and PC346BI as its expression follows MRP1 expression quite closely. 
MDR1 is not likely to cause the diff erence in VCR response as it is not expressed in 
the xenografts. Data on expression and function of other MRP isoforms or other 
MDR factors in the xenografts remain to be obtained. Addition of MK-571 resulted 
in a more moderate anti-tumour eff ect in PC339 than was seen in PC346BI. This may 
have been a consequence of administration of a lower dose of MK-571 in PC339, 
due to dose-limiting toxicity. Also, the achievable anti-tumour eff ect of MK-571 
may have been related to the level of MRP1 expression, resulting in a relatively 
stronger eff ect in PC346BI as compared to the eff ect in PC339. During the course 
of the 14 day experiments, no tumour re-growth was seen in PC339 and mice were 
sacrifi ced after 14 days. However, in PC346BI re-growth became apparent after 7 
days. Half-life in man for vincristine is one day with normal liver function and two 
to three hours for MK-571. Although half-life in mice is unknown, decreased func-
tional levels of VCR and/or MK-571 may have explained the regrowth of surviving 
tumour cells after a week, as observed in PC346BI. As NMRI mice formed the car-
rier for both PC339 and PC346BI, this does not explain the diff erences observed in 
these xenografts. One may speculate that during exposure to vincristine and MK-
571 multidrug resistance mechanisms may have been up-regulated in PC346BI, 
resulting in increased resistance against treatment regimens. This may also explain 
the limited eff ect of a second treatment that was given in PC346BI.
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CONCLUSION
These results demonstrate expression of MRP1 and MRP2 in in vitro and in vivo
models for human prostate cancer. Also, chemosensitization in vitro and, impor-
tantly, the possibility to modulate the response to chemotherapy of prostate can-
cer by inhibiting MRP1 in an in vivo setting was demonstrated. Further fi ne-tuning 
of regimens and use of alternative chemotherapeutic agents and MDR modulators 
may improve anti-tumour activity and reduce toxicity. Therefore, further study on 
the metabolism of chemotherapeutic agents and modulators in an in vivo system, 
as well as assessment of expression of MDR mechanisms other than described in 
this paper, is required. Upregulation of MDR mechanisms during or after treatment 
of xenografts with chemotherapeutic agents with or without modulators should 
be investigated. Also, in the absence of treatment options for patients with hor-
mone-refractory prostate cancer, clinical application of combination therapy of a 
cytotoxic drug and an MRP1 modulator should be investigated and its curative or 
palliative value should be evaluated in a clinical trial.
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CHAPTER 7
General discussion
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BACKGROUND
Failure of chemotherapy as treatment modality for patients with advanced pros-
tate cancer that have progressive disease despite hormone deprivation therapy 
has elicited the present study in which two main questions were addressed.
Primarily, which mechanism causes or which mechanisms cause failure of che-
motherapy in prostate cancer? Secondly, can results of chemotherapy be improved 
by challenging such mechanisms, aiming at an increased cytotoxic eff ect on pros-
tate cancer cells?
Metastatic prostate cancer is resistant to a broad range of antineoplastic agents. 
Although several studies have reported favourably on response rates to chemo-
therapeutical regimens, results of chemotherapy in prostate cancer, single- as well 
as multiple agent regimens, have been disappointing, so far[1-5]. At present, none 
of them have exhibited a clear survival advantage, although two recent random-
ized clinical trials have reported on a two to four month survival benefi t with com-
bination therapies of docetaxel and prednisone or docetaxel and estramustine as 
compared to mitoxantrone and prednisone, respectively. Taxane docetaxel, phos-
phorylates Bcl-2 in vitro. This leads to its inactivation and to eventually to cell death 
by apoptosis[41]. This Bcl-2 pathway may play a role in clinical prostate cancer. It 
is known that anti-apoptotic protein Bcl-2 is increased in advanced prostate can-
cer. Interestingly, the taxoid docetaxel was studied earlier in vivo on doxorubicin 
resistant multidrug resistance protein expressing HT1080/DR4 tumour xenografts 
(sarcoma). Docetaxel showed signifi cant anti-tumour activity and it was suggested 
that docetaxel was not as readily transported by the multidrug resistance protein 
as paclitaxel. Docetaxel may therefore have therapeutic advantages in the clinical 
treatment of multidrug resistance protein expressing tumours[42]. The (limited) 
survival advantage in advanced prostate cancer treated with docetaxel, its in vitro
eff ect on Bcl-2 and the in vivo fi nding that docetaxel has superior anti-tumour ac-
tivity in an multidrug resistance protein expressing sarcoma model indicate that 
MDR pathways may infl uence the response of prostate cancer to chemotherapy. 
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The multidrug resistance (MDR) phenomenon may play a role in progressive ther-
apy resistant prostate cancer and may explain resistance against a variety of struc-
turally- and functionally distinct cytotoxic agents. Tumours may have acquired- or 
induced MDR and can display intrinsic MDR: they are primarily unresponsive to 
chemotherapeutic regimens. Various MDR pathways have been identifi ed over the 
years. Approaches to overcome MDR of chemotherapy-unresponsive tumours have 
been developed or are the subject of present investigations (reviewed in chapter 
2).
RESEARCH SET-UP
Clearly, the fi nal goal of our fi eld of research is to decrease prostate cancer morbid-
ity (improvement of quality of life) and mortality. Before reaching this ultimate step 
with clinical application of strategies to overcome resistance of prostate cancer 
against chemotherapy, many questions have to be answered, as little data exist on 
this matter.
Therefore, we have chosen a straightforward approach towards the development 
of a strategy to overcome resistance of prostate cancer against chemotherapy 
leading from experimental- to clinical prostate cancer. 
Our research was started at the basic level of in vitro prostate cancer, using 
established cell cultures of human prostate cancer. After identifi cation of several 
proteins in in vitro prostate cancer that are known for their role in the multidrug 
resistance phenomenon we proceeded to researching clinical prostate cancer 
material. Identifi cation of several multidrug resistance factors in clinical prostate 
cancer samples confi rmed the relevance of the in vitro expression of certain resis-
tance proteins. However, this provided only indirect evidence of contribution of 
these proteins to the failure of chemotherapy. Consequently, we developed in vitro
models of resistant prostate cancer cells in order to perform functional studies 
to provide direct evidence of involvement of chemotherapy resistance factors in 
prostate cancer cells. Also, such models could provide tools to study strategies to 
overcome resistance against chemotherapy. After confi rming a functional role of 
several previously detected chemotherapy resistance factors, successful applica-
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tion of such a strategy to overcome chemotherapy resistance was demonstrated in 
in vitro prostate cancer. In sight of clinical application of this treatment in prostate 
cancer patients, it is clear that testing of this approach in in vivo models for human 
prostate cancer is essential to confi rm safety and effi  cacy. Therefore, we performed 
a study using in vivo models, that have been developed in our laboratory. This 
showed the possibility to safely apply a strategy to overcome resistance against 
chemotherapy of clinical prostate cancer and bio-activity was demonstrated.
Our attempt to develop a treatment for hormone refractory advanced prostate 
cancer has put us on the doorstep to clinical application of a strategy to overcome 
resistance against chemotherapy. However, for optimal outcome, fi ne-tuning of 
treatment regimens should be carried out and clinical safety and effi  cacy should 
be assessed in a controlled clinical trial.
This discussion will elaborate on the fi ndings and conclusions of our studies, and 
future perspectives will be set out.
IN VITRO STUDIES – CELL LINES; IMMUNOCYTOCHEMISTRY
To obtain insight into the role of the multidrug resistance (MDR) phenomenon in 
hormone-independent progressive prostate cancer the in vitro study as described 
in chapter 3 was initiated. The expression of various multidrug resistance related 
proteins was determined using immunocytochemistry and Western blotting. Fur-
thermore, the intrinsic resistance against chemotherapy was determined. Estab-
lished human prostate cell lines PC3[6], TSU-Pr1[7], DU145[8], LNCaP[9] derivatives 
LNCaP-R[10], LNCaP-LNO[11] and LNCaP-FGC were used for this purpose.
Based on a literature study (described in chapter 2) an inventory was made of 
several MDR related proteins including drug transporter proteins Pgp[12] and 
MRP1[13], detoxifying enzyme Glutathione-S-transferase-p (GST-π)[14], which is 
part of the glutathione metabolism, proteins that are important in programmed 
cell death or apoptosis Bcl-2[15] and Bax[16], and topoisomerases I, IIα and IIβ[17] 
that may cause multidrug resistance when their expression and/or activity is al-
tered.
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Pgp, which has long been considered as the predominant protein responsible for 
MDR in malignancies, was not expressed in the human prostate cancer cell lines, 
whereas our chemo-resistant positive control cell line[18] RC21E (renal cell cancer) 
showed a clear signal in the Western blotting experiments. This result is in line with 
our fi nding in further experiments, in which Pgp was expressed neither in clini-
cal prostate cancer samples at diff erent stages of progression (chapter 4), nor in 
chemo-selected multidrug resistant prostate cancer cell lines (chapter 5), nor in 
prostate cancer xenografts (chapter 6). A role for Pgp (MDR1) is therefore not likely 
in chemo-resistance of prostate cancer.
In contrast to Pgp, the multidrug resistance associated protein MRP1, another 
drug transporter protein, which was detected in MDR cell lines that lacked Pgp[13], 
was variably but clearly expressed in the prostate cancer cell lines. The relevance 
of the MRP1 expression for the resistance against chemotherapy in prostate cancer 
has played a central role in our further research (chapters 4, 5 and 6), especially 
because encouraging results of preliminary experiments, aiming at reversal of pu-
tative MRP1 mediated drug resistance in prostate cancer cell lines, were obtained.
GST-π was expressed in PC3, TSU-Pr1 and DU145, but not in the LNCaP deriva-
tives which may be due to hypomethylation or hypermethylation of GST-π promo-
tor sequences, respectively[19]. Further studies were performed regarding clinical 
GST-π expression (chapter 4) and expression of GST-π in chemo-selected prostate 
cancer cell lines and modulation of glutathione mediated drug detoxifi cation by 
cellular depletion of glutathione by buthioninesulfoximine (chapter 5).
Bcl-2, the protein that inhibits apoptosis and may cause resistance against apop-
tosis-inducing chemotherapeutics, was expressed in only one cell line in our ex-
periments, namely TSU-Pr1. In contrast to our fi ndings, other studies reported Bcl-2 
expression in LNCaP and in a drug resistant variant of PC3 [20]. We have elaborated 
on Bcl-2 by determining expression in clinical prostate cancer samples (chapter 4), 
but we have not carried out functional studies, because of confl icting data on Bcl-2 
expression in prostate cancer. However, experiments with sequence-specifi c down-
regulation of Bcl-2 using antisense oligonucleotides may be worthwhile [21].
Bcl-2 counterpart Bax was variably expressed in prostate cancer cell lines. The 
balance between Bax and Bcl-2 may determine the response of prostate cancer 
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cells to chemotherapy. As for Bcl-2, Bax expression in clinical samples was assessed, 
but functional studies were not done.
Expression of topoisomerase I, IIα and IIβ was determined in the prostate cancer 
cell lines. The topoisomerases I and IIβ were equally expressed in all cell lines and 
expression of topoisomerase IIα was related to BrdU stainings, which refl ects prolif-
erative activity. Topoisomerase enzymes are essential for several cellular processes 
and constitute targets for a number of clinically important drugs, which induce 
lethal damage by irreversibly stabilizing Topo-DNA complexes. Topoisomerase 
directed drugs, such as etoposide and doxorubicin are generally believed to be tar-
gets to the IIα isotype[22], although Topo I[23] and IIβ[24] may constitute targets 
as well. Expression of the topoisomerases was further studied in clinical samples at 
diff erent stages of progression and it was concluded that increased expression in 
more progressive disease could not be matched with resistance to chemotherapy 
(see below and chapter 4). We could not detect changes in topoisomerase activity 
in preliminary studies (data not shown), although an other group found that selec-
tion of a prostate cancer cell line for 9-nitrocamptothecin resistance resulted in 
altered topoisomerase IIα activity and increased sensitivity to etoposide [25]. Table 
7.1 summarizes the expression of MDR factors in cell lines studied in chapter 3.
IN VITRO STUDIES – CELL LINES; RESPONSE TO CYTOTOXIC DRUGS
To obtain insight in the relation between expression of multidrug resistance as-
sociated factors and response to chemotherapy we determined the intrinsic re-
sistance against three chemotherapeutic agents which are commonly used in the 
treatment of several malignancies, whose action is known to be aff ected by MDR: 
etoposide, doxorubicin and vinblastine. Vinblastine, etoposide and doxorubicin 
are substrates for the drug transporters Pgp and MRP1. Doxorubicin and etopo-
side (and not vinblastine) are conjugated to less toxic and more easily excretable 
metabolites by glutathione. Bcl-2 may block etoposide and doxorubicin induced 
apoptosis. Changes in expression or activity of Topoisomerases may decrease eto-
poside or doxorubicin induced toxicity. The cell lines were in proliferative growth 
when tested and responded variably to exposure to cytotoxic drugs.
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Possibly, response to chemotherapy is infl uenced by a combined action of MDR 
factors, which makes interpretation of dose response curves versus expression of 
MDR factors speculative and diffi  cult. Also, proliferative activity, measured with 
BrdU incorporation in our experiments may infl uence response of cells to che-
motherapy. This is illustrated by cell lines TSU-Pr1 and DU145, which are rapidly 
proliferating and the most sensitive to chemotherapy.
To further determine the importance of one specifi c MDR factor in the resistance 
of prostate cancer cells, experiments are needed with cells that either express only 
one MDR factor or in which one MDR factor is specifi cally challenged. In our opin-
ion, the former approach would not closely match a clinical situation, in which one 
can expect multiple MDR factors to be of infl uence. Therefore, we have chosen the 
latter approach as described in chapter 5.
TSU FGC PC3 LNO R DU145 Group 1 (%) Group 2 (%) Group 3 (%)
P-glycoprotein - - - - - - 0 0 0
Multidrug resistance 
associated protein 1
+ + + + + + 53 100 100
Lung resistance 
protein
nd nd nd nd nd nd 32 47 71
Glutahtione-S-
transferase-π
+ - + - - + 0 18 53
P53 nd nd nd nd nd nd 5 29 65
Bcl-2 + - - - - - 47 47 82
Bax + + + + + + 100 100 100
Topoisomerase I + + + + + + 79 94 94
Topoisomerase IIα + + + + + + 16 59 100
Topoisomerase IIβ + + + + + + 89 100 100
Ki-67 nd nd nd nd nd nd 16 65 82
Table 7.1 summarizing the expression of MDR factors in cell lines studied in chapter 3 and the percent of tumours expressing the MDR 
factors in clinical prostate cancer studied in chapter 4: locally confi ned (group 1), hormonally untreated disseminated prostate carcinoma 
(group 2) and hormone independent prostate carcinoma (group 3). Nd= not determined.
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IN VITRO STUDIES –CLINICAL HISTOLOGICAL MATERIAL
In chapter 4, we addressed the question of clinical relevance of the MDR factors 
that were detected in human prostate cancer cell lines. The purpose of this research 
was to identify proteins that may be involved in the multidrug resistance of clinical 
prostate cancer and assess their expression in the context of tumour progression 
using immunohistochemistry. Three diff erent prostate cancer patient groups, that 
were clearly distinct with regard to disease progression, were examined. Group 1 
consisted of paraffi  n embedded prostate tissue of patients that underwent surgery 
(radical prostatectomy) for locally confi ned disease (pT2N0M0). This group repre-
sented early phase prostate cancer. Group 2 consisted of transurethral resection 
of the prostate material obtained from patients with metastatic prostate cancer 
that were treated for urinary problems, before receiving antihormonal therapy. 
This group represented intermediate phase prostate cancer. Group 3 consisted 
of hormonally-treated metastatic prostate cancer patients that received a pallia-
tive transurethral resection because of progressive disease despite antihormonal 
therapy. This group represented advanced hormone independent prostate cancer. 
The proliferative activity, as refl ected by Ki-67 immunohistochemical stainings, 
was signifi cantly increased in the non-locally confi ned patient groups, in concor-
dance to the clinical phase of tumour progression and this was correlated with 
topoisomerase IIα expression, which is known to be a proliferation marker, as well. 
Pgp (MDR1) was not expressed in any clinical prostate cancer sample, whatever 
the phase of progression. Therefore, it seems unlikely that Pgp plays a role in the 
resistance of clinical prostate cancer.
In contrast to Pgp, MRP1 is clearly expressed in the clinical prostate cancer sam-
ples and, interestingly, we found a signifi cantly increased expression in advanced 
disease, with a signifi cantly higher histological grade of MRP1 positive tumours. 
MRP1 was detected in all cases of metastatic prostate cancer. A relation of MRP1 
expression with tumour progression has been suggested[26] and is confi rmed in 
our study. MRP1 overexpression in advanced tumours may contribute to the MDR 
phenotype of advanced prostate cancer. These results in clinical prostate cancer 
samples, together with the in vitro results (chapter 3), prompted us to pursue in-
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vestigations concerning the relevance of MRP1 in prostate cancer focussing on its 
functional importance. This issue was addressed in vitro (chapter 5) and in vivo
(chapter 6).
We assessed the expression of glutathione-S-transferase-π, a detoxifying en-
zyme which is part of the glutathione detoxifying pathway. We found a signifi cant 
increase in the number of patients expressing this protein in the group with ad-
vanced hormone independent prostate cancer. GST-π was not expressed in organ 
confi ned prostate cancer, in concordance with earlier reports[19, 26]. MRP1 is a 
glutathione-S- conjugate carrier[27]. Possibly, over expression of MRP1 and GST-π 
in advanced prostate cancer may result in increased drug resistance.
The lung resistance protein (LRP) [28] is thought to be involved in the transmem-
brane transport of several substrates. Although its clinical relevance for MDR in 
cancer remains to be proven, we assessed its expression in our panel of clinical 
prostate cancer. We found LRP expression in one third of the organ confi ned pros-
tate cancers and its expression was signifi cantly increased in metastatic disease. 
This fi nding may be of interest in the context of MDR of advanced prostate cancer. 
Altogether, three out of four members of the panel of drug transporter and de-
toxifying proteins were more frequently expressed in hormone independent pros-
tate cancer, possibly refl ecting that chemotherapy failure in progressive disease is 
caused by these mechanisms of multidrug resistance.
Programmed cell death (apoptosis) is triggered by several cytotoxic drugs. 
Changes in proteins that regulate apoptosis can induce resistance against chemo-
therapy. In our immunohistochemical research, three important apoptosis related 
proteins were investigated: Bax, Bcl-2 and p53.
Bax[16] is thought to be a pro-apoptotic protein. Expression of Bax was homoge-
neous in normal prostate tissue and in prostate cancer, regardless of the phase of 
prostate cancer progression.
In contrast, its counterpart Bcl-2[15], an anti-apoptotic protein, is signifi cantly 
more often expressed in the patient group with hormone independent prostate 
cancer, as compared to organ confi ned prostate cancer and hormonally untreated 
metastatic prostate cancer. Bcl-2 expression in hormone independent disease may 
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be one of the factors infl uencing the resistance of this patient group against che-
motherapy.
Furthermore, p53 expression was signifi cantly increased in hormone indepen-
dent disease and its expression was signifi cantly related to a higher histological 
grade. This fi nding matches previous publications, with mutations of p53 occurring 
as a late event in prostate cancer [29]. Wild-type p53 promotes apoptosis. P53 mu-
tation, refl ected by overexpression in immunohistochemistry, results in decreased 
apoptosis and may cause resistance to apoptosis inducing cytotoxic agents. In 
the group with advanced hormone independent disease, p53 over expression 
may therefore result in a decreased susceptibility to apoptosis inducing cytotoxic 
drugs. However, one should bare in mind that immunohistochemical expression 
of p53 does not necessarily represent p53 mutation[30]. The monoclonal p53 anti-
body DO7 detects both wild type and mutated p53, but mutated p53 protein has 
a longer half-life.
Altogether, anti-apoptotic factors appear to be present in hormone independent 
disease, and these may cause MDR of progressive disease.
Because the nuclear topoisomerases are targets for several cytotoxic drugs and 
decreased expression and/ or change in enzymatic activity causes multidrug re-
sistance, we investigated the presence of topoisomerases I, IIα and IIβ in clinical 
prostate cancer after confi rming expression in in vitro prostate cancer. We found 
that expression of topoisomerases I, IIα and IIβ was increased in progressive dis-
ease. Increased expression does not point at a role for topoisomerases in MDR of 
prostate cancer, although we have not determined changes in enzymatic activity. 
On the other hand, increased expression of topoisomerases may favour the ap-
plication of topoisomerase targeting drugs in advanced prostate cancer, although 
the effi  cacy of such drugs may be limited by increased drug effl  ux, detoxifi cation 
and decreased apoptosis by MRP1, LRP, GST-π, p53 mutations and decreased Bax/
Bcl-2 ratio, respectively.
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FUNCTIONAL IN VITRO STUDIES
The presence of several MDR factors in prostate cancer and their altered expression 
in advanced clinical prostate cancer is an indication for their role in the failure of 
chemotherapy. Functional studies will have to clarify this issue. For this reason, we 
developed in vitro models for prostate cancer (chapter 5).
To obtain in vitro models of chemotherapy resistant prostate cancer we applied 
chemo-selection: the prostate cancer cell lines PC3 and DU145 were exposed to 
etoposide. In our opinion, etoposide was the most suitable drug for selection, 
although it is not commonly used in the treatment of prostate cancer. Etoposide 
is know to be a substrate for Pgp and MRP1, it is detoxifi ed by the glutathione 
metabolism, its function is impaired by increased Bcl-2 expression and, fi nally it 
is a topoisomerase targeting drug. Exposure to and selection with etoposide may 
induce cellular changes that involve the MDR factors which are subject of our 
investigations. After multiple cycles of exposure to cumulative concentrations of 
etoposide, increasingly resistant clones were obtained with the limiting dilution 
technique. Finally, this resulted in two chemo-selected in vitro prostate cancer 
models: PC3-R (from PC3) and DU-R (from DU145), which were used for further 
experiments. For these cell lines we determined the resistance against etoposide, 
doxorubicin and vincristine. We found that the multidrug resistance phenomenon 
occurred: cells had not only acquired resistance against etoposide but also to 
doxorubicin and vincristine.
In further experiments we investigated the roles of MRP1 and glutathione, be-
cause increased expression of both MRP1 and GST-π in PC3-R and DU-R was found 
in preliminary immunocytochemical stainings (data not shown). Also, preliminary 
functional studies aiming at these proteins produced encouraging results in terms 
of reversal of resistance against chemotherapy. Increased MRP1 expression in the 
multidrug resistant cell lines PC3-R and DU-R was confi rmed in Western blotting 
experiments. Furthermore, glutathione content was increased in PC3-R in contrast 
to DU-R. Subsequently, with the assumption that MRP1 causes drug resistance in 
the prostate cancer cells, we attempted to block MRP1 function. Using the cell 
viability assay (MTT)[31], cells were exposed to an inhibitor of MRP1-mediated 
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transport, leukotriene D4 antagonist MK-571[32], as well as another leukotriene 
inhibitor, zafi rlukast[33]. From the chemical structure of MK-571 and the fact it was 
designed to bind to cysteinyl leukotriene receptors, it is generally presumed that 
MK-571 competes with the LTC4 binding site(s) of MRP1 which overlaps or is the 
same as the drug binding site(s)[43]. Application of MK-571 resulted in signifi cant to 
complete reversal of acquired resistance in our in vitro models. Furthermore, non-
chemoselected MRP1 expressing cells were sensitised. The possibility to decrease 
drug resistance in chemo-naïve cells is important, because most prostate cancer 
patients have not been exposed to chemotherapy, previously. Zafi rlukast appeared 
to be less eff ective, although signifi cant reversal of resistance was achieved in cell 
line DU-R when combined with vincristine. Application of buthioninesulfoximine 
(BSO) signifi cantly reduced cellular glutathione levels. However BSO did not con-
sistently reduce resistance. In PC3 there was a signifi cant reduction of vincristine 
resistance when BSO depleted glutathione. Etoposide and doxorubicin resistance 
decreased with application of BSO in cell line DU-R. Possibly, diff erent cell lines re-
quire diff erent glutathione concentrations for MRP1-mediated drug transport. The 
relation between the multidrug resistance protein and the glutathione metabo-
lism has been reviewed in chapter 2. In preliminary studies we blocked MRP1 and 
simultaneously depleted glutathione which led to strongly increased cell death, 
even without addition of a cytotoxic drug. This may be a result of MRP1-mediated 
transport of glutathione-S-conjugated endo- and xenobiotics in prostate cancer 
cells.
To actually measure MRP1 mediated cellular transport in our prostate cancer 
models we used a modifi cation of a previously described assay[34] in which 
carboxyfl uorescein was used as a MRP1 substrate. This allowed us to measure 
fl uorescence intensity, and calculate cellular substrate content at diff erent time 
intervals. This showed effl  ux of carboxyfuorescein in untreated cells. When MK-571 
was added, effl  ux was signifi cantly reduced, refl ecting blocking of the MRP1 pump. 
In analogy to this fi nding, it is likely that impaired MRP1 function results in intra-
cellular drug accumulation in prostate cancer cells that are exposed to cytotoxic 
drugs that are MRP1 substrates. This will eventually lead to increased cell death. 
Again, MDR1 did not play a role in our chemo-selected prostate cancer models as 
140
C
ha
pt
er
 7
measured with a rhodamine-retention assay, using PSC833 as a substrate. MDR1 
could neither be detected in Western blotting experiments nor in experiments 
with fl uorescent tagging of MDR1-expressing cells with specifi c antibodies. MDR1 
function and expression in positive control experiments, confi rmed the validity of 
our experiments. For future clinical application, it is important to note that MK-571 
concentrations used in our experiments are 20 times less than clinically achievable 
peak plasma levels[35]. Also, BSO levels as used in our experiments are lower than 
clinically achievable[36]. The experiments described in chapter 5 off er evidence of 
involvement of MRP1 and the glutathione metabolism in the resistance of prostate 
cancer against chemotherapy. Although we have demonstrated that involvement 
of MDR1 is unlikely, we have not ruled out a role of other MDR mechanisms. This 
remains a subject for future studies.
FUNCTIONAL IN VIVO STUDIES
Focussing further on MRP1 as an important factor of drug resistance in prostate 
cancer, important questions remained to be addressed: can the strategy to block 
MRP1 eff ectively be applied in a physiological environment and can such a strat-
egy safely be applied? A confi rmative answer is a prerequisite to proceed to clini-
cal studies. Therefore, we studied effi  cacy and toxicity in the biological setting of 
NRMI athymic nude mice bearing human hormone independent prostate cancers 
(chapter 6). Unfortunately, eff orts to implant and culture our newly established 
chemo-selected multidrug resistant human prostate cancer cell lines into xeno-
grafts failed, due to lack of growth after subcutaneous injection on the shoulders 
of NRMI athymic nude mice. Alternatively, we used established human prostate 
cancer xenografts, that have been developed in our laboratory.
First of all, we determined expression of MDR1, MRP1 and MRP isoform MRP2 in a 
panel of human prostate cancer xenografts and in xenograft derived cell line PC346C 
with Western blotting experiments. As in our other experiments (chapter 3 to 5) 
MDR1 was not expressed. In contrast, both MRP1 and MRP2 were expressed at varying 
level in xenografts and cell line. MRP2 expression appears to follow MRP1 expression 
relatively closely. It has been described that kinetic transport properties of MRP1 and 
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MRP2 are diff erent but substrate specifi cities of MRP1 and MRP2 are quite similar[37]. 
This may indicate that MRP2, next to MRP1, may be of importance in MDR of prostate 
cancer. Further study should be carried out to confi rm this hypothesis.
Cell line PC346C, which is derived from xenograft PC346 [38] was used to a con-
fi rm a role of MRP1 in our experiments. The cell line strongly resembles clinical 
prostate cancer as it expresses androgen receptors and produces PSA. In concor-
dance with the experiments performed in chapter 5 cell viability assays were used 
to study chemosensitization of PC346C to etoposide, doxorubicin and vincristine 
with a non-toxic dose of MK-571. This resulted in sensitisation of PC346C for all 
chemotherapeutic drugs, which may be a result of intracellular accumulation of 
the cytotoxic drugs caused by MRP1 pump activity inhibition by MK-571. Further 
studies with fl uorescence assays revealed a signifi cantly increased concentration 
of MRP1 substrate carboxyfl uorescein in the presence of MK-571. MK-571 inhib-
its MRP1 mediated carboxyfl uorescein cellular effl  ux in PC346C, as well as in the 
control cell lines. This clearly points at a functional role of drug transporter MRP1 
in prostate cancer, represented by cell line PC346C. Furthermore, MK-571 appears 
to be valuable for chemosensitization of prostate cancer. We also examined the 
leukotriene D4 (LTD4) receptor antagonist ONO-1078, which is used for the treat-
ment of allergic asthma and other immediate hypersensitivity diseases (data not 
shown). ONO-1078 has been applied as MRP inhibitor in vitro[39] and could be 
of interest for our studies because it is already in clinical use, as described above. 
ONO-1078 did not decrease the viable cell count of prostate cancer cells, exposed 
to vincristine in MTT assays, nor did it cause accumulation of DCFDA in FACS analy-
ses, performed as described for MK-571. Therefore, it is not likely that ONO-1078 
has clinical value for the treatment of advanced prostate cancer.
After confi rming the feasibility of our strategy in the xenograft derived cell line, we 
proceeded to functional studies in a physiological setting: the NMRI athymic nude 
mice transplanted with a human prostate cancer. As stated previously, proof of ef-
fi cacy and acceptable toxicity of chemosensitization strategies in vivo is an impera-
tive step towards their clinical application. NRMI athymic nude mice xenografted 
with PC339 and PC346BI (derived from human adenocarcinoma of the prostate) 
were used in in vivo experiments and these tumours expressed relatively high and 
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relatively low levels of MRP isoforms (MRP1 and MRP2), respectively. Vincristine 
was selected as cytotoxic drug, because combination of this drug with MK-571 
produced the most signifi cant in vitro chemosensitization. Toxicity of vincristine 
alone, MK-571 alone or combinations of vincristine and MK-571 was assessed in 
non-tumour bearing mice. Toxicity for mice has been defi ned in guidelines of the 
“Code of Practice of the use of experimental animals in cancer research”. Defi ned 
dosages were used in xenografts PC339 and PC346BI.
In PC339 both vincristine alone and vincristine in combination with MK-571 re-
sulted in signifi cant tumour volume reduction. The eff ect appeared to be stronger 
in the combination therapy, but not signifi cantly stronger. In PC346BI vincristine 
alone did not have a signifi cant anti-tumour eff ect. However, the combination 
of vincristine and MK-571 resulted in signifi cant tumour volume reduction, and 
therefore it is likely that MK-571 chemosensitized xenograft PC346BI, although re-
growth occurred after 7 days. It is speculative whether during exposure to vincris-
tine and MK-571 multidrug resistance mechanisms may have been up-regulated in 
PC346BI, resulting in increased resistance against further treatment regimens.
Importantly in chapter 6, the possibility to modulate the response to chemother-
apy of prostate cancer by inhibiting MRP1 in an in vivo setting was demonstrated. 
Further fi ne-tuning of treatments and application of alternative chemotherapeutic 
drugs and MDR modulators, may improve anti-tumour effi  cacy and reduce toxicity.
FUTURE DIRECTIONS
As a result of the studies, which are described in this thesis, several mechanisms have 
been identifi ed that potentially cause failure of chemotherapy in clinical prostate 
cancer. Also, we have successfully increased the cytotoxic eff ect of chemotherapy 
on prostate cancer cells by challenging multidrug resistance mechanisms.
Investigation into expression and function of described and newly emerging 
factors that may cause multidrug resistance is of importance, as well as further 
refi nement of in vitro and in vivo chemosensitization strategies: chemotherapeutic 
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drugs and chemosensitization strategies may be combined, depending on expres-
sion patterns of MDR factors in prostate cancer cells. Newly emerging cytotoxic 
drugs and chemosensitizers could be tested in our in vitro and in vivo prostate 
cancer models. Upregulation of MDR mechanisms during or after treatment with 
chemotherapeutic drugs with or without modulators should be investigated. Fur-
thermore, studies on the in vivo metabolism of cytotoxic drugs and modulators are 
needed, to achieve optimal treatment.
In the absence of successful treatment options for patients with hormone-refrac-
tory prostate cancer, clinical application of combination therapy of a cytotoxic drug 
and a chemosensitizer (for instance a MRP1 modulator) should be investigated and 
its curative or palliative value should be evaluated in a clinical trial. One could tailor 
this treatment to the individual patient by making an inventory of the expression 
of MDR factors in the patient’s prostate cancer tissue samples, using appropriate 
(combinations of ) cytotoxic drugs and chemosensitizers, after assessing the safety 
of their application.
Preceding animal experiments will be crucial to decide on the proper selection of 
chemotherapeutic drug and modulator as well as on timing and mode of applica-
tion. In our studies, the combination of vincristine and MK571 was demonstrated 
to eff ectively circumvent MRP1 related chemoresistance. Peak plasma levels of 
vincristine are reached under a continuous intravenous regimen and amount to 
nanomoles (>10-9 M) [44]. In our in vitro experiments vincristine concentrations 
needed for a cytotoxic eff ect were 2ng/ml (≈10-9 M), which is in agreement with 
clinically achievable peak plasma concentration. As such vincristine appears to be 
suitable to be used in a clinical trial. In clinical trials , MK571 has been used orally at 
750 mg (once) or split over 3 equal doses over 24 hours [45] or intravenously at 160 
mg once [46]. In healthy volunteers the achievable peak serum levels amount to 
313 ng/ml [47], which is 20 times higher than the concentrations used eff ectively in 
our in vitro studies (15.4 µg/ml or 30 µM) and which is not toxic by itself to prostate 
cancer cells. As such, the leukotriene D4 receptor agonist MK 571 again appears to 
be a suitable modulator in a clinical trial. We have shown that in vivo toxicity of the 
combination of vincristine and M-571 is limited.
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Such a clinical trial should aim at improving on standard chemotherapy and could 
be performed in symptomatic hormone unresponsive metastatic prostate cancer 
patients with MRP1 positive tumours. The aim of this study would be to assess 
safety and effi  cacy of the combination Vincristine and MK-571. Clinical endpoints 
of this trial would be: cancer specifi c and overall survival, number and duration of 
objective and prostate specifi c antigen (PSA) responses, and quality of life.
The study design would be a sequential phase II trial (Gehan design[40]) in which 
14 patients should be recruited in this trial fi rst. In this scheme the trial would 
have to be discontinued if no response had been observed after 14 patients, with 
further enrolment depending of the number of patients needed to estimate the 
real response rate with a required precision of 10% in terms of the standard error 
(maximum 25 patients).
The therapy would consist of vincristine, followed by vincristine and MK-571 in 
non-responders. The duration of treatment would be until progressive disease, un-
acceptable toxicity or until patient’s refusal occurred. A tumour response is defi ned 
as an objective response: either complete disappearance of all known tumour 
deposits for a minimum of one month (complete response) or reduction of all bi-
dimensionally measurable tumour deposits by more than 50% for a minimum of 
one month (partial response), or a PSA response consisting of a PSA reduction to ≤ 
50% of the pre-treatment value, confi rmed by one control measurement, together 
with an improvement of WHO performance score ≥ 1 scale or an improvement at a 
5 step pain score by ≥ 2 scales. Progression is defi ned as any increase in number of 
metastatic deposits (new lesions) or increase of the volume of all bi-dimensionally 
measurable tumour deposits by ≥ 25%, or a PSA increase of ≥ 50% of the pre-
treatment value, confi rmed by one control measurement together with a decrease 
of WHO performance score ≥ 1 scale or a decrease of a 5 step pain score by ≥ 
2 scales. In addition, a general stopping rule for the trial applies. In case of 2 or 
more unexplained serious adverse events (SAE, defi nition in accordance with GCP 
guidelines) the investigational trial has to be halted and, if left unresolved, to be 
discontinued. Safety of the trial and trial conduct will be monitored in accordance 
with GCP guidelines.
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SUMMARY AND CONCLUSIONS
Advanced hormone refractory prostate cancer constitutes a therapeutic challenge, 
because all available treatment strategies have failed to substantially increase 
cancer specifi c survival. Among these strategies, a multitude of chemotherapeutic 
approaches did not off er a superior life expectancy longer than a few months. Fail-
ure of chemotherapy may be caused by multidrug resistance (MDR) mechanisms 
protecting cancer cells against cytotoxic drugs. The question arises whether the 
MDR phenomenon plays a role in prostate cancer. Several pathways known to 
lead to MDR such as the P-glycoprotein (Pgp; MDR1), isoforms of the multidrug 
resistance associated protein (MRP), glutathione, apoptosis and topoisomerases 
have been examined and are reviewed in chapter 2. Evidence for the involvement 
of several MDR mechanisms in the chemoresistance of prostate cancer in vitro and 
in vivo is accumulating. Reversal, circumvention or overcoming of MDR pathways 
in advanced prostate cancer may be feasible and will lead to new strategies with 
improved treatment effi  cacy in otherwise untreatable disease.
The aim of the study described in chapter 3 was to obtain an inventory of MDR fac-
tors in human prostate cancer cell lines representing progressive prostate cancer 
and to assess their response to chemotherapy.
Using immunocytochemistry and Western blotting expression of P-glycoprotein 
(Pgp), Multidrug resistance associated protein (MRP), Glutathione-S-transferase-π 
(GST-π), Bcl-2, Bax, Topoisomerase (Topo) I, IIα and IIß was determined in the hu-
man prostate cancer cell lines PC3, TSU-Pr1, DU145 and LNCaP derivatives -R, -LNO 
and -FGC. Proliferative activity was assessed by immunocytochemistry. MTT assays 
were used to determine the sensitivity to Etoposide, Doxorubicin and Vinblastine.
Pgp was not expressed in any of the cell lines. MRP was variably expressed. GST-π 
was expressed in TSU-Pr1, PC3 and DU145. Expression of Bcl-2 was restricted to 
TSU-Pr1, whereas Bax was found in all cell lines. Topo IIα was expressed at the high-
est level in the rapidly proliferating cell lines TSU-Pr1 and DU145. Topo I and IIß 
were equally expressed. Resistance profi les varied among the cell lines, with TSU-
Pr1 being the most sensitive and LNCaP-LNO relatively resistant. It was concluded 
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that multiple MDR proteins are expressed in prostate cancer cell lines and may well 
infl uence response to chemotherapy.
The study described in chapter 4 aimed at identifying proteins that may be involved 
in multidrug resistance in clinical prostate cancer. Expression of these proteins was 
examined in the context of tumour progression. Paraffi  n-embedded formalin fi xed 
prostate cancer specimens from archival sources of three distinct patient groups 
were examined. These groups were clearly distinct with regard to pathological 
stage and responsiveness to anti-hormonal therapy. Group 1 consisted of patients 
with organ confi ned prostate cancer, treated by radical prostatectomy (early pros-
tate cancer, pathological stage (p) T2N0M0 tumours). Group 2 had disseminated 
prostate cancer and was treated with transurethral resection of the prostate (TURP) 
for urinary obstruction before receiving anti-hormonal therapy (early advanced 
prostate cancer). Group 3 had disseminated prostate cancer and relapsed despite 
anti-hormonal treatment (late advanced prostate cancer) and were treated with 
TURP to relieve symptoms of urinary obstruction. Immunohistochemistry was used 
for detection of Pgp, MRP1, lung resistance protein (LRP), GST-π, p53, Bcl-2, Bax, 
Topo I, IIα and IIβ and Ki-67. Advanced tumours could be distinguished from lo-
cally confi ned tumours because they exhibited a signifi cantly higher histological 
grade and proliferative activity than organ confi ned prostate cancer. Expression of 
MRP, p53, Topo IIα, Ki-67 and Topo IIβ was signifi cantly related to a higher Gleason 
sum score. The number of patients expressing MRP, LRP, GST-π, p53, Bcl-2, Topo IIα 
and Ki-67 was signifi cantly increased in the group with advanced disseminated 
prostate cancer. Topo I and Topo IIβ were homogeneously and highly expressed 
in all stages of prostate cancer progression. Pgp was not expressed in any of the 
tumours, regardless of the patient group. It was concluded that up-regulation of 
expression of drug transporters MRP and LRP, detoxifying enzyme GST-π and apop-
tosis inhibiting proteins Bcl-2 and P53 may off er an explanation for the resistance 
of disseminated progressive prostate cancer to chemotherapy. Increased prolifera-
tion, as shown by up-regulation of Ki-67 and Topo IIα, refl ects the aggressiveness 
of metastatic prostate cancer.
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The objective of the study described in chapter 5 was to assess the involvement of 
MRP1 and the glutathione (GSH) pathway in the MDR phenotype of prostate cancer 
in vitro. Chemo-selection of human prostate cancer cell lines PC3 and DU145 with 
etoposide, resulted in the cell lines PC3-R and DU-R. Resistance against etoposide, 
doxorubicin and vincristine and its reversal with leukotriene D4 antagonists MK-
571 and zafi rlukast, and buthioninesulfoximine (BSO) was studied in MTT assays. 
Western blot analysis of MRP1 expression and GSH content measurements were 
performed. MRP1 function was studied in fl uorescence assays. MRP1 was increased 
in the MDR models. The GSH content was signifi cantly higher in PC3-R. No increase 
in GSH was found in DU-R. Addition of non-toxic doses of MK-571, zafi rlukast or 
BSO signifi cantly increased sensitivity of the MDR models to cytotoxic drugs. In-
hibition of MRP1 function was achieved with MK-571 in the MDR models. It was 
concluded that MRP1 and glutathione mediate MDR in newly developed prostate 
cancer models.
The objective of the study described in chapter 6 was to investigate the possibil-
ity to chemosensitize prostate cancer in vivo and in vitro aiming at modulation of 
MRP1-related MDR. Expression of MDR1, MRP1 and MRP2 was determined with 
Western blotting in a panel of human prostate cancer xenografts and in the xe-
nograft derived cell line PC346C. Chemosensitization with MK-571 of PC346C to 
vincristine (VCR), doxorubicin (DOX) and etoposide (VP-16) was assessed in MTT 
assays. Carboxyfl uorescein effl  ux blocking with MK-571 in PC346C was measured 
in fl uorescence assays. Toxicity and effi  cacy of VCR and VCR combined with MK-571 
was determined in vivo with human prostate cancer xenografts PC339 and PC346BI. 
MRP1 and MRP2 were expressed in all xenografts and in PC346C. No expression 
of MDR1 was found. Signifi cant chemosensitization was achieved with MK-571 in 
PC346C. MRP1-mediated carboxyfl uorescein effl  ux was demonstrated in PC346C 
and signifi cantly inhibited with MK-571. In vivo application of tolerable doses of 
intravenous VCR resulted in signifi cant reduction of tumour volumes in xenograft 
PC339 in vivo experiments. Intravenous VCR combined with intraperitoneal MK-571 
resulted in signifi cant in vivo chemosensitization to VCR in xenograft PC346BI. It 
was concluded that eff ective chemosensitization with MK-571 was demonstrated, 
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both in vitro and in vivo, indicating that MRP1 plays a role in the in vitro and in vivo
MDR phenotype of prostate cancer.
Altogether, these fi ndings may encourage clinical chemosensitization strategies 
aiming at improving the results of chemotherapy in advanced prostate cancer 
patients.
Samenvatting en conclusies 155
SAMENVATTING EN CONCLUSIES
Hormoonongevoelige prostaatkanker in een vergevorderd stadium van progressie 
vormt een therapeutische uitdaging aangezien alle behandelingsstrategieën inef-
fectief blijken te zijn. Chemotherapie verbetert de levensverwachting bij patiënten 
met een dergelijke prostaatkanker niet langer dan enkele maanden. Het falen van 
chemotherapie wordt mogelijk veroorzaakt door multidrug resistentie (MDR) 
mechanismen, die kankercellen tegen chemotherapeutica beschermen. De vraag 
doet zich voor of het MDR fenomeen een rol speelt bij prostaatkanker. Verscheidene 
mechanismen, waarvan bekend is dat zij MDR veroorzaken, zoals P-glycoproteine 
(Pgp; MDR1), varianten van het multidrug resistentie geassocieerde eiwit (MRP), 
glutathione, apoptose en topoisomerases zijn onderzocht en beschreven in het 
overzichtsartikel in hoofdstuk 2. Bewijs voor de rol die diverse MDR factoren in vitro
en in vivo bij prostaatkanker spelen is in meerdere studies geleverd. Het omkeren, 
omzeilen of overwinnen van MDR mechanismen bij patiënten met uitbehandelde 
prostaatkanker komt in zicht en zal naar nieuwe behandelingsvormen leiden met 
een verbeterde eff ectiviteit.
Het doel van de studie, beschreven in hoofdstuk 3, was het inventariseren van 
het voorkomen van MDR factoren bij cellijnen van humane prostaatkanker en het 
vaststellen van het eff ect van chemotherapie op deze prostaatkankercellen.
Met immunocytochemie en Western blotting werd de expressie van Pgp, Mul-
tidrug resistance associated protein (MRP), Glutathione-S-transferase-π (GST-π), 
Bcl-2, Bax, Topoisomerase (Topo) I, IIα en IIß bepaald in cellijnen PC3, TSU-Pr1, 
DU145 en LNCaP afgeleiden -R, -LNO and -FGC. Proliferatie activiteit werd bepaald 
met immunocytochemie. Met MTT proeven werd de gevoeligheid voor etoposide, 
doxorubicine en Vinblastine vastgesteld. Pgp kwam in geen enkele van de cellijnen 
tot expressie. MRP expressie was variabel. GST-π kwam tot expressie in TSU-Pr1, 
PC3 en DU145. Expressie van Bcl-2 was beperkt tot TSU-Pr1, Bax kwam in alle cel-
lijnen voor. Topo IIα kwam het meest tot expressie in snel delende cellijnen TSU-Pr1 
en DU145. Topo I en IIß kwamen gelijkwaardig tot expressie. Resistentie profi elen 
varieerden tussen de cellijnen, waarbij TSU-Pr1 het meest gevoelige en LNCaP-LNO 
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relatief resistent tegen chemotherapie was. Concluderend werd gesteld dat meer-
dere MDR eiwitten tot expressie komen in prostaatkankercellijnen en dat deze 
mogelijk de eff ectiviteit van chemotherapie beïnvloeden.
Het doel van de studie, beschreven in hoofdstuk 4, was het identifi ceren van 
eiwitten die mogelijk betrokken zijn bij multidrug resistentie bij het klinische 
prostaatcarcinoom. Expressie van deze eiwitten werd onderzocht in relatie tot 
tumour progressie. Paraffi  ne coupes van met formaline gefi xeerd prostaatkanker 
materiaal uit het pathologisch archief van drie verschillende patiëntengroepen 
werden onderzocht. Deze groepen onderscheidden zich duidelijk wat betreft 
pathologische stagering en reactie op antihormonale therapie. Groep 1 bestond 
uit patiënten met prostaatkanker die beperkt was tot de prostaat. Deze patiënten 
werden met een radicale prostatectomie behandeld (“vroege” prostaatkanker, pa-
thologische stagering (p) T2N0M0). Groep 2 bestond uit patiënten met uitgezaaide 
prostaatkanker en werd behandeld met een transurethrale resectie van de prostaat 
(TURP) vanwege obstructieve mictieklachten, alvorens behandeld te worden met 
antihormonale therapie (“intermediaire” prostaatkanker). Groep 3 had uitgezaaide 
prostaatkanker en was progressief onder antihormonale therapie (“late” prosta-
atkanker) en werd met een TURP behandeld omwille van verlichting van symp-
tomen van obstructieve mictieklachten. Immunohistochemie werd toegepast om 
Pgp, MRP1, lung resistance protein (LRP), GST-π, p53, Bcl-2, Bax, Topo I, IIα en IIβ 
en Ki-67 te detecteren. Uitgezaaide kanker kon onderscheiden worden van tot de 
prostaat beperkte carcinomen omdat uitgezaaide kanker een signifi cant hogere 
histologische graad en proliferatie activiteit had dan niet uitgezaaide ziekte. Ex-
pressie van MRP, p53, Topo IIα, Ki-67 en Topo IIβ was signifi cant gerelateerd aan een 
hogere Gleason score. Het aantal patiënten met tumoren die MRP, LRP, GST-π, p53, 
Bcl-2, Topo IIα en Ki-67 tot expressie brachten was signifi cant hoger in de groep 3. 
Topo I en Topo IIβ kwamen gelijkelijk en in hoge mate tot expressie in alle drie de 
groepen. Pgp kwam in geen enkele tumour tot expressie, ongeacht de progressie 
van prostaatkanker. De conclusie luidde dat verhoogde expressie van de (chemo-
therapie) transport eiwitten MRP en LRP, ontgiftend enzym GST-π en apoptose rem-
mende eiwitten Bcl-2 en p53 de resistentie tegen chemotherapie van uitgezaaide 
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klinische progressieve prostaatkanker kunnen verklaren. Toegenomen celdeling, 
aangetoond door verhoogde expressie van Ki-67 en Topo IIα, weerspiegelen het 
progressieve karakter van uitgezaaide prostaat kanker.
Het doel van de studie, beschreven in hoofdstuk 5, was het vaststellen van 
betrokkenheid van MRP1 en het glutathione (GSH) metabolisme bij het MDR 
fenotype van in vitro prostaatkanker. Selectie van humane prostaatkankercelli-
jnen PC3 en DU145 door blootstelling aan het chemotherapeuticum etoposide, 
resulteerde in het ontstaan van MDR cellijnen PC3-R en DU-R. Resistentie tegen 
etoposide, doxorubicine and vincristine en omkeren van resistentie met leukotri-
ene D4 antagonisten MK-571 and zafi rlukast, en met buthioninesulfoximine (BSO) 
werd bestudeerd door middel van MTT proeven. Western blot analyses van MRP1 
expressie en GSH concentratie metingen werden uitgevoerd. MRP1 functie werd 
bestudeerd met fl uorescentie experimenten. Expressie van MRP1 was verhoogd in 
de MDR cellijnen PC3-R en DU-R. De GSH concentratie was signifi cant toegenomen 
in PC3-R. Toename van GSH concentratie werd niet gevonden in DU-R. Toevoeg-
ing van niet-toxische doses van MK-571, zafi rlukast of BSO resulteerde in een sig-
nifi cant hogere gevoeligheid van de cellijnen PC3, PC3-R, DU145 en DU-R voor de 
chemotherapeutica. Inhibitie van MRP1 functie werd bereikt met MK-571 in alle 
cellijnen. Er werd geconcludeerd dat MRP1 en glutathione MDR veroorzaken bij de 
bestaande en nieuw ontwikkelde prostaatkankercellijnen.
Het doel van de studie, zoals beschreven in hoofdstuk 6, was het bestuderen van 
de mogelijkheid om in vivo en in vitro prostaatkanker te chemosensitizeren, gericht 
op het beïnvloeden van MRP1-gerelateerde MDR. Expressie van MDR1, MRP1 en 
MRP2 werd vastgesteld met Western blotting in een panel van prostaatkankerx-
enografts (heterotransplanteerbare humane prostaatcarcinomen; modellen 
waarbij stukjes humane prostaatkanker onderhuids in naakte immuundefi ciënte 
(thymusloze) muizen geïmplanteerd worden, die vervolgens uitgroeien tot tumo-
ren) en in xenograft-afgeleide cellijn PC346C. Chemosensitizering met MK-571 van 
cellijn PC346C voor vincristine (VCR), doxorubicine (DOX) en etoposide (VP-16) 
werd vastgesteld met MTT proeven. Blokkering van carboxyfl uorescein (DCFDA) 
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effl  ux met MK-571 in PC346C werd gemeten met fl uorescentie experimenten. 
Toxiciteit en eff ectiviteit van VCR en VCR in combinatie met MK-571 werd in vivo
bestudeerd bij in vivo humane prostaatkankermodellen PC339 en PC346BI. Zowel 
MRP1 als MRP2 kwamen tot expressie in alle in vivo modellen en in cellijn PC346C. 
MDR1 kwam niet tot expressie. Signifi cante chemosensitizering werd met MK-571 
bereikt in cellijn PC346C. MRP1-gemedieerde DCFDA effl  ux werd aangetoond in 
PC346C en kon in signifi cante mate geremd worden met MK-571. In vivo toepass-
ing van niet-toxische doses intraveneuze VCR op model PC339 resulteerde in een 
signifi cante afname van tumour volumes. Intraveneuze toediening van VCR in 
combinatie met intraperitoneaal gespoten MK-571 resulteerde in een signifi cante 
in vivo chemosensitizering voor VCR in model PC346BI. De conclusie luidde dat het 
mogelijk is, zowel in vivo als in vitro, met MK-571 eff ectief voor chemotherapie te 
sensitizeren, hetgeen een rol aanduidt voor MDR eiwit MRP1 in het in vivo en in 
vitro MDR fenotype van prostaatkanker.
De bevindingen, beschreven in dit proefschrift, brengt het toepassen van klinische 
chemosensitizeringsstrategieën dichterbij, met als doel het verbeteren van de 
behandelingsresultaten van gemetastaseerde prostaatkankerpatiënten met che-
motherapie.
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NAWOORD
De in het woord “doctorandus” besloten belofte ben ik bij deze nagekomen!
Het verliezen van de “s” is mooi. Maar, het doet me met name veel goed dat dit 
promotieonderzoek, ondanks de veranderingen in mijn loopbaan, afgerond is. Dat 
was ik aan mijzelf verplicht en aan allen die mij op enigerlei wijze geholpen heb-
ben met dit werk.
Professor Schröder, u belde mij om halfnegen op een zaterdagochtend met het 
aanbod om onderzoek te doen, in afwachting van een plaats in de kliniek. Hoewel 
er aanvankelijk geen sprake was van een promotieonderzoek, liep het al snel uit de 
hand. Dank voor de mogelijkheid die u mij gaf in het urologisch lab te werken en 
het project op congressen te presenteren. En dank dat u mijn promotor wilt zijn. Ik 
heb uw sportieve reactie zeer gewaardeerd, toen ik schoorvoetend kwam vertellen 
dat ik toch chirurg wilde worden.
Dit geldt zeker ook voor professor Mickisch, tevens mijn promotor. Beste Gerald, 
met jou had ik de eerste gesprekken over het onderzoek. Na een doordringende 
blik van jouw kant, begon je te vertellen over multidrug resistentie – toen nog 
nooit van gehoord – en dat gesprek is tot op heden niet beëindigd. Jij liet mij de 
vrijheid om de onderzoekslijnen uit te zetten, af en toe sturend en motiverend en 
altijd enthousiast. Ondanks de indrukwekkende stapels werk op je bureau, kon ik 
immer bij je terecht. Je was voor mij een onuitputtelijke bron van klinische- en 
literatuurkennis en wist bovendien overal ter wereld de beste kroegen. Helaas is 
de afstand tussen ons nu groter. De ontmoetingen met jou en Marianne, met goeie 
recepten en “Le trou Normand”, waren altijd bijzonder gezellig. Alle reden om ein-
delijk eens een keer naar Bremen te gaan.
De leden van de leescommissie, hoogleraren Scheper, Sonneveld en van der Kwast 
dank ik voor de beoordeling van het manuscript. Theo, bedankt voor de commen-
taren en je komst uit Canada. 
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Dr. van Steenbrugge, beste Gert Jan, ik werd bij jou in het lab geplaatst en jij werd 
mijn directe begeleider, waarvoor dank. Wekelijks hadden we besprekingen over 
het onderzoek, ondanks de enorme klus die je had aan de verhuizing van de 10e 
naar het Josephine Nefkens Instituut. Je stond altijd klaar om voor de medewerk-
ers van het lab in de bres te springen. Naast een groot talent als organisator, ga je 
voor mij ook door het leven als bestrijder van Mycoplasma, hetgeen mogelijk de 
redding was voor meerdere laboratoria.
Zo’n periode in het lab is een bijzondere ervaring. Ik ben ervan overtuigd dat de 
basis voor vooruitgang in de Geneeskunde in het experimentele werk ligt. Be-
wondering heb ik voor de wetenschappers, voor hun nieuwsgierigheid naar het 
onbekende en hun gevecht met de wet van Murphy, onder druk van het “publish 
or perish”. Het is de kunst om de kloof tussen de werelden van het lab en de kliniek 
te overbruggen. Dat dit geen makkelijke opgave is heb ik ondervonden. Er worden 
verschillende talen gesproken en er is meer dan een tweetalige opvoeding voor 
nodig om die te begrijpen. Mijn gebrek aan opleiding voor het doen van labwerk 
speelde me geregeld parten. Gelukkig kon ik dan aankloppen voor hulp en advies 
bij de collegae in het lab. Met name Wilma Teubel, Monique Oomen, Marja Verleun, 
Corrina de Ridder en Cindy Bolder waren onmisbaar bij het praktische werk. Robert 
Kraaij was mijn vraagbaak, Hans Romijn, Wytske van Weerden, Arjen Noordzij en 
Hans Scheltema gaven goeie adviezen. Ries Kranse en Mark Wildhagen waren be-
hulpzaam wat betreft de statistiek. In het hematologisch lab werkte ik met plezier 
samen met Erik Wiemer, Paula Vossebeld en Arie Prins. De medewerkers van de pa-
thologie waren behulpzaam met antilichamen en coupes, en Frank van de Panne 
hielp mij regelmatig met het fotowerk.
Naast degenen die in het onderzoek zelf betrokken waren, zijn er meerdere 
mensen die mij stimuleerden en prikkelden (is je boekje al af?), als mijn gedachten 
afdwaalden van het onderzoek.
Mijn opleiders en de stafl eden van het St. Elisabeth ziekenhuis hielpen mij de bal 
aan het rollen te houden door mij enkele keren “schrijfvrij” te geven.
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Dr. Roukema, beste Rouk, als we samen aan tafel stonden vroeg je steevast: “heb 
je al een datum?”. Als ik dan mompelde dat ik ermee bezig was, liet je me fi jntjes 
weten dat je dat niets interesseerde, alleen die datum wilde je horen. Zestien 
november 2005! Natuurlijk was jij wel de eerste die de voorlopige versie van dit 
proefschrift van commentaar voorzag. Ook gaf jij Jan op andere fronten meerdere 
keren het zetje dat hij nodig had…veel dank!  
De leden van de Rotterdam Love Express, Wouter Vles, Jacques van der Meulen, 
Erik Walbeehm en Jur Vellema wil ik danken voor de ruim 200.000 veilige kilome-
ters inclusief ontbijt. En dat met een totale vertraging van slechts vier uur. Met 
veel plezier denk ik in dit kader terug aan het achteruitrijdend aankomen bij het 
ziekenhuis, met de knalpijp slepend over het wegdek. De wijze lessen in de RLE zijn 
van onschatbare waarde geweest, ook voor dit proefschrift!
Mijn collegae in Tilburg moesten een stapje extra doen als ik aan het schrijven was, 
dank hiervoor!
Prof.dr. H.J. Bonjer en prof.dr. R.P. Bleichrodt maakten het mij, onder andere, mo-
gelijk om de eindsprint in te zetten.
Jaren geleden werd de promotie-wisseltrofee ingesteld. Dit begerenswaardig 
voorwerp valt mij nu ten deel, al is het maar van korte duur (1 fl es Whisky). Joris 
Meijaard, Stephan Slingerland en Jorrit Hoff , onze gesprekken over promoveren 
veranderden meestal snel via gymnasiale discussies in vrij associëren. Inmiddels 
wordt er meer en meer over de volgende generatie gesproken!
Het thuisfront, zowel in Rotterdam, in Leiden als in Kamperland is ongelofelijk 
belangrijk voor het totale plaatje, waar dit proefschrift ook lange tijd deel van uit 
heeft gemaakt.
Papa, jij liet me kennismaken met de wetenschap, toen ik als jochie met je meeg-
ing naar de Nonnensteeg en door de hortus zwierf. Daar snoof ik de geur van 
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historie, het laboratorium en viltstiften op. Toen had ik niet gedacht zelf ook met 
kweekkasten en centrifuges aan de slag te gaan. Met je adviezen en je grote (soms 
wat bezorgde) interesse naar de vorderingen van het onderzoek, heb jij mij veel 
geholpen.
Maman, tu as toujours été là, pour moi et mes frères Pieter et Nicolas et maintenant 
aussi pour Veerle et Luc. Tu es vraiment  fantastique!
Rien en Lia, veel dank voor alle steun, ik zal m’n computer niet meer meenemen 
naar Zeeland…
Nicolas en Jean, paranimfen, ik ben er trots op door jullie gefl ankeerd te worden 
tijdens het uur U!
Lieve Caroline, over jou kan ik een boek schrijven en dat is zo veel leuker en mooier 
dan het schrijven van dit boekje! Wat jij allemaal voor me betekent…blijft tussen 
ons. Je t’aime!
Rotterdam, 16 november 2005
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Opgroeiend onder het toeziend bronzen oog van Boerhaave, genietend van een Nederlands-Franse 
opvoeding, doorkruiste ik gedurende mijn middelbare schoolperiode per fiets Leiden, op weg naar het 
Stedelijk. Tijdens deze inspirerende periode ontmoette-, en kort erna ontdekte- ik Caroline met wie ik het 
leven deel, samen met onze kinderen Veerle en Luc.
Met nummer 2513 uitgeloot voor Geneeskunde, begon ik aan de studie Biologie, maar werd na een maand 
alsnog geplaatst voor Geneeskunde aan de Vrije Universiteit te Amsterdam, om na drie weken weer te wor-
den overgeplaatst naar de Rijksuniversiteit Leiden. Gedurende een verder vlot verlopende studie, roeide ik 
wedstrijd bij de K.S.R.V. Njord.
De doctoraalfase werd in 1991 afgesloten met een afstudeerproject in het lab van Prof.dr. H.E. ter Keurs, 
aan de University of Calgary, Alberta, Canada, waarbij ik ritmestoornissen in rattenhartspieren onder inv-
loed van ouabaïne onderzocht. 
De wachttijd voor de co-schappen (doorlopen in regio Leiden) bracht ik, samen met Caroline, door in 
Lagdo, Noord-Kameroen, waar we, in het kader van keuze co-schap, de prevalentie van Schistosoma Hema-
tobium infecties in de regio in kaart brachten, onder supervisie van Dr. A.M. Polderman, afdeling Parasitolo-
gie van de Rijksuniversiteit Leiden.
Meteen na het artsexamen, reisde ik af naar Bolton, Lancashire, United Kingdom, waar ik gedurende een 
korte periode mijn eerste schreden als House Officer zette, op de afdeling chirurgie en urologie van het Bolton 
Royal Infirmary. Vervolgens werkte ik gedurende een jaar als AGNIO chirurgie in het Rijnland ziekenhuis, te 
Leiderdorp.
Na deze klinische periode, startte ik, op uitnodiging van Prof.dr. F.H. Schröder en onder supervisie van 
Prof.dr. G.H.J. Mickisch met experimenteel onderzoek in het urologisch lab. De resultaten worden in dit proef-
schrift gepresenteerd.
Na het verkrijgen van een opleidingsplaats Urologie, doorliep ik de vooropleiding Chirurgie in het St. Elisa-
beth ziekenhuis te Tilburg. Daar raakte ik zeer geënthousiasmeerd door de Chirurgie. Hoewel ik de opleiding 
Urologie in het Dijkzigt ziekenhuis begon, besloot ik van specialisme te veranderen. In 2002 verkreeg ik een 
opleidingsplaats Chirurgie en deed mijn perifere opleiding in het St.Elisabeth ziekenhuis. Gedurende mijn 
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  I love fools’ experiments. I am always making them.
Charles Darwin

